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Resumen 
 
 
Los canales de potasio dependientes de voltaje (Kv) son proteínas de membrana involucradas en diversos 
procesos fisiológicos y fisiopatológicos. De hecho, el funcionamiento electrofisiológico normal del corazón está 
determinado por la propagación ordenada de potenciales de acción (PA) generados en miocitos individuales. Por 
lo tanto, anomalías en la génesis, propagación, duración o configuración de estos PA constituyen la causa de 
arritmias cardíacas. Las corrientes de K+ determinan la repolarización del PA cardíaco, el potencial de 
membrana, el ritmo cardíaco, la refractariedad del tejido cardíaco y, por tanto, constituyen importantes dianas 
moleculares para la acción de diversos moduladores de la función cardíaca. Los canales Kv1.5 son los 
principales responsables de la génesis de la corriente de salida ultrarápida de potasio (IKur) y, debido a que se 
expresan mayoritariamente en aurícula, la IKur determina la duración del PA auricular. Así, estos canales 
representan una diana farmacológica para el desarrollo de fármacos útiles en el tratamiento de arritmias 
supraventriculares. Estos canales se ensamblan con diversas subunidades Kvβ. En particular, las subunidades 
Kvβ1.3 modifican las características electrofisiológicas de los canales Kv1.5, induciendo una inactivación rápida y 
parcial, un mayor grado de inactivación lenta, un desplazamiento de la curva de activación hacia potenciales más 
electronegativos, y una disminución en la sensibilidad del canal al bloqueo inducido por fármacos. Tras inhibir la 
PKC con calfostina C los canales Kv1.5-Kvβ1.3 generan corrientes de pequeña magnitud y sin inactivación rápida 
inducida por la Kvβ1.3. En esta Tesis Doctoral hemos investigado los mecanismos subyacentes a este fenómeno 
utilizando técnicas electrofisiológicas y de imagen en sistemas heterólogos (células HEK293) y en tejidos nativos 
(miocardio de rata y humano). Los resultados obtenidos demuestran la existencia de un canalosoma funcional de 
Kv1.5, estrechamente regulado por PLC y PIP2, y constituido por, al menos, Kvβ1.3, el receptor de quinasas C 
activadas (RACK1), PKCβI, PKCβII, y PKCθ en células HEK293. En este canalosoma, las subunidades Kvβ1.3 
parecen tener un papel ‘conector’ entre Kv1.5 y RACK1 y, por tanto, con el resto de componentes del mismo. Un 
canalosoma Kv1.5 muy similar se encontró en ventrículo de rata pero no en aurícula. La inhibición de PKC 
inducida por calfostina C también modifica la inactivación dependiente de voltaje de los canales Kv1.5-Kvβ1.3, así 
como sobre su farmacología que resulta ser más similar a la de Kv1.5. De hecho, los valores de IC50 para 
bupivacaína y quinidina fueron similares a los obtenidos para el bloqueo de Kv1.5. Dado que la inhibición de la 
PKC disminuye la magnitud de las corrientes generadas por los canales Kv1.5-Kvβ1.3, estudiamos el reciclaje de 
los canales Kv1.5-Kvβ1.3. Observamos que la inhibición de la PKC promueve una reducción de la densidad de 
canales Kv1.5 en membrana y un aumento de los canales internalizados sin modificar la cantidad total de los 
mismos. Experimentos en los que transfectamos Rab11 constitutivamente activo demostraron que PKC está 
involucrada en el reciclaje lento de los canales Kv1.5-Kvβ1.3 mediado por Rab11. Por último, analizamos el papel 
funcional de la proteína Lgi1, que interfiere con la inactivación rápida inducida por Kvβ1 sobre los canales Kv1 y 
que ha sido relacionada con ciertos tipos de epilepsia. Tras demostrar su expresión en el tejido cardíaco de rata, 
con un patrón de expresión similar a Kvβ1.3, demostramos que Lgi1 anula la inactivación rápida inducida por 
Kvβ1.3, tanto tras transfectar Lgi1, como tras añadirla a la solución interna de la pipeta; lo que se acompañaba 
de una disminución en la cantidad de canal en la membrana celular y de modificaciones del citoesqueleto. 
Además, demostramos que el patrón de expresión de Lgi1 es muy similar al de Kv1.5 en el ventrículo humano, lo 
que nos lleva a proponer a Lgi1 como un nuevo e importante modulador del complejo Kv1.5-Kvβ1.3. 

Abstract 
 
 
Voltage dependent potassium channels (Kv) are membrane proteins involved in several physiological and 
pathological events. In fact, the normal electrophysiological behavior of the heart is determined by the ordered 
propagation of action potentials generated in the individual myocytes. Therefore, abnormalities of the generation, 
propagation, duration or configuration of individual cardiac action potentials (AP) are the basis of cardiac 
arrhythmias. K+ currents control the repolarization process of the cardiac AP, membrane potential, heart rate, 
myocardium refractoriness and, thus, they represent important molecular targets for the actions of 
neurotransmitters, hormones, drugs and toxins known to modulate cardiac function. Activation of Kv1.5 channels 
generates the ultrarapid outward potassium current (IKur) and because these channels are mostly expressed in 
atrial tissue, this current determines the atrial AP duration, representing a pharmacological target for the 
development of antiarrhythmic drugs useful in the treatment of supraventricular arrhythmias. Kv1.5 channels 
assembly with several Kvβ subunits (Kvβ1.2, Kvβ1.3 and Kvβ2.1). In particular, Kvβ1.3 subunits modify the 
electrophysiological characteristics of Kv1.5 channels, inducing a fast and partial inactivation, a greater degree of 
slow inactivation, a shift of the activation curve towards more negative potentials, and a decrease in the sensitivity 
of the channel to drug-induced blockade. Previous studies have shown that inhibition of PKC with calphostin C 
results in a small currents without the Kvβ1.3-induced fast inactivation. In the present Doctoral Thesis the 
mechanisms underlying this phenomenon, using electrophysiological and imaging techniques, were investigated 
in both heterologous (HEK293 cells) and native systems (rat and human cardiac tissue). The results obtained 
revealed the existence of a functional Kv1.5 channelosome, tightly regulated by PLC and PIP2, and conformed by, 
at least, Kvβ1.3, the receptor for activated C kinase (RACK1), PKCβI, PKCβII, and PKCθ in HEK293 cells. In this 
channelosome, Kvβ1.3 subunits seem to have a ‘linker’ role between Kv1.5 and RACK1 and, therefore, with the 
others components. Interestingly, a very similar Kv1.5 channelosome was found in rat ventricular but not in atrial 
tissue. PKC inhibition calphostin C-mediated also modifies the voltage dependent inactivation of Kv1.5-Kvβ1.3 
channels and in their pharmacology that appear to be similar to that displayed by Kv1.5 channels alone. Indeed, 
the IC50 values for bupivacaine and for quinidine were similar to those reported for Kv1.5 block. Since PKC 
inhibition results in a reduction of the current magnitude, the recycling of Kv1.5-Kvβ1.3 channels was studied. We 
observed that PKC inhibition promotes a reduction of Kv1.5 density at the cell membrane and an increase in the 
channel internalized without modifying the total amount of the channel. Experiments in which Rab11 constitutively 
active was transfected, demonstrated that PKC activity was involved in the slow recycling of Kv1.5-Kvβ1.3 
channels Rab11-meadiated. Finally, the functional role of the Lgi1 protein was analyzed. Lgi1 interferes with the 
fast inactivation Kvβ1-induced of Kv1 channels and mutations in this protein have been linked to certain types of 
epilepsy. After demonstrate its expression in rat cardiac tissue, with a similar expression pattern to Kvβ1.3, we 
have shown that Lgi1 prevents the Kvβ1.3-induced fast inactivation, either when Lgi1 was transfected or when the 
Lgi1 protein was added to the internal solution of the patch pipette with a decrease in the surface channel amount 
and cytoskeleton disorders. In addition, we show that the pattern of expression of Lgi1 is very similar to that 
shown by Kv1.5 in the human ventricle, leading us to propose Lgi1 as an important Kv1.5-Kvβ1.3 modulator. 
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1.1 ION CHANNELS 
 
Ion channels are part of the mechanism of cellular signaling of almost all live cells. Our ability to do 
gymnastic, to perceive a colorful world and to process language relies on rapid communication among 
cells. Such signaling, the fastest in our bodies, involves electrical fluxes produced when ion channels open 
and close. Ion channels are intrinsic membrane proteins acting as gated pores that regulate the movement 
of ions across cell membranes. Thus, they are part of the rapid communication mechanism of cellular 
signaling of almost all live cells. Fast electrical signaling is made possible by the homeostatic mechanisms 
that establish the standard environment and content of animal cells: high Na+ [Na+] and Ca2+ 
concentrations [Ca2+] (but low [K+]) in the blood and extracellular fluid, and high [K+] (but low [Na+] and 
[Ca2+]) in the cytoplasm. Ion gradients are established following Goldman-Hodgkin-Katz equation 
(Goldman, 1943; Hodgkin & Katz, 1949) and maintained by active transporters and pumps, which prepare 
the way for rapid changes in membrane voltage produced by passive transport through ion channels. 
These pore-forming proteins allow ions to flow only “downhill”, as dictated by their electrochemical 
gradients, but they do it rapidly (the rate of passage of ions through one open channel is often more than 
106 ions per second) and selectively. Opening a Na+ or Ca2+ selective channel permits Na+ or Ca2+ to flow 
down its gradient into a cell, making the intracellular voltage more positive. Opening a K+ selective channel 
permits K+ to flow from the cell and restores the voltage to a more negative value. The dimensions of a 
typical cell and its membrane allow the voltage to be changed rapidly back and forth many times, with 
relatively small changes in concentration. This is essentially how all cellular electrical signaling is produced 
(Hille et al., 1999). 
Ion channels play a key role in the physiology of cells and defects in their function have profound 
physiological effects in excitable tissues (Hodgkin & Huxley, 1952). Moreover, ion channels play also 
crucial roles not only in excitable tissues, but also in other phenomena such as activation of immune cells 
(T-cells and macrophages), regulation of the cellular volume and function of the pancreatic β cells (Lewis 
& Cahalan, 1995; Villalonga et al., 2010; Moreno et al., 2013); blood pressure regulation (Joseph et al., 
2013), learning and memory (Need et al., 2003); or cellular and tumor proliferation (Wang et al., 2002). In 
fact, there have been described that some ion channels inhibit proliferation and, therefore, they are 
considered therapeutic targets in some types of cancer (Pardo et al., 1999; Villalonga et al., 2008). These 
relevant effects into the body functions convert ion channels into pharmacological targets in the treatment 
of several diseases (Wickenden, 2002a) such as cardiac arrhythmias (Tamargo et al., 2004), epilepsy 
(Wickenden, 2002b), autoimmune disorders (Wulff et al., 2003; Rangaraju et al., 2009), cancer (Wang et 
al., 2002), or diabetes (MacDonald et al., 2003). All these process can be carried out, thanks to the 
intracellular communication among the different tissues of the body and, therefore, between cells or ‘cell-
cell signaling’. Indeed, channel mutations may results in the genesis of several pathologies named 
‘channelopathies’. In the last years, and helped by the last technological advances, the initial vision of the 
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ion channels has changed from static proteins, to another one much more dynamic, constantly modulated 
and tightly regulated by both intracellular and physiological processes. 
 
1.2 VOLTAGE-GATED POTASSIUM CHANNELS 
 
 Voltage-gated ion channel protein superfamily, formed by more than 140 members, is one of the 
largest groups of signal transduction proteins (Hille et al., 1999; Yu et al., 2005). Among them, voltage-
dependent potassium channels are the largest and most diverse family of ion channels and they are 
mainly characterized because “sense’’ differences in the voltage potential across the cell membrane and 
open or close in response to changes in the membrane potential. The first K+ channel to be identified 
came from the cloning of the SHAKER gene of Drosophila sp. which causes flies to shake when exposed 
to ether (Choe, 2002). However, ion channels have been found also in bacterial, archaeal, and eukaryotic 
cells (both plant and animal cells) since their amino acid sequences are very easy to recognize because 
K+ channels contain a highly conserved segment called the potassium signature sequence [G(Y/F)GD] 
(Papazian et al., 1987; Aiyar et al., 1996). This sequence forms the structural element known as the 
selectivity filter, which prevents the passage of sodium ions, even when this ion is smaller, and allows 
potassium ions through the ion channel pore at rates approaching the diffusion limit.  
The resolution of KcsA structure, a non-voltage-gated potassium channel in Streptomyces lividans, 
resulted in an essential advance in the knowledge and comprehension of the ion permeability mechanism 
across the ion channels (Doyle et al., 1998), since it was obtained a detailed image of the potassium 
conductance mechanism (Morais-Cabral et al., 2001; Zhou et al., 2001). Based on their molecular 
architecture, different channel classes were distinguished (Figure 1) (Catterall, 1988; Sigworth, 1994; 
Snyders, 1999; Swartz, 2004). The simplest structural type of K+ channels is visible in the 2TM/1P class, 
named after their typical composition of two transmembrane helixes (TM) and one P-loop (P), and is 
represented by the inward rectifier K+ channels (Kir) (Figure 1A). The second group is referred to voltage-
gated K+ channels (Kv), which are composed by six TM (S1-S6) and one P-loop, resulting in the 6TM/1P 
class (Figure 1B). The two-P K+ channels family is constituted by the non-voltage-gated outward rectifier 
channels that have eight TM architecture containing two P-regions per subunit (8TM/2P, Figure 1C) and 
the class of the so-called “background” or “leakage” channels made up of two P-regions, hence 
structurally referred to as 4TM/2P type (Roden & George, Jr., 1997; Hille, 2001) (Figure 1D). KcsA 
belongs to the ion channels conformed by two transmembrane segments (2TM) and one P-loop (1P) or 
2TM/1P channels, in which, the 2TM are related with the fifth and sixth transmembrane domains in Kv 
channels (Benavides-Haro et al., 2003). 
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Figure 1: The four main classes of potassium channels. A, 2TM/P channels (which consist of two 
transmembrane (TM) helices with a P-loop between them), exemplified by inwardly rectifying K+ channels and by 
bacterial K+ channels such as KcsA. B, 6TM/P channels that are the predominant among ligand- and voltage-gated 
K+ channels. C, 8TM/2P channels, which are hybrids of 6TM/P and 2TM/P, and were first found in yeast. D, 4TM/2P 
channels, which consist of two repeats of 2TM/P channels. 8TM/2P and 4TM/2P probably assemble as dimers to 
form a channel. 4TM/2P channels are far more common than was originally thought. These so-called 'leakage' 
channels are targets of numerous anesthetics. S4 is marked with plus signs to indicate its role in voltage sensing in 
the voltage-gated K+ channels [taken from (Choe, 2002)]. 
 
To date, twelve different subfamilies of Kv channels subunits have been described (Kv1-12) 
(Goldstein et al., 2001; Gutman et al., 2005). Kv channels are formed by co-assembly of four α subunits, 
each containing six α-helical TM segments (S1-S6), with both N- and C-termini on the intracellular side of 
the membrane. Each subunit comprises two membrane-integrated functionally distinct modules; one forms 
the voltage-sensor (S1-S4) and the other the K+ selective pore with the gate (S5-P-S6) (Figure 2A).  
In the cytoplasmic side there is a specific sequence of amino acids in the N-terminus of voltage-
gated K+ channel proteins responsible for channel inactivation as well as for recognition between voltage-
gated K+ channel subunits. This sequence supervises the proper assembly of specific tetrameric channels 
(Li et al., 1992) and it is called tetramerization domain, “T1” (Shen et al., 1993) (Figure 2B). This domain 
determines the specificity of channel subunit assembly and also serves as a platform for binding of 
auxiliary Kv cytoplasmic β-subunits. The cytoplasmic C-terminus of Shaker K+ channels has no obvious 
domain structure. By contrast, other Kv channels are characterized by the presence of a subunit assembly 
domain and/or a sensor domain in the C-terminus. These include Kv7 and Kv10-12 channels, as well as 
potassium channels gated by voltage and intracellular Ca2+ (e.g. KCa1 channels) and channels gated 
exclusively by intracellular ligands like Ca2+ (e.g. KCa2 channels) (Figure 2C). The auxiliary subunits 
known to be associated with this family (KCNE) are transmembrane proteins that appear to be intimately 
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associated with the pore domain and may displace the voltage-sensor domain or interact with it directly 
(Deal et al., 1996; Kurokawa et al., 2001; Yellen, 2002; Barros et al., 2012). 
A
B
C
 
Figure 2: Summary of structural components of Kv channels. A, Schematic representation of the tetrameric 
organization of a Kv channel. A structural folding model of one of the four α-subunits is shown on the right. B, 
General organization of the Kv1–Kv4 channels group with the T1 “tetramerization domains” hanging centrally below 
the transmembrane core and attached to it through four linkers continued from the first transmembrane helices. In 
this case, the C-terminal structures probably track to the periphery surrounding T1 and extending to its bottom. C, 
General cytoplasmic architecture of the Kv7 and Kv10–Kv12 channels characterized by a C-terminus (i.e., the C-
linker/CNBD region of the Kv10–Kv12 channels or the A–D helical regions of the Kv7 channels) forming a compact 
tetrameric structure in a central position immediately below the cytoplasmic pore opening. In this case the N-terminus 
probably surrounds the C-terminus and extends to its bottom establishing extensive contacts with its top and side 
surfaces. Note that in both models the initial N-terminal structures are likely to interact with the gate surroundings in 
the transmembrane core. S4 segment is also depicted as a reference [adapted from (Barros et al., 2012)]. 
 
1.2.1.  The voltage sensor 
For Kv channels, very small changes in the voltage membrane of the cell (Sigworth, 2003) 
determine whether they are opened or closed, and therefore, they provide a way for the membrane 
voltage to feed back onto itself, a key property for generating electrical impulses (Hodgkin & Huxley, 
1952). Although the role of the voltage sensor has been classically attributed to the S4 segment (Jiang et 
al., 2003), different reports have revealed that the S1-S4 region acts as the voltage-sensor of Kv channels 
(Papazian et al., 1991; Seoh et al., 1996; Peyser & Nonner, 2012) (Figure 3). Thus, the S4 segment, 
which exhibits four-eight positively charged residues (Stuhmer et al., 1989; Bezanilla, 2000) is the major 
component of the sensor for gating, although charged amino acids present in S1, S2 and S3 also 
contribute to this process. S3 is formed by two helixes referred to as S3a and S3b (Figure 3). In all crystal 
structures determined, S3b forms together with S4 a helix-turn-helix structure called the voltage-sensor 
paddle (Bezanilla & Stefani, 1998; Long et al., 2005a; Chanda & Bezanilla, 2008). Depolarization of the 
cell membrane causes a physical outward movement of S4, which has been electrically monitored as the 
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gating current (Mannuzzu et al., 1996; Bezanilla & Stefani, 1998), or also by means of fluorescence (Tao 
et al., 2010). This movement induces further conformational changes that open the channel pore and 
permit selective K+ permeation (Tristani-Firouzi et al., 2002).     
A B
C D
 
Figure 3: Schematic view of the voltage-sensor of K+ channels. A, View of the voltage sensor and S4-S5 linker 
helix of the open conformation from Kvchim. Side chains of the positively charged residues on S4 (labeled as R0, R1, 
R2, R3, R4, and K5) and the negatively charged residues forming ionizing hydrogen bonds (dashed black lines) with 
the positive charges, as well as those of the three residues (labeled F, E, and D) forming an occluded binding site in 
the voltage sensor, are shown as sticks and colored according to atom types (yellow, carbon; blue, nitrogen; red, 
oxygen; and green, phenylalanine) [taken from (Moreno, 2013)]. B, Scheme of the modulation of the K+ ion channel. 
The pore-forming unit is shown in orange and the four surrounding VSDs in green with S1–S4 labeled in one subunit 
[taken from (Borjesson & Elinder, 2008)]. C, Structure of the of Kv1.2 channel, determined by x-ray crystallography 
[taken from (Long et al., 2005b)]. The voltage-sensing and pore-forming modules of two subunits are indicated in a 
cross-section through the structure normal to the plane of the membrane. Note the labels indicating that the voltage-
sensing module of subunit 4 interacts with the pore-forming module of subunit 1 (left) while the voltage-sensing 
module of subunit 2 interacts with the pore-forming module of subunit 3 (right). Transmembrane segments are 
colored: S1, dark blue; S2, light blue-green; S3, light green; S4, dark green; S5, yellow-green; S6, orange. The S4-
S5 linker covalently connecting pore-forming and voltage-sensing modules are highlighted in magenta. Positions of 
the Cβ atoms of gating charge-carrying arginines in S4 (labeled as R1 through R4 and colored in purple) and 
negatively charged residues in S2 (labeled E1 (for An1) and E2 (for An2) and colored in brown) are shown in sphere 
representation. D, Rosetta membrane resting state model of Kv1.2 channel. The model is colored and labeled as in 
panel C. [C and D panels taken from (Catterall, 2010)]. 
 
1.2.2.  The selectivity filter and the ion pore 
The essential role of K+ channels is selectively conducting K+ ions across the cell membrane. The 
atomic radius of K+ is 1.33 Å and that of Na+ is 0.95 Å. Instead of this difference, K+ channels has to be 
capable to select K+ over Na+ ions and these channels do it by a factor of more than 1000. Moreover, this 
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strong selectivity for K+ is achieved without compromising the rates of conduction, which approach the 
diffusion limit. The K+ channel pore is comprised of four usually identical subunits that encircle with four-
fold symmetry a central ion conduction pathway (MacKinnon, 1991; Doyle et al., 1998; Zhou et al., 2001). 
The first K+ channel to be crystallized was the bacterial KcsA channel (Figure 4). Each subunit contains 
two fully transmembrane α-helices termed inner (nearest the ion pathway) and outer (nearest the 
membrane) helixes (equivalent to S5 and S6 of Kv channels), and a tilted pore loop or ‘P-loop’ that runs 
half way through the membrane, pointing its C-terminus negative charge toward the ion pathway 
(MacKinnon, 1991). A stretch of eight amino acids within the pore loop is responsible for potassium 
selectivity (Heginbotham et al., 1992). In addition, as it can be seen in the Figure 4, three ions appear in a 
queue within the pore, a result predicted more than 40 years earlier by Alan Hodgkin and Richard Keynes 
(Hodgkin & Keynes, 1955; Hille et al., 1999). Near the midpoint of the membrane, the ion pathway is 
nearly 10 Å in diameter, forming a central water-filled cavity. Indeed, the design of the potassium channel 
includes this water-filled cavity to raise the dielectric constant at the membrane center, and oriented α-
helices to provide favorable electrostatic interactions (Hille et al., 1999). In this way, an hydrated K+ ion 
remains suspended at the center of the cavity in the crystal structure (MacKinnon, 2003). Potassium 
channels remove the hydration shell from the ion when it enters the selectivity filter. The selectivity filter is 
formed by five residues (TVGYG-in prokaryotic species) in the P-loop from each subunit, which have their 
electro-negative carbonyl oxygen atoms aligned towards the center of the selectivity filter of the ion pore 
and form an anti-prism similar to a water-solvating shell around each potassium binding site. The distance 
between the carbonyl oxygen and the potassium ions in the binding site of the selectivity filter is the same 
as between water oxygen in the first hydration shell and a potassium ion in water solution, providing an 
energetically favorable route for de-solvation of the ions. On the contrary, passage of sodium ions would 
be energetically unfavorable, since the strong interactions between the filter and pore helix that would 
prevent the channel from collapsing to the smaller sodium ion size. The selectivity filter opens towards the 
extracellular solution, exposing four carbonyl oxygens to a glycine residue. The next residue towards the 
extracellular side of the protein is the negatively charged Asp80 (in KcsA). This residue, together with the 
five filter residues form the pore, connects the water-filled cavity in the centre of the protein with the 
extracellular solution. The result is that K+ enters the channel easily, whereas Na+ does not (Doyle et al., 
1998). 
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Figure 4: The ion conduction pore of K+ channels. A, Two of the four subunits from the KcsA pore are shown 
with the extracellular side on top. Each subunit contains an outer helix close to the membrane, an inner helix close 
to the pore, a pore helix (red) and a selectivity filter (gold). Blue mesh shows electron density for K+ ions and water 
along the pore. B, Close-up view of the selectivity filter with dehydrated K+ ions at positions 1 through 4 (external to 
internal) inside the filter and a hydrated K+ ion in the central cavity below the filter. C, Electron density in the filter 
corresponds to two configurations of K+ ions (green) alternating with water molecules (red): 1,3 contains K+ at 
positions 1 and 3, 2,4 contains K+ at positions 2 and 4 [taken from (MacKinnon, 2003)]. 
 
Potassium selectivity is determined by the selectivity filter, located in the extracellular third of the 
ion pathway, between the central cavity and the extracellular solution. The K+ channel signature 
sequence amino acids [G(Y/F)GD] (Papazian et al., 1987; Aiyar et al., 1996; Doyle et al., 1998), 
conserved in K+ channels throughout the phylogeny, form the selectivity filter. Here, K+ ions bind in an 
essentially dehydrated state, surrounded by eight oxygen atoms from the protein, four ‘above’ and four 
‘below’ each ion. The arrangement of protein oxygen atoms surrounding each binding site in the 
selectivity filter mimics the hydrated K+ ion observed in the central cavity. Potassium ions are therefore 
able to diffuse from water into the selectivity filter where the energetic cost of dehydration is 
compensated. Sodium ions, on the other hand, do not seem to enter the selectivity filter in crystal 
structures even when Na+ is present in vast excess (Zhou et al., 2001; Zhou & MacKinnon, 2003). It is 
also important to remark that the structure of Kv channels differs from that of the non-voltage-gated 
bacterial potassium channel KcsA due to a sharp-bend in the S6 helices (equivalent to the inner helices 
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of the KcsA channel). This bend occurs at a Pro-X-Pro sequence that is absolutely conserved in the Kv1-4 
family of channels, but it was not found in KcsA (del Camino et al., 2000; del Camino & Yellen, 2001). 
 
1.3. MODULATORY SUBUNITS 
 
The diversity of Kv channels structure and function is enhanced by heteromultimerization of 
different α-subunits and also by the effects of accessory β subunits (Tamargo et al., 2004). Although the 
assembly of these regulatory subunits with the pore-forming α-subunit is not mandatory to form the ion 
channel, they form complexes with the α-subunit that modify their electrophysiological characteristics. 
Therefore, recapitulation of the physiological features of the native K+ current frequently requires the 
introduction of the actions of accessory β-subunits. K+ channel β-subunits represent a diverse molecular 
group, which includes cytoplasmic proteins (Kvβ1-3; the K Channel Interacting Protein or KChIP, mainly 
associated with Kv4 family; and the K Channel Associated Protein or KChAP) that interact with the 
intracellular domains of Kv channels; and transmembrane proteins, such as KCNE1 and KCNE2 subunits 
encoded by the KCNE gene family with 1TM; DPPX proteins or dipeptidil-aminopeptidases CD26-related 
also with only 1TM; and, on the other hand, proteins like K+ channel regulator protein 1 (KCR1) for Kv10.1 
channels, or the sulfonylurea receptors (SUR) for the inward rectifiers Kir6.1-6.2, with 12TM (Tamargo et 
al., 2004; Pongs & Schwarz, 2010). Moreover, coexpression of β subunits with α-subunits regulates cell 
surface expression, gating kinetics and drug-sensitivity of K+ channels. Most Kvβ2 subunits assemble with 
α-subunits giving rise to a α4β4 complex (Orlova et al., 2003; Gonzalez et al., 2010). However, it has been 
described that the Kvβ1 family (like the Kvβ subunit in which this Doctoral Thesis is focused) is consistent 
with the α4βn model (where n equals 0, 1, 2, 3, or 4) depending upon the relative concentration of alpha 
and beta subunits (Xu et al., 1998). Kv channels play critical roles in the electrical responses throughout 
the cardiovascular system, being responsible for establishing the resting membrane potential and cellular 
repolarization in heart and peripheral vascular beds (Nelson & Quayle, 1995; Nerbonne & Kass, 2005; 
Jackson, 2005).  
1.3.1. Kvβ subunits 
The Kvβ subunits are cytoplasmic proteins with a molecular weight of ~40 kDa. The proteins β1, β2, 
and β3 are encoded by different genes, and additional variability is produced by alternative splicing of the 
KCNAB1 gene on the N-terminal region, which generates the Kvβ1.3 subunit in which is based this 
Doctoral Thesis (England et al., 1995a; Pongs et al., 1999). These Kvβ subunits are aldo-keto reductase 
proteins forming a sensor of the redox state into the cell (Majumder et al., 1995; Bahring et al., 2001; 
Weng et al., 2006). As it was confirmed by its crystal structure, Kvβ2 is an oxidoreductase enzyme 
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complete with a nicotinamide co-factor (NADP+) in its active site which is structurally competent to mediate 
hydride transfer chemistry (Gulbis et al., 1999). Therefore, these subunits may result relevant for the 
coupling between the cellular redox state and channel activity (Bahring et al., 2001; Tipparaju et al., 2005; 
Tipparaju et al., 2007; Pan et al., 2011). As stated above, Kvβ proteins follow the α4βn model (where n 
equals 0, 1, 2, 3, or 4) depending upon the relative concentration of alpha and beta subunits (Xu et al., 
1998). The C-termini of the Kvβ bind to the T1 domains of the α-subunits, which form a docking platform 
for these subunits (Gulbis et al., 2000) (Figure 2). Along to modulating the channel activity at the cell 
surface, Kvβ subunits control the surface expression of the α-subunit (Shi et al., 1996) as well as the 
inactivation kinetics of the channels which interact with. Indeed, some beta subunits modify the slow 
inactivation kinetic of those channels which interact with, from a slow inactivation to another much faster 
inactivation (Majumder et al., 1995; Morales et al., 1995; Uebele et al., 1998). 
Table 1. Biophysical properties and characteristics of Kvβ subunits [taken from (David, 2009)]. 
 
MODULATORY Kvβ SUBUNITS 
 
β subunit 
 
Gene and 
chromosome 
 
Interacting 
channel 
 
Expression 
 
Functions 
 
Kvβ1 
 
KCNAB1; 
Chromosome 3; 3q26.1 
 
Kvα1 
 
Heart  
Brain 
 
Induces fast inactivation 
Increase the surface 
expression of the channel 
 
Kvβ2 
 
KCNAB2; 
Chromosome 1; 1p36.3 
 
Kvα1 
Kvα4 
 
Nervous system 
T-Lymphocytes 
 
Increase the surface 
expression of the channel 
 
Kvβ3 
 
KCNAB3; 
Chromosome 17; 
17p13.1 
 
Kvα1.2 
Kvα1.3 
Kvα1.4 
Kvα1.5 
 
Human heart 
Rat brain 
 
Induces fast inactivation 
Increase the surface 
expression of the channel 
Enhances the slow 
inactivation of the 
channel 
 
The interaction of Kv1 α-subunits and Kvβ subunit polypeptides is an early event in Kv1 
biosynthesis, occurring in the endoplasmic reticulum (Shi et al., 1996; Nagaya & Papazian, 1997). Despite 
dramatic differences in their effects on channel gating (Table 1), each Kvβ subunit displays robust 
trafficking effects. Indeed, Kvβ1.1, β1.2, β2, and β3 subunits increase the membrane expression and the 
mature form of Kv1.2 when they are co-expressed (Shi et al., 1996; Nagaya et al., 1997).  
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Therefore, although some cytoplasmic Kv1 channel β-subunits modify the inactivation kinetics of 
the α-subunits, a more general and perhaps more important role is to mediate the biosynthetic maturation 
and surface expression of Kv channel complexes. 
 
1.4 OTHER K+ CHANNEL MODULATORY SUBUNITS 
 
The LGI1 gene (Chernova et al., 1998), carries four and a half tandem repeats of a leucine rich 
repeat motif at the N-terminal end and is a secreted protein (Senechal et al., 2005). Lgi1 acts through its 
cell receptors which have been defined so far as the disintegrin and metalloprotease (ADAM) members 22 
and 23 (Kunapuli et al., 2009) and the Nogo receptor 1 (Thomas et al., 2010). ADAM 22/23 molecules do 
not carry metalloproteinase domains and appear to be involved in cell adhesion (Liu et al., 2009). The 
Nogo-66 receptor family (NgR) consists in three glycophosphatidylinositol (GPI)-anchored receptors 
(NgR1, NgR2 and NgR3), which are primarily expressed by neurons in the central and peripheral 
mammalian nervous system and they are involved in neurodegenerative diseases (Borrie et al., 2012).  
It has been described that Lgi1 protein interferes with Kvβ1-conferred inactivation of Kv1 channels, 
suggesting that can modulate the gating of Kv1 channels although the molecular basis of the Lgi1 effect on 
Kv1 channel inactivation is presently unknown (Schulte et al., 2006). Even when Kvβ1.3 and Kv1.5 subunits 
are expressed in human myocardium, none current with the Kv1.5-Kvβ1.3 phenotype have been registered 
in any territory of the human heart. A possible explanation could be that a given protein present in this 
tissue modifies the Kvβ1.3 activity. Lgi protein has four different isoforms (Lgi1-4) and it has been reported 
that they are expressed in the human heart (Gu et al., 2002). In addition, Lgi1 mutations have been linked 
to certain types of epilepsy, some of them associated to autonomic symptoms (visceral/epigastric and 
cardiac palpitations) that occurred in 45% of patients (Ottman et al., 1995). Also, it has been demonstrated 
that its differential expression in mice, reults in a model of cardiac hypertrophy (Mohamed et al., 2012). 
Unfortunately, the role of Lgi1 at this level is unknown at the present time. 
 
1.5 Kv1.5 CHANNELS 
 
Kv1.5 channel is a ‘Shaker-like’ K+ channel (Papazian et al., 1987), that was first cloned from 
human ventricle (Tamkun et al., 1991) and then from atrium (Fedida et al., 1993). Kv1.5 channels deserve 
special mention since their activation generates an atria-selective current of the human cardiac atrial 
repolarization (IKur) (Snyders et al., 1993; Wang et al., 1993; Fedida et al., 1993; Mays et al., 1995; Ravens 
& Wettwer, 2011), despite mRNA and protein expression of Kv1.5 has been described both in atria and 
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ventricle (Mays et al., 1995) (Figure 5). This channel is encoded by the KCNA5 gene; and, very recently, it 
has been proposed that both gain- and loss-of-function mutations in this gene enhance atrial fibrillation 
(AF) susceptibility (Christophersen et al., 2013). Beside of the location of these channels at the 
intercalated disks (Mays et al., 1995), a pattern which is disrupted after ischemic damage (Tamargo et al., 
2004), these channels have also been identified in vascular smooth muscle cells (Nelson & Quayle, 1995; 
Archer et al., 1998; Cogolludo et al., 2003), where they play a pivotal role in maintaining the resting 
membrane potential as well as in the response to hypoxia and different vasoactive agents, such as nitric 
oxide, endothelin-1, angiotensin-II or serotonin (Nelson & Quayle, 1995; Zhao et al., 1997; Shimoda et al., 
1998; Hayabuchi et al., 2001; Cogolludo et al., 2003; Cogolludo et al., 2006; Iwata et al., 2014). In 
addition, they are expressed in many other tissues, including pulmonary arteries (Wang et al., 1997), 
skeletal muscle (Matsubara et al., 1994), brain (Swanson et al., 1990), and immune cells (Jou et al., 1998; 
Villalonga et al., 2010). Kv1.5 are also involved in the maintenance of vascular smooth muscle tone, 
glucose-stimulated insulin release by β-pancreatic cell, cell volume regulation and cell growth (Hille et al., 
1999). Their important role in the cardiovascular system explains why Kv1.5 channels are potential targets 
for the development of new drugs useful in the treatment of several diseases like atrial fibrilation (AF) or 
chronic hypoxic pulmonary hypertension (Michelakis et al., 2002; Pozeg et al., 2003; Cogolludo et al., 
2006; Cogolludo et al., 2009). 
 
Figure 5: Inward depolarizing and outward repolarizing currents that underlie the atrial and ventricular 
action potential. Inward currents: INa sodium current; ICa,L L-type calcium current; Ito transient outward current; IKur 
ultra rapidly activating delayed rectifier current; IKr and IKs rapidly and slowly activating delayed rectifier current; IK1 
inward rectifier current; IK,ACh acetylcholine-activated potassium current. Note that IKur is present in atria only. Phase 
0, rapid depolarization; phase 1, rapid early repolarization; phase 2, slow repolarization (‘plateau’ phase); phase 3, 
rapid late repolarization; phase 4, resting membrane potential [Adapted from (Ravens & Cerbai, 2008)]. 
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Heterologous expression of Kv1.5 results in an outward current with a midpoint for activation 
potential of ≈0 mV (Snyders et al., 1992; Snyders et al., 1993; Fedida et al., 1993; Valenzuela et al., 
1995a). Kv1.5 channels display outward rectification and very slow inactivation during strong 
depolarizations. At room temperature, current activates rapidly at potentials between 0 and +60 mV (τact 
<10 ms) and inactivates slowly and partially, i.e. by 10-20% after 250 ms at +60 mV. Temperature-
dependent inactivation follows a bi-exponential slow time course with time constants of ≈240 and 2700 ms 
(Valenzuela et al., 1996; Amos et al., 1996; Macias et al., 2010). Kv1.5 channel subunits can assemble as 
homo- or heterotetramers (Coetzee et al., 1999; Villalonga et al., 2010; Moreno et al., 2013) through T1 
domain as well as the first transmembrane segment (S1) (Babila et al., 1994). In addition, they can 
associate with different β subunits, increasing the diversity of potassium currents in the human 
myocardium and other tissues (Coetzee et al., 1999; Moreno et al., 2013), which is further increased 
because the expression pattern of the channel subunits (α and β) is distinct between different tissues 
(myocardium vs. vascular smooth muscle) and between different regions within the same tissue 
(ventricular endocardium vs. ventricular epicardium) (Rhodes et al., 1995; Shamotienko et al., 1997; 
Martens et al., 1999; Abbott et al., 2007; Qin et al., 2012). Even more, the expression pattern of both α 
and β subunits can be altered in different pathologies, which may lead to dramatic changes in the 
electrophysiological characteristics of a given Kv current. Gating kinetics, together with the relative 
expression levels of each Kv channel type in a particular cell, are determinants of the action potential 
characteristics. Therefore, in order to design more clinically useful drugs we need to understand how the 
alpha subunits generate Kv currents and how different effectors facilitate and influence subunit assembly 
and trafficking, as well as channel regulation (regulatory subunits, enzymes and other modulators) (Abbott 
et al., 2007; David et al., 2012). 
1.5.1.   Kv1.5 pharmacology  
Kv1.5 channels deserve special mention in the cardiac pharmacology since their activation 
generates an atria-selective current (it is absent in ventricle). Thus, Kv1.5 channels are considered drug 
targets with antiarrhythmic potential (Ravens et al., 2013). The anticipated antiarrhythmic mechanism of 
IKur blockers is the prolongation of the atrial action potential duration (APD) and effective refractory period 
(ERP) without any effect on QT-interval (Amos et al., 1996; Li et al., 1996; Caballero et al., 2001; Matsuda 
et al., 2001; Knobloch et al., 2002; Brendel & Peukert, 2003). For these reasons, IKur has received a lot of 
interest as a potential drug target for the development of new antiarrhythmic drugs effective in the 
treatment of AF (Ford & Milnes, 2008; Tamargo et al., 2009; Ravens, 2010; Ravens & Wettwer, 2011) 
and/or atria flutter without the risk of ventricular proarrhythmia (Brendel & Peukert, 2003). Indeed, 
numerous compounds have been screened for high Kv1.5 selectivity against all major cardiac ion 
channels, electrophysiologically characterized in isolated cardiomyocytes and cardiac tissue, and tested 
for their antiarrhythmic activity in various animal models of AF (Ravens et al., 2013). The pharmacological 
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characterization of this channel revealed that IKur is almost insensitive to external TEA (Snyders et al., 
1993; Grissmer et al., 1994), Ba2+ and class III antiarrhythmics of the methanesulfonanilide group 
(Grissmer et al., 1994; Feng et al., 1997), but is highly sensitive to 4-AP and internal TEA (Snyders et al., 
1993; Wang et al., 1993; Grissmer et al., 1994; Wang et al., 1995). Despite these efforts, proof-of-concept 
of antiarrhythmic efficacy in human is still lacking. In order to fill this gap, a ‘first-in-human’ study was 
recently reported with the highly selective IKur blocker MK-0448 (Pavri et al., 2012). However, the question 
of whether or not IKur block is effective in pharmacological conversion of recent onset AF into SR and/or 
reducing AF burden by maintenance of SR remains unanswered. 
Kv1.5 channels are also very sensitive to block produced by antiarrhythmic drugs and local 
anesthetics which are weak bases that predominate in their cationic form at physiological pH. The neutral 
form of these drugs crosses the lipid membrane establishing an equilibrium between the external and the 
internal side of the cell membrane. These drugs dissociate (both at the external and at the internal side of 
the membrane) into their cationic forms establishing an equilibrium that will depend on the pH. The active 
form of these drugs is the cationic form that binds from the inside of the membrane to a receptor site 
located at the internal mouth of the ionic pore (Snyders et al., 1992; Valenzuela et al., 1995a; Valenzuela 
et al., 1996; Franqueza et al., 1997; Valenzuela et al., 1997). It has been proposed that most of the critical 
residues for hydrophobic binding of quinidine in the Kv1.5 channel are aligned on one side of the putative 
S6, so that it is hypothesized that this region is the pore-lining one and is important in determining drug 
affinity and specificity (Snyders et al., 1992). Stereoselective bupivacaine block of Kv1.5 channels 
(Valenzuela et al., 1995b) is determined by a polar interaction with T507 and two hydrophobic interactions 
at positions L510 and V514 (Franqueza et al., 1997). The length of the alkyl substituent at position 1 of 
bupivacaine-related local anesthetics determine their potency and stereoselectivity, likely because this 
alkyl chain interacts with a hydrophobic residue (L510) in the S6 of the channel (Longobardo et al., 1998). 
In contrast, at low concentrations, uncharged-neutral as benzocaine (Delpon et al., 1999; Caballero et al., 
2002), nifedipine (Zhang et al., 1997), loratadine (Delpon et al., 1997) and negatively charged drugs as 
angiotensin II type 1 receptor antagonists (Caballero et al., 2000; Caballero et al., 2001; Moreno et al., 
2003) modify the gating properties of Kv1.5 channels without obvious blockade. At higher concentrations, 
these drugs produce a voltage-dependent block, but their voltage-dependence is exactly a mirror image of 
that observed in the presence of cationic drugs (Fedida, 1997; Franqueza et al., 1998; Caballero et al., 
2001). Furthermore, the residues in the S6 segment that determine the binding of quinidine and 
bupivacaine also determine the binding of neutral and acid drugs [benzocaine (Caballero et al., 2002)] 
suggesting the existence of a common receptor site at the channel level (Decher et al., 2004). The 
involved residues face towards the central cavity and overlap with putative binding sites for other blockers 
and Kv channels, like Kv10.1 and Kv7.1, suggesting a conservation of drug binding sites among different K+ 
channel families (Tamargo et al., 2004). However the pharmacology of these channels can be modified by 
the presence of variations in their structure like polimorfism (Drolet et al., 2005; Simard et al., 2005) or 
Introduction 
 
16 
 
their assembly with modulatory subunits, such as the Kvβ1.3 subunit, which explains itself why in the 
presence of this modulatory protein the potency of bupivacaine and quinidine block of these channels is 
reduced, as well as the degree of stereoselective block (Gonzalez et al., 2002; Arias et al., 2007). It has 
been also reported that there exists an external binding site for the cationic form of bupivacaine, although 
its molecular nature is unknown (Longobardo et al., 2000; Longobardo et al., 2001). 
1.5.2.   Kv1.5 recycling 
The complexes conformed by Kv1.5 and Kvβ subunits are assembled at an early stage of channel 
synthesis in the endoplasmic reticulum. Channel density at the cell surface, with or without β subunits, is a 
function of the equilibrium between trafficking to the surface and internalization dynein motor-dependent 
(Choi et al., 2005). The fate of internalized Kv1.5 channels can be controlled by punctual residues located 
in the channel-pore domain (Manganas et al., 2001), as well as by post-translational modifications 
including phosphorylation (Holmes et al., 1996; Kwak et al., 1999a; Kwak et al., 1999b; Nesti et al., 2004), 
sumoylation (Benson et al., 2007), thioacylation (Zhang et al., 2007), or modulation by PKA (Mason et al., 
2002) and PKC (Williams et al., 2002). 
The Kv1.5 channel recycling is highly controlled by specific Rab-GTPase. Thus, the internalization 
of the channel is carried out via Rab5 and it is rapidly targeted for recycling to the plasma membrane 
although a fraction of the channels are Rab7-targeted for degradation (Zadeh et al., 2008). A fraction of 
Kv1.5 channels on the cell membrane is rapidly internalized with a half time of ≈10 min and some of the 
channels return quickly to the surface membrane with a half time of ≈30 min, and also with a slower 
recycling rate 2 h<τ<24 h, Rab4- and Rab11-meadiated respectively (McEwen et al., 2007).  
Specific concentration- and time-dependent internalization of Kv1.5 channels with possible 
permanent degradation of channels after long-term treatment, may also contribute to IKur reduction in 
therapy with conventional antiarrhythmic drugs, e.g. quinidine (Schumacher et al., 2009). Surprisingly, 
within the Kv1.5 channel protein there is partial, but not complete, overlap in the binding sites required for 
quinidine-induced internalization and pore block and this fact highlight again the possibility for 
development of new agents that specifically enhance Kv1.5 channel internalization as an alternative and 
potentially beneficial new therapeutic strategy (Schumacher & Martens, 2010). Therefore, it would be of 
interest to determine how this system is used by the heart to modulate the expression of Kv1.5 and other 
ion channels as a mechanism to regulate cardiomyocyte excitability, and how other channels are affected 
by perturbations of retrograde trafficking. It is also possible that in certain disease states associated with 
channel remodeling, like atrial fibrillation and congestive heart failure, the trafficking or endocytosis 
mechanisms described above may be of key importance in determining the final population of surface-
expressed channels. For example, it has been reported that microtubule abundance is increased in the 
myocytes of patients with congestive heart failure (Aquila et al., 2004). 
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1.5.3.   Kv1.5-mediated channelopathies 
Although AF is not primarily considered an inheritable disease, recent epidemiological studies have 
provide evidence that gene polymorphisms may substantially enhance disease susceptibility 
(Gudbjartsson et al., 2007; Kaab et al., 2009; Ellinor et al., 2010; Fedele et al., 2013). A few cases of 
familial AF have been associated with genetic abnormalities relating to mutations in genes encoding for 
ion channels (Lubitz et al., 2009). Patients with ‘lone’ AF lack heart disease or risk factors. Screening 
these patients for genetic aberration revealed a nonsense mutation in KCNA5 in one patient with familial 
AF, which is absent in several hundred unrelated control individuals. When this mutation is heterozygously 
expressed, the defective gene encodes for a truncated Kv1.5 channel that fails to generate IKur (Olson et 
al., 2006). Absence of IKur may excessively prolong atrial APD with an enhanced risk of early after-
depolarizations that can trigger and/or maintain AF. Three further KCNA5 loss-of-function mutations have 
been recently reported in 4 of the 120 unrelated AF families (Yang et al., 2009; Christophersen et al., 
2013). 
 
1.6 Kv1.5-Kvβ1.3 CHANNELS: CHARACTERISTICS AND MODULATION 
 
Until now, a large number of β subunits, able to modify Kv1 channels, have been cloned from brain 
(Scott et al., 1994; Rettig et al., 1994; Heinemann et al., 1995) and heart (Majumder et al., 1995; Morales 
et al., 1995; England et al., 1995a; England et al., 1995b). Based on the high homology between their 
sequence, these regulatory β subunits have been classified into three subfamilies: Kvβ1, Kvβ2 and Kvβ3 
(England et al., 1995b). The assembly between alpha and beta subunits is produced through specific 
domains at the N-terminus of the alpha subunit and the C-terminus of the β subunit. The sequences of the 
C-termini of β subunits are highly conserved, with the greatest differences in the N-termini (Yu et al., 1996; 
Wang et al., 1996; Sewing et al., 1996). More specifically, until date three β subunits have been cloned 
from human myocardium: Kvβ1.2, Kvβ1.3 and Kvβ2.1, all of them cytoplasmic and with the ability of 
modulate Kv1.5 channels (Deal et al., 1996). Kvβ1.2 and Kvβ1.3 are products of alternative splicing of the 
same gene (KCNAB1), with an identical C-terminus. The activation kinetics of channels formed by the 
assembly of Kv1.5 and Kvβ1.2 or Kvβ1.3 was not changed in comparison with that of Kv1.5 channels. 
However, Kvβ1.x change Kv1.5 current from a typical delayed rectifier to another with an incomplete fast 
inactivation superimposed to the slow inactivation characteristic of the Kv1.5 channels. 
More specifically, Kvβ1.3 subunit interacts with Kv1.5 channel by two negatively charged residues 
on the core domain and three positively charged ones on the N terminus (Pan et al., 2011). This 
interaction provides a number of functions to the channel, including a fast and partial inactivation 
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component, which is mediated by an equilibrium binding of the N-terminus of Kvβ1.3 between PIPs and the 
inner pore region of the channel (Decher et al., 2008) that overlaps with the bupivacaine and quinidine 
binding site of the channel (Decher et al., 2005; Gonzalez et al., 2010). An enhancement of the slow 
inactivation characteristic of Kv1.5 channel, a shift of the activation curve toward more negative potentials, 
functionally distinct from the inactivation (Uebele et al., 1998); a 7-fold decrease in the sensitivity of the 
channel to the block induced by antiarrhythmic drugs and local anesthetics, and a decrease in the degree 
of stereoselective blockade (Gonzalez et al., 2002; Decher et al., 2005; Arias et al., 2007). In addition, 
interaction of Kvβ subunits with Kv1.5 controls channel trafficking to the plasma membrane (Shi et al., 
1996; Accili et al., 1997; Kuryshev et al., 2001). Kv1.5 channels are highly regulated by the adrenergic 
system, which is differentially modulated by α and β stimulation (Li et al., 1996) via PKC and protein 
kinase A (PKA), respectively (Murray et al., 1994; Kwak et al., 1999a; Kwak et al., 1999b). PKC and PKA 
activities are also required for the Kv1.5 modulation by the auxiliary subunits Kvβ1.2 and Kvβ1.3 (Kwak et 
al., 1999a; Kwak et al., 1999b; Williams et al., 2002), since their effects are abolished after removal of a 
consensus PKA phosphorylation site on the Kvβ1.3 N-terminus (S24) or following incubation with 
calphostin C, a PKC inhibitor (Kwak et al., 1999b). 
1.6.1.  PKC modulation of Kv1.5-Kvβ1.3 channels 
Kv1.5 has one consensus site for phosphorylation by PKC located on the extracellular S4–S5 linker 
and 4 consensus sites for PKA located in the N- and C-terminal domains. Isoproterenol increases IKur in 
human atrial myocytes and this effect is mimicked by direct stimulation of adenylate cyclase and 
suppressed by a PKA inhibitor peptide (Li et al., 1996). In the presence of propranolol, phenylephrine 
inhibits IKur, an effect that is prevented by the PKC inhibitor bisindolylmaleimide. These results indicate that 
β-adrenergic stimulation enhances, whereas α-adrenergic stimulation inhibits IKur and suggest that these 
effects are mediated by PKA and PKC, respectively (Tamargo et al., 2004), and therefore those kinase 
activities may have an important role in the treatment of cardiac diseases. In fact, cardiac hypertrophy is 
associated with an up-regulation of different PKC isoforms (Takeishi et al., 1999; Kerkela et al., 2002; Braz 
et al., 2002; Hahn et al., 2003). Similarly, δ-calmodulin kinase II (δ-CaMKII) expression increases during 
atrial fibrillation (Tessier et al., 1999). Furthermore, one of the most effective treatments for atrial fibrillation 
is the oral administration of β-blockers (Kuhlkamp et al., 2000), which induce a pharmacological 
remodeling that is capable of reversing the electrical dysfunction typically observed during atrial fibrillation 
(Workman et al., 2003; Valenzuela, 2003). Regarding the PKA effect, it has been proposed that the 
coexpression of both in Kv1.5 and Kvβ1.3 is required for the PKA-mediated increase in K+ current (Ravens 
& Wettwer, 2011). Indeed, the enhancing effect on Kv1.5 inactivation by coexpression of Kv1.5 with Kvβ1.3 
is attenuated when Kvβ1.3 is phosphorylated explaining the β-adrenoceptor-stimulated current increase 
(Kwak et al., 1999a).  
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Stimulation of PKC has little effect on expressed Kv1.5 channels alone. However, co-assembly of 
Kvβ1.2 with Kv1.5 enhances the response of the channel to PKC activation with a reduction in the K+ 
current (Williams et al., 2002). These results suggest that phosphorylation sites for PKC are probably 
located in the Kvβ1.2 or in a residue of the channel exposed after the association with it. It has been also 
described that PKC inhibition by calphostin C reverses the Kvβ1.3-dependent electrophysiological effects 
(Kwak et al., 1999b). However, it has been described that this effect was not observed when several 
inhibitors PKC isoforms-specific were used, was not due to a dissociation of both subunits, and the 
channel conforms a protein complex with, at least, RACK1 and PKCβII (David et al., 2012). However, the 
specific mechanism by which calphostin C produces an abolishment of the effect Kvβ1.3-meadiated 
remains unknown. 
1.6.2. PIP2 effects on Kv1.5-Kvβ1.3 
Phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2 or PIP2) is the most abundant 
phosphoinositide localized at plasma membranes of eukaryotic cells (Logothetis et al., 2010). PIP2 is a 
well-recognized lipid precursor molecule that has garnered appreciation as a regulator of many 
physiological processes in both animal and plant cells for more than three decades (Michell, 2009). Since 
the mid-1990s, when three reports of PIP2 regulation of KATP channel activity appeared (Furukawa et al., 
1996; Hilgemann & Ball, 1996; Fan & Makielski, 1997), there has been an explosion of reports 
demonstrating a dependence of the activity of most ion channels on the presence of phosphoinositides. In 
fact, co-expression of Kv1.5 channels and human thrombin or rat serotonin receptors, two receptors that 
increase phospholipase C (PLC) activity, inhibits Kv1.5 current amplitude without modifying the kinetics or 
voltage sensitivity of activation (Timpe & Fantl, 1994; Cogolludo et al., 2006). Simultaneous injection of 
inositol 1,4,5-trisphosphate and superfusion of PMA reproduces the modulation of the Kv1.5 current 
suggesting that these receptors modulate Kv1.5 channels by increasing PLC activity.  
PIP2 antagonizes N-type inactivation of Kv3.4 by binding to its N-terminal domain and immobilizing 
the inactivation ball and that removes fast inactivation of Kv1.1 channels by immobilization of Kvβ1.1 
(Oliver et al., 2004). In addition, Kvβ1.3-mediated inactivation of Kv1.5 is mediated by an equilibrium 
binding of the N-terminus of Kvβ1.3 between phosphoinositides (PIPs) and the inner pore region of the 
channel (Decher et al., 2008). 
Given the key role that membrane phosphoinositides play in regulating channel activity, it is 
important to highlight that fluctuations in intracellular PIP2 levels due to Gq-coupled receptor stimulation 
might be relevant for the inactivation of K+ channels and therefore, for electrical signaling in both heart and 
brain (Decher et al., 2008; David, 2009). Thus, it is surprising that only a small number of channelopathies 
have been linked to phosphoinositides. And, for this reason, it has been proposed that channel-PIP2 
interactions should be tested mainly in those channels whose activity is PIP2-dependent and in cases in 
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which ion channel mutations, important for that modulation lipids-mediated, can lead to channelopathies 
(Logothetis et al., 2010). 
 
1.7 PHYSIOLOGICAL ROLE: THE CARDIAC ACTION POTENTIAL 
 
The normal electrophysiological behavior of the heart is determined by the ordered propagation of 
excitatory stimuli resulting in rapid depolarization and slow repolarization, generating action potentials (AP) 
in individual myocytes. At the most generic level, abnormalities of impulse generation, propagation, or the 
duration and configuration of individual cardiac action potentials form the basis of disordered cardiac 
rhythm. These concepts evolved during the twentieth century from clinical descriptions of arrhythmias, to 
descriptions of AP in specific regions of cardiac tissue, and led to the identification of specific whole-cell 
and single-channel ionic currents whose integrated activity generates action potentials. In the past 
decade, those genes whose expression generate specific molecular components, including pore-forming 
ion channel proteins, underlying individual ion currents in cardiac myocytes were defined. K+ currents 
control the repolarization process of the cardiac action potential, determines membrane potential, the 
heart rate, myocardium refractoriness and, therefore, they represent important targets for the actions of 
neurotransmitters, hormones, drugs and toxins known to modulate cardiac function (Snyders, 1999; 
Coetzee et al., 1999; Nerbonne, 2000; Ravens & Cerbai, 2008). The cardiac ventricular action potential 
exhibits five distinct phases (Figure 6): Phase 0 corresponds to the rapid depolarization (or action potential 
upstroke) that ensures once the cell reaches the voltage threshold. At rest, the dominant membrane 
conductance is provided by the potassium channels. However, once the cell reaches a threshold level of 
approximately −65 mV, membrane sodium channels open. Hence, at threshold, the membrane rapidly 
switches from being mostly permeable to K+ to being largely permeable to Na+. The sodium current (INa) 
represents a very large and rapid transition. When the conductance to sodium suddenly increases, the 
large transmembrane gradient of Na+ leads to a rush of ions into the cell in the form of an inwardly directed 
negative INa. Thus, the membrane rapidly depolarizes, and results in the upstroke of the action potential. In 
fact, given that during this phase the cell membrane is mostly permeable to Na+, the membrane potential 
becomes transiently positive as it moves toward ENa (approximately +40 mV). However, the increase in 
sodium conductance is very brief, and after a few milliseconds, the sodium channels enter in a 
nonconductive state. The membrane potential does not reach the sodium equilibrium potential, but stops 
at approximately ≈+30 mV and then begins to repolarize. Phase 1 corresponds to the brief, rapid 
repolarization that is initiated at the end of the action potential upstroke and it is interrupted when the cell 
reaches the “plateau level” or phase 2. As shown in Figure 6, the end of the action potential upstroke is 
brought by the inactivation of the sodium channels. During the initial phase of repolarization of the action 
potential, or phase 1, potassium channels provide the dominant membrane conductance. Although there 
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can be important differences in the ionic currents that are activated at this stage, depending on the region 
of the heart from which the cells originate (and also depending on the animal species studied), in most 
cases the so-called “transient outward current” (Ito) provides most of the repolarizing charge. This rapidly 
activating potassium conductance turns on during the end of the action potential upstroke. When the 
sodium channels enter into their nonconductive state, repolarization begins in earnest, with the membrane 
potential heading toward the reversal potential for potassium. Ito inactivates also very rapidly, and its 
contribution to the repolarizing process during phases 2 and 3 of the action potential is smaller than that 
observed during phase 1. During the plateau or Phase 2 repolarization progresses very slowly. Other 
voltage dependent membrane channels are also activated by cell depolarization, although they activate at 
a slower rate (Figure 6). Consequently, these channels provide a sizable current only several milliseconds 
after the end of the action potential upstroke. The two dominant currents during the phase 2 of the action 
potential are the inward calcium current (ICa) and the delayed rectifier potassium outward current (IK), 
(including, the L-type calcium current and electrogenic sodium–calcium exchanger). The potassium 
current IK includes, at least, two separate components: a rapid component (IKr) and a slow component (IKs). 
Note that, as it was stated above, the ultrarapid component (IKur) only appears in the atrial action potential 
as it can be observed in Figure 5. Given the concentration gradient for Ca2+, opening of calcium channels 
leads to movement of calcium from the extracellular to the intracellular space (i.e., an inwardly directed, 
depolarizing current). Potassium ions, on the other hand, move in the opposite direction. The result is that, 
while the calcium channels remain open, repolarization by potassium currents is prevented by the 
presence of calcium current that is moving positive charges into the cell. Thus, during the plateau, the 
membrane potential depends on the balance between inward ICa and outward IK currents. Although in 
some cells (e.g., Purkinje fibers, Figure 6) outward currents dominate and the plateau tends to have a 
consistently negative slope, in other cells there may be an actual slight depolarization before repolarization 
continues (in a “dome like” shape). Eventually a final phase of rapid repolarization, or Phase 3, ensures it. 
Inactivation of the calcium channels leads to the end of the plateau (Figure 6). Only potassium channels 
remain active; and consequently, the membrane potential returns relatively rapidly toward EK. The delayed 
rectifier currents (IKr and IKs, and IKur in case) tend to close as the cell repolarizes, and thus the inward 
rectifier current (IK1) predominates. Finally, Phase 4 is the period between the last repolarization and the 
onset of the subsequent action potential. In atrial or ventricular myocytes, phase 4 corresponds to the 
resting membrane potential. In addition, there are differences in the expression patterns of the various 
voltage-gated K+ current in cardiac cells isolated from different species, as well as in cells from different 
regions of the heart in the same species and these distinct K+ current expression patterns contribute to 
regional differences in action potential waveforms (Figure 6). In atrial and ventricular muscle cells, the 
resting potential remains constant throughout the diastolic interval. In these cell types, the inward-rectifier 
current IK1 remains the dominant conductance at rest and it is largely responsible for setting the resting 
membrane potential. An additional small background conductance, with a more positive equilibrium 
potential, keeps the resting potential slightly more depolarized than the value estimated by the potassium 
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equilibrium potential. Atrial and ventricular myocytes remain at this level of potential until a new excitatory 
stimulus brings the membrane potential to threshold, thus eliciting a new active response. However, those 
cells which have spontaneous activity, require an hyperpolarization-activated inward current named ‘funny 
current’ or If current, also characterized by allowing both Na+ and K+ ions to pass through it. This current 
contributes to the spontaneous pacemaker activity in regions such as SA node, atrium, and AV node, and 
is believed to be a major factor in generating the pacemaker potential in Purkinje fibers (DiFrancesco, 
2010). 
Phase 1
Phase 0
Phase 2
Phase 3
A B
 
Figure 6: The cardiac action potential. A, Schematic representation of a Na+-dependent action potential [taken 
from (David, 2009)]. B, Action potential waveforms are variable in different regions of the heart. Schematic 
representation of the heart; action potential waveforms recorded in different regions of the heart are illustrated. Action 
potentials are displaced in time to reflect the temporal sequence of propagation through the heart. SA, sino-atrial; AV, 
atrio-ventricular; RV, right ventricle; LV, left ventricle [taken from (Nerbonne, 2000)]. 
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The subcellular location of signal transduction proteins, enzymes, substrates and mediators has 
been revealed as an essential feature for an optimal, fast and efficient transmission of signals either from 
the extracellular or from intracellular medium. Thus, ion channels are present, in the different tissues, 
forming signaling complexes or channelosomes. In the past decade a myriad of protein-protein 
interactions involved in intracellular signaling have been described (Hubbard & Cohen, 1993; Mochly-
Rosen, 1995; Burack & Shaw, 2000). The subcellular location of signal transduction proteins, enzymes, 
substrates and mediators has been revealed as an essential feature for an optimal, fast and efficient 
transmission of signals either from the extracellular or from intracellular medium (Pawson & Nash, 2003). 
Thus, ion channels present in the different tissues are forming signaling complexes or channelosomes. 
Inhibition of PKC prevented the Kvβ1.3-induced fast inactivation (Kwak et al., 1999b). We have recently 
demonstrated that only the inhibition of PKCβ isoforms was necessary to prevent the Kvβ1.3-induced fast 
inactivation; supporting that each PKC isoform mediates unique subcellular functions (Dempsey et al., 
2000; Jaken & Parker, 2000) depending on the substrate that they phosphorylate (Carpenter et al., 1987; 
Parker et al., 1989). In this study, we show the existence of a Kv1.5 channelosome in rat ventricle, that is 
absent in atria, in which RACK1 acts as a link between Kv1.5 channels, the membrane and the 
cytoplasmic environment. This complex is formed by, at least, Kv1.5, Kvβ1.3, RACK1, PKCβI and PKCβII. 
Interestingly, we also observed that PLC also modulates the Kvβ1.3-induced fast inactivation (Disatnik et 
al., 1994; David et al., 2012). Thus, the variety of signal transduction proteins and enzymes linked to 
RACK1 (Schechtman & Mochly-Rosen, 2001) including PKCβ (Ron et al., 1994; Csukai et al., 1997) can 
be due to its ability to act as a scaffold protein not only for PKCβ isoforms, but also for PLC (Disatnik et al., 
1994) and other regulators such as Src (Chang et al., 1998) and dynamin-1 (Rodriguez et al., 1999) 
among others. This can explain the diversity of responses generated by PKA and PKC on IKur.  
RACK1 is a scaffolding protein and a member of the WD repeat family of proteins (Mochly-Rosen 
et al., 1995). Its role in the immune system, the heart and the brain and its contribution to disease states 
such as cancer, cardiac hypertrophy and addiction has been described (Pass et al., 2001; Korzick et al., 
2001; Corsini et al., 2001; Al-Reefy et al., 2010). These proteins have a unique architectural assembly that 
facilitates protein anchoring and the stabilization of protein activity. A large body of evidence is 
accumulating which is helping to define the versatile role of RACK1 in assembling and dismantling 
complex signaling pathways from the cell membrane to the nucleus in health and disease (Ron et al., 
2013). In many RACK1-associated pathological states, aberrant RACK1 signaling, which underpins the 
condition, arises from either increased or decreased expression of the scaffolding protein (Ron et al., 
2013). Presumably, sub-optimal protein levels of RACK1 interfere with its compartmentalization and, in 
turn, hinder the formation of signaling complexes with correct stoichiometry at discrete intracellular 
locations. Thus, it is reasonable to hypothesize that the therapeutic potential of RACK1 could be realized 
by small molecules that selectively target RACK1 interacting proteins.  
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The LGI1 gene (Chernova et al., 1998), carries four and a half tandem repeats of a leucine rich 
repeat motif at the N-terminal end and is a secreted protein (Senechal et al., 2005). Lgi1 receptors that 
have been defined so far, and depending on cell context, are the disintegrin and metalloprotease (ADAM) 
members 22 and 23 (Kunapuli et al., 2009) and the Nogo receptor 1 (Thomas et al., 2010). The ADAM 
22/23 molecules do not carry metalloproteinase domains and appear to be implicated in cell adhesion 
(Liu et al., 2009), which is consistent with the suggestion that LGI1 influences cell movement and invasion 
through reorganization of the actin cytoskeleton (Kunapuli et al., 2010a). Lgi1 interferes with Kvβ1-
conferred inactivation of Kv1 channels, suggesting that Lgi1 can modulate the gating of Kv1 channels. The 
molecular basis of the Lgi1 effect on Kv1 channel inactivation is presently unknown (Schulte et al., 2006). 
We know that, even when Kvβ1.3 and Kv1.5 subunits are expressed in human myocardium, the current 
with the Kv1.5-Kvβ1.3 phenotype had not been registered in any territory human heart (atrium or 
ventricle). One possible explanation could be that a particular protein present in this tissue effect 
modification activity Kvβ1.3 subunit. Thus, we have studied the electrophysiological effects of Lgi1 on 
Kv1.5-Kvβ1.3. We observed that Lgi1 prevents the Kvβ1.3-induced fast inactivation and also that the 
current amplitude was smaller than under control conditions, effects that are due to a decreased 
expression of the channel in the cell membrane. Moreover, experiments from our laboratory demonstrate 
that Lgi1 is present in rat ventricle but not in atria, and also that Kv1.5 channel coimmunoprecipitates with 
Lgi1. Unfortunately, although it is known that Lgi1-4 isoforms are expressed in human heart, their roles at 
this level are unknown at the present time.  
The Hypothesis of the present Doctoral Thesis is that Kv1.5 channels form signaling complexes in 
which Kv1.5-Kvβ1.3 channels are regulated and physically linked to PLC, PKCβI, PKCβII and RACK1 
(David et al., 2012) and that modulation of the PKC or PLC activity may affect the electrophysiological 
and pharmacological properties of these channels. 
The Main Objective of the present Doctoral Thesis is to analyze how the inhibition of PKC 
modifies the electrophysiological and pharmacological properties of Kv1.5-Kvβ1.3 channels, as well as if 
Lgi1 is a new partner of the Kv1.5 channelosome. 
In order to achieve this Objective, our specific objectives are to analyze: 
1. The mechanisms by which PKC inhibition eliminates the Kvβ1.3-induced fast inactivation. 
2. The pharmacological consequences of PKC inhibition, by studying the effects of 
bupivacaine and quinidine on Kv1.5-Kvβ1.3 channels. 
3. The effects of the PKC inhibition on the traffic and recycling of Kv1.5 channels. 
4. The role of Lgi1 on Kv1.5-Kvβ1.3 channels.  
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3.1. BIOLOGICAL MATERIAL  
 
 The experiments performed in this Doctoral Thesis were performed in HEK293 cells, rat and human 
cardiac tissue. 
3.1.1. HEK293 cells: cellular culture  
The HEK293 cell line was obtained from the American Type Culture Collection (RocKville, MD, US) 
and cultured at 37ºC in DMEM supplemented with 10% FBS and antibiotics (1% v/v: penicillin G 100 U/mL 
and streptomycin 100 g/mL, respectively; all from Gibco) in a 5% CO2 humidified atmosphere. The 
culture cell medium was changed every 2-3 days, and the cells were briefly trypsinized every 4-5 days.  
3.1.2. Rat samples 
Rat heart samples were kindly provided by Dr. Ángel Cogolludo and Dr. Francisco Pérez-Vizcaíno 
(Universidad Complutense de Madrid), for immunoprecipitation experiments. Adults (8–12 weeks old) male 
Wistar rats, housed in a 12 h light–dark cycle animal facility and a temperature of 242°C, were used in this 
study. All procedures with animals were specifically approved by the “Ethics Committee for Animal 
Experimentation” of the Universidad Complutense de Madrid and carried out in accordance with the protocols 
issued which followed National (normative 1201/2005) and International recommendations (Directive 2010/63 
from the European Communities Council). Special care was taken in all cases to minimize animal suffering. 
3.1.3. Human samples 
Slices of human heart samples embedded in paraffin were kindly provided by Dr. Javier Regadera 
(Universidad Autónoma de Madrid), for immunohistochemistry assays performed. Myocardial samples of 
individuals without cardiovascular histories were obtained from autopsy procedures at La Paz Hospital 
(Madrid). Fully written informed consent was obtained from the family of all donors. Gross and 
histopathological study of hearts did not show acute myocardial lesions. For histopathologic procedures, 
tissues were processed by fixing in 4% buffered formaldehyde and embedded in paraffin wax. Paraffin-
embedded tissue sections were obtained from the archives of the pathology laboratories of the Hospital La 
Paz. The study protocol was approved by the respective institutional review boards and ethics committees. 
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3.2. cDNA CONSTRUCTIONS AND CELL TRANSFECTION 
 
3.2.1. pBK-Kvβ1.3-IRES-Kv1.5-HA  
This construction was made in order to be used in live cell imaging and in immunocytochemistry 
experiments, since we needed a construction which ensures that Kvβ1.3 subunit was present in all 
transfected cells and also that we can detect the presence of the channel in the membrane by the external 
side of the cell. Briefly, HA tag was digested with BlpI and AflII of a Kv1.5-HA construct kindly provided by 
Prof. DJ Snyders (University of Antwerpen, Belgium), and this cDNA fragment was exchanged, in the 
same position, within Kvβ1.3-IRES-Kv1.5 construction using the T4 DNA ligase (M1801, Promega) (see the 
scheme of this process in Figure 7). 
IRES
BlpI
AflII
IRES
BlpI
AflII
BlpI
AflII
IRES
BlpI
AflII
BlpI
AflII
 
Figure 7:  Scheme of the technique used to clone the pBK-Kvβ1.3-IRES-Kv1.5-
HA construction. Firstly, it is necessary to have unique restriction points around de 
HA-tag in the donor vector and that, at the same time, this point only cut once in the 
acceptor vector. Once we got these restriction sites, and using these enzymes, 
we exchanged the insert of interest in the acceptor vector in order to get the final 
construction, Kv1.5-HA channel into the bicistronic construction. 
 
3.2.2. pBK-Kvβ1.3-IRES-Kv1.5-FLAG 
A FLAG epitope (DYKDDDDK) was inserted into the external side of the Kv1.5 (between S1-S2) of 
the Kvβ1.3-IRES-Kv1.5- cDNA construction. This construction was used for biotinylation experiments in 
order to increase the biotinylation efficiency. To insert this amino acid sequence between BlpI and AflII 
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sites in Kv1.5, flanked by single glycine codons, into the extracellular loop between S1 and S2 
transmembrane segments of the channel [specifically between residues 307 and 308 according the 
method described by Zadeh and coworkers in 2008 (Zadeh et al., 2008)], the overlapping PCR technique 
previously described was used (Higuchi et al., 1988) (Figure 8). The following couples of primers were 
utilized:  
on one hand,  
forward (5’- cggctgggctcagcgatgggcccaaggagccggc-3’) and 
reverse (5’-  ccccttgtcatcgtcgtccttgtagtccccgccagaggcgggggccatgaccccgctgccg -3’);  
and on the other hand, 
forward (5’-ggggactacaaggacgacgatgacaaggggcctacggtggcaccgctcctgcccCGTACG -3’) and  
reverse (5’- gctcttccttaaggactgccggctcctcgtgatcc -3’),  
where the underlined nucleotides indicate the recognition sequences of restriction endonucleases BlpI and 
AflII, respectively; the bold ones indicate nucleotides corresponding to the FLAG sequence; the 
nucleotides in italics represent glycines added to provide flexibility at the front and at the back of the insert; 
the nucleotides in uppercase correspond with the insertion of a punctual and non-sense mutation which 
results in a single BsiWI restriction site which serve as reporter of the insertion; and the nucleotides in 
normal type corresponds to the normal sequence of the channel. PCR conditions included an initial 
denaturation step that were, in the case of the two first PCR: 98ºC (5’) followed by 35 cycles of 98ºC for 1 
min, 80ºC for 1 min, and a step at 72ºC for 2 min, and a final elongation step at 72ºC for 10 min; and in the 
case of  overlapping PCR: a step at 95ºC for 30 s, followed by 20 cycles of 95ºC for 30 s, 57ºC for 30 s, 
and 72ºC for 1 min, and a final elongation step at 72ºC for 10 min. 
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Figure 8:  Schematic representation of overlapping PCR technique employed to make pBK-
Kvβ1.3-IRES-Kv1.5-FLAG construction. Firstly, it is necessary to find two unique restriction points 
around the insertion point (between S1 and S2 transmembrane segments), BlpI and AflII in this case. 
Then, we ran two ‘normal’ PCRs, which have the fragment of interest in common, in order to amplify 
both segments separately. After this step, we put them together taking advantage of the overlapped 
fragment (FLAG-tag, in red) reconstituting the whole insert that, after the digestion with the restriction 
enzymes was ready to be inserted in the vector of interest. Note that the introduction of a punctual 
reporter and silence mutation, which result in the introduction of a novel restriction point (BsiWI in our 
case; in blue), which is highly recommended step in order to can check the different colonies after its 
bacterial transformation. 
 
3.2.3. Cell transfection 
For electrophysiological studies, HEK293 cells were transiently transfected with 0.8 μg of a 
construction widely characterized (Uebele et al., 1998). Briefly, human Kv1.5 and Kvβ1.3 were cloned into 
the same pBK vector, with the Kv1.5 subunit placed 3′ to the Kvβ1.3 subunit and preceded by an internal 
ribosome entry sequence (pBK-CMV-Kvβ1.3-IRES-Kv1.5), thus generating a bicistronic messenger RNA 
as previously described (Kwak et al., 1999b) (kindly provided by Dr. MM Tamkun, Colorado State 
University, Fort Collins, CO, USA).  In all cases, transfection was performed together with 1.6-1.8 μg of the 
reported plasmid EBO-pcD-Leu2-CD8 (for future selection of the transfected cells). All amounts of cDNA 
reported were used per 35 mm culture dish. 
For the immunocytochemistry assays experiments, 3 μg of different constructions were used:  
- pBK-CMV-Kv1.5-HA. Construction with a HA tag introduced into the extracellular Kv1.5 
S1-S2 loop was used (kindly provided by Prof. DJ Snyders). 
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- pCMV-Tag5A-Kvβ1.3. Construction in which the gene encoding Kvβ1.3 was subcloned 
between the SacII and NotI restriction sites within the polylinker of the pCMV-Tag5A 
vector, which generates a recombinant Kvβ1.3-Myc protein. 
- pBK-CMV-Kvβ1.3-IRES-Kv1.5-HA. Construction made using the Prof. DJ Snyders´s 
Kv1.5-HA construct and exchanging the fragments got after BlpI and AflII enzyme-
digestion between this and Kvβ1.3-IRES-Kv1.5 constructions. 
- pBK-CMV-Kvβ1.3-IRES-Kv1.5-FLAG: Construction made using the overlapping-PCR 
technique described below pBK-CMV-Kvβ1.3-IRES-Kv1.5. 
For protein expression studies, coimmunoprecipitation, biotinylation and western blot assays, cells 
were transfected with 8 μg of total amount of cDNA per 100 mm culture dish, of the construction that 
express Kvβ1.3-IRES-Kv1.5, Kv1.5-HA, Kvβ1.3-myc or Kvβ1.3-IRES-Kv1.5-HA proteins. In the case of 
FRET and TIRF-FRET experiments, cells were transfected with pECFP-C1-Kv1.5 (kindly supplied by Dr. A 
Felipe from Universidad de Barcelona), pEYFP-N1-RACK1 cloned between EcoRI and NotI in the Dr. P de 
la Peña’s laboratory (Universidad de Oviedo) using the pcDNA3.1-RACK1-myc construction kindly 
provided by Dr. K Ito. In all cases, cells were transfected with 1-2 μg of the total cDNA. For live cell 
imaging experiments, cells were transfected with 3 μg Kv1.5-HA construction per μ-Dish 35mm, high (from 
Ibidi). 
In all cases, transient transfections were carried out in HEK293 cells at 60% confluence following 
the FuGENE6-transfection method (Promega) and the experiments were carried out 48 h post-
transfection. The ratio μg cDNA:μl Fugene was always 1:3. 
 
3.3. ELECTROPHYSIOLOGICAL RECORDINGS 
 
The patch-clamp technique was first used to resolve currents through single acetylcholine-activated 
channels in cell-attached patches of membrane of frog skeletal muscle (Neher & Sakmann, 1976). This 
method is a refinement of the voltage-clamp technique that uses, as an electrode, a glass micropipette 
pulled to a fine tip of approximately 1-4 μm. The recording electrode or “patch pipette” is filled with a saline 
solution and sealed (with a high resistance, GΩ) onto a patch on the surface of the cell membrane, 
allowing the researcher to keep the voltage constant while measuring the current flowing across the 
membrane of a cell or even form a single channel localized in the membrane patch. 
Several configurations of the patch-clamp technique have been developed. The most commonly 
used, when studying ion currents across the cell, is the whole-cell patch-clamp technique. In this 
approach, after the seal formation between the electrode and the cell membrane, an additional suction it 
has to be applied, rupturing the cell membrane in the patch and gaining access to the cytoplasm. 
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Consequently, the internal pipette solution enters in direct contact with the intracellular space. The 
membrane of the whole cell is voltage clamped, and the recorded currents are a composite of the currents 
flowing through all the active channels (Figure 9).  
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Figure 9: Patch-clamp configurations. Scheme of the different configurations of the patch-clamp 
technique. This Doctoral Thesis has been focused in whole-cell configuration in which there is continuity 
between the intracellular space and the pipette-filling solution. Dialysis of the cytoplasm is avoided when the 
perforated patch is used [modified from (Malmivuo & Plonsey, 1995)] 
 
Before experimental use, cells were incubated with polystyrene microbeads precoated with anti-
CD8 antibody (Dynabeads, Invitrogen) (Gonzalez et al., 2002; Arias et al., 2007; David et al., 2012). A 
suspension of cells was placed on a chamber mounted on the stage of an inverted microscope. Currents 
were recorded using the whole-cell configuration of the patch-clamp technique by using an Axopatch 200B 
amplifier (Molecular Devices). Experiments were performed at room temperature (222°C). Current 
recordings were low pass-filtered and sampled at 2 kHz with an analog-to-digital converter DigiData 1440A 
(Molecular Devices) (data acquisition system). Command voltages and data storage were controlled with 
pClamp9 software (Molecular Devices). Patch electrodes were pulled from borosilicate glass capillaries 
(GD-1, Narishige) with a P-87 puller (Sutter Instruments) and were heat polished with a microforge (MF-
83, Narishige). After heat-polishing, the resistance of the patch electrodes tip (filled with the internal 
solution) averaged 2-4 MΩ. The cells were continuously perfused with an external solution containing (in 
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mM): NaCl 130, KCl 4, CaCl2 1.8, MgCl2 1, HEPES 10, and glucose 10 (adjusted to pH 7.4 with NaOH). 
The electrode solution contained (in mM): K-aspartate 80, KCl 50, phosphocreatine 3, KH2PO4 10, MgATP 
3, HEPES-K 10, EGTA-K 5 (adjusted to pH 7.25 using KOH), and sterilized with an Acrodisc Syringe 
Filters with 0.2 μm pore sizes (Pall, Life Science). Gigaohm seal formation was achieved by suction (≈20 
GΩ). Capacitance and series resistance compensation were optimized and, usually, 80% compensation of 
the effective access resistance was obtained.  
The holding potential was set to -80 mV, and the interpulse interval was set to a minimum of 10 
seconds. The different voltage protocols used in this Doctoral Thesis were adjusted to adequately 
determine the biophysical properties of the channels. Time constants of deactivation were determined by 
fitting the currents recordings with a single or double exponential function: 
y = Asexp (-t/s) + Afexp (-t/f) + C 
where f and s are the system time constants, As and Af are the amplitudes of each component of the 
exponential, and C is the baseline value. The voltage dependence of channel activation was fitted to a 
Boltzmann equation: 
y = 1/[1 + exp((EEh)/s)] 
in which s represents the slope factor, E represents the applied voltage, and Eh the voltage at which 50% 
of the channels are open.  
Drug-induced block was measured at the end of 250-ms depolarizing pulses from -80 to +60 mV. 
The degree of inhibition (f) obtained for each drug concentration (D) was used to calculate the IC50 and 
Hill coefficient (nH) values from fitting of these values to Hill equation:  
f = 1/[1 + (IC50/[D]nH] 
Concentration-response curve with two components were fitted to a biphasic Hill equation. Microcal 
Origin 8.5 (Microcal Software) and CLAMPFIT software were used to analyze data and for data 
presentation. 
 
3.4. DRUGS AND REAGENTS 
 
Racemic bupivacaine and quinidine (B5274 and Q0750 respectively, Sigma-Aldrich) were dissolved in 
distilled deionized water to yield stock solutions of 10 mM, from which further dilutions were made as 
previously described (Valenzuela et al., 1995a; Franqueza et al., 1997; Longobardo et al., 2000; Longobardo 
et al., 2001; Gonzalez et al., 2002; Arias et al., 2007). 
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Calphostin C (Calbiochem) is a cell permeable, highly specific inhibitor of protein kinase C (IC50 = 
50 nM) that interacts with the protein regulatory domain by competing at the binding site of diacylglycerol 
(DAG) and phorbol esters. At higher concentrations calphostin C also inhibits MLCK (IC50>5 μM), PKA 
(IC50>50 μM), protein kinase G (IC50>25 μM) and p60v-src tyrosine kinase (IC50>50 μM). However, it does 
not compete with Ca2+ or phospholipids. In the experiments presented in this Doctoral Thesis, calphostin C 
was previously activated by exposure to fluorescent light for five minutes (following the manufacturer 
recommendations). Subsequently cells were incubated, with the minimum volume required to cover the 
dish, for 2 hours with calphostin C at 3 μM and diluted in culture medium at 37 °C under an atmosphere of 
5% CO2. 
In those experiments in which the soluble protein in the internal pipette solution was used, the Lgi1 
Human Recombinant protein at concentration of 0.5 μg/ml was purchased from Tebu-Bio. 
  
3.5. PROTEIN EXTRACTION 
 
48 hours after transfection, culture cells dishes were washed twice with chilled PBS and centrifuged 
at 3,000 × g for 10 min. The pellet was incubated for 5 min with an ice-cold lysis buffer (50 mM Tris-HCl, 
pH 7.4, 150 mM NaCl, 1mM EDTA, 1% Triton X-100), supplemented with Complete Protease Inhibitor 
Cocktail Tablets (Roche Diagnostics) and then lysed by repeated passing (10 times) through a 25G (0.45 
× 16 mm) needle. Homogenates were further centrifuged at 10,000 × g for 5 min in order to precipitate the 
cellular organelles. Samples were separated into aliquots and stored at -20°C until their utilization. All 
steps were carried out at 4ºC and protein concentration was determined using a NanoDrop spectrophotometer 
(NanoDrop ND-1000 UV-Vis Spectrophotometer). 
3.5.1. Western blot assays 
In a similar way than immunoprecipitation samples, cell lysates containing equal amounts of protein 
(30-60 μg per lane) were resuspended in Laemmli Buffer and boiled at 95ºC for 5 min. Protein extracts were 
loaded and size-separated in 7-10% acrylamide/bis-acrylamide (Bio-Rad) SDS-PAGE gels at 110 mV for 2 h 
at room temperature. Gels were equilibrated in transfer buffer for 15 min at room temperature previously to 
transfer them (either, at 375 mA for 2 h or at 90 mA overnight, always at 4°C) to PVDF membranes (GE 
Healthcare). Membranes were blocked with 5% dry milk in 0.1% v/v PBS-Tween20 for 1 h at room 
temperature, washed with 0.5% dry milk in 0.1% v/v PBS-Tween20 three times for 10 min at room 
temperature and processed as recommended by the antibodies suppliers (see Table 2). Specie-specific 
horseradish peroxidase-conjugated secondary antibodies were used (dilution 1:10,000, Calbiochem). 
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Immunoblot signals were visualized by chemiluminescence using ECL-plus reagent (Amersham, GE 
Healthcare). Quantification of band intensity was performed with the Image J software. 
 
Table 2. Primary antibodies used in Western Blot assays. 
Antibody Type and Host Dilution Reference and Origin 
Anti-β-actin Polyclonal Goat 1:20,000 Sc-1615, Santa Cruz Biotechnology 
Anti-α-tubulin Monoclonal Mouse 1:40,000 T5168, Sigma-Aldrich 
Anti-GAPDH Monoclonal Mouse 1:1000 MAB374, Merck Millipore 
Anti-Kv1.5 Polyclonal Rabbit 1:500-1:1,000 APC-004, Alomone 
Anti-Kv1.x Monoclonal Mouse 1:500 [S40-17] (ab99012), Abcam Limited 
Anti-PKC α Monoclonal Mouse 1:200 sc-8393, Santa Cruz Biotechnology 
Anti-PKCI Polyclonal Rabbit 1:200 sc-209, Santa Cruz Biotechnology 
Anti-PKCII Polyclonal Rabbit 1:200 sc-210, Santa Cruz Biotechnology 
Anti-PKCγ Polyclonal Rabbit 1:200 sc-211, Santa Cruz Biotechnology 
Anti-PKCι Polyclonal Rabbit 1:200 sc-727, Santa Cruz Biotechnology 
Anti-PKCδ Polyclonal Rabbit 1:200 sc-937, Santa Cruz Biotechnology 
Anti-PKCε Monoclonal Mouse 1:200 sc-1681, Santa Cruz Biotechnology 
Anti-PKCζ Polyclonal Rabbit 1:200 sc-216, Santa Cruz Biotechnology 
Anti-PKCθ Polyclonal Goat 1:200 sc-1875, Santa Cruz Biotechnology 
Anti-RACK1 Monoclonal Mouse 1:500 sc-17754, Santa Cruz Biotechnology 
Anti-Lgi1 Polyclonal Goat 1:200 sc-9581, Santa Cruz Biotechnology 
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3.5.2. Membrane protein in cell surface: proteinase K assays 
Digestion of surface proteins was carried out as described by Manganas and coworkers in 2001 
(Manganas et al., 2001). Briefly, each 35-mm dish was incubated with an enzymatic buffer containing (in 
mM): HEPES 10, NaCl 150, CaCl2 2 (pH 7.4) with or without 200 μg/ml Proteinase K at 37°C for 30 min. 
Then, cells were harvested and centrifuged at 4°C at 1,000 × g in a refrigerated microcentrifuge. 
Proteinase K digestion was quenched by adding ice-cold PBS containing 25 mM EGTA supplemented 
with Complete Protease Inhibitor Cocktail Tablets. This treatment was followed by washing three times 
with ice-cold PBS. Cleared lysates were prepared and analyzed by immunoblotting, as described above. 
3.5.3. Co-immunoprecipitation assays 
As previously described (David et al., 2012) the protein homogenates obtained were centrifuged at 
150,000 x g for 90 min and the pellet was resuspended in HEPES 30 mM (pH 7.4 with NaOH) or in the 
immunoprecipitation buffer described below. The amount of protein required in the experiments (always 
>300 μg) of the protein homogenates was dissolved in a final volume of 150 μl of immunoprecipitation 
buffer or IPB [10 mM HEPES (pH 7.6), 150 mM NaCl, 1% Triton X-100, supplemented with Complete 
Protease Inhibitor Cocktail Tablets (Roche)], and homogenized by orbital shaking at 4°C for 1 h.  
In all cases, samples were pre-washed with 20 μl of immunoprecipitation buffer-prewashed protein 
A/G-Sepharose beads (Santa Cruz Biotechnology) for 2 h at 4°C in order to eliminate non-specific binding 
between the reagents used and the proteins. After this time, protein A/G was precipitated (5,000 x g for 45 
sec) and discarded. The washed supernatant obtained was incubated with 4 ng of antibody per μg of total 
protein at 4°C overnight and homogenized by orbital shaker. 24 hours later, 50 μl of protein A/G-
Sepharose beads were added to the sample and incubated 2 h at 4°C. Finally, antibody-bound sepharose 
beads (and therefore, protein-bound antibody) were centrifuged at 5,000 x g for 45 s at room temperature 
and then washed  three times with wash buffer (0.1% Triton X-100, 10 mM HEPES (pH 7.6) and 150 mM 
NaCl) to remove all the antibody and channel unbound or non-specifically bounded. 
In the case of experiments carried out in cardiac tissue, and for detection of the Kvβ1.3 subunit (that 
has a similar molecular weight that the antibody used in the immunoprecipitation protocol), we covalently 
bound the anti-Kv1.5 antibody to A/G protein with Pierce® Direct IP Kit (Thermo Scientific) and this mixture 
was added to the protein extract. Using this procedure, the antibody used in the immunoprecipitation will 
not be present in the western blot and it will be possible to detect the beta subunit if it is present in the 
protein complex.  
All experiments were carried out in parallel together with a negative control in which the primary 
antibody that detects the protein of interest was not added. This negative control led us to discriminate 
false positives. 
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Protein samples, immunoprecipitates and immunoprecipitation-obtained supernatants were 
resuspended in 20-50 μl of Laemmli SDS Loading Buffer (10% w/v SDS, 10% v/v glycerol, 5% w/v 2-β-
mercaptoethanol, 0.002% w/v bromophenol blue, 62.5 mM Tris-HCl, pH 7.4), boiled for 5 min at 95 ºC, 
and then centrifuged for 3 min at 5,000 x g at room temperature. Protein extracts was separated by SDS-
PAGE and analyzed by western blotting.  
 
3.6. IMAGE EXPERIMENTS 
 
3.6.1. Immunocytochemistry 
One squared coverslip of 18 mm in each side, and placed into a 35 mm dish (Falcon) per 
experimental condition, was exposed to UV light for 20 min in order to be sterilized. Then, cells were seeded 
in them. 48 hours post-transfection cells were washed and fixed with 4% paraformaldehyde for 20 min at 
37°C. Then cells were permeabilized with PBS 0.1% v/v Triton X-100 for 20 min at 37°C, blocked (against 
the non-specific binding of the primary antibody) with goat serum 5% (since none of primary antibodies 
used were performed in goat) in PBS for 30-60 min at 37°C; and, finally, cells were incubated with the 
primary antibody that recognizes an extracellular epitope (HA-tag) or the RACK1 protein (Table 3). After 
that, cells were incubated with the proper secondary antibody, indicated in each Figure or, in the case of 
the detection of c-myc-tag, with an anti-c-myc-CY3 antibody (a primary antibody tagged directly with a 
fluorophore). Between each one of the steps described above, cells were washed three times with PBS for 
5 min. Finally, and before of mounting the coverslips with Aqua Poly/Mount (Polysciences); cells were 
incubated with DAPI 1:10,000 (D1306, Molecular Probes) for 20 min at 37°C. Stained cells were 
visualized using a LSM510 ZEISS (Carl Zeiss) or Leica TCS SP5 (Leica Microsystems) confocal 
microscopes, and images were analyzed with Zeiss, Leica, and ImageJ software (NIH). 
Table 3. Primary antibodies used in immunocytochemistry assays. 
Antibody Type and Host Dilution Reference and Origin 
Anti-Kv1.5 Polyclonal Rabbit 1:500-1:1,000 APC-004, Alomone 
Anti-c-myc-CY3 Monoclonal Mouse 1:250 C6594, Sigma 
Anti-HA Polyclonal Mouse 1:250-1:500 NB600-366, Novus Biologicals 
Anti-RACK1 Monoclonal Mouse 1:500 sc-17754, Santa Cruz Biotechnology 
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For the internalization experiments, four coverslips per experimental condition were exposed to UV 
light for 20 min to sterilize them. Then, cells were seeded into 35 mm dishes (Falcon). 48 h post-transfection 
the antibody anti-HA was added to the culture media without serum and antibiotics, for 30 min at 4°C 
under soft shaking conditions, previous to the incubation indicated in the Figures of this Doctoral Thesis. 
After 2 h at 37°C, cells were fixed with 4% paraformaldehyde for 20 min, then were blocked with goat 
serum 5% in PBS and then incubated with the secondary antibody (goat Anti-rabbit Alexa-568 1:500). 
After that, cells were washed and permeabilized with 0.5% v/v Triton X-100 and Goat Serum 5% in PBS 
for 30 min at 37°C. Then, cells were incubated with a similar blocking solution and incubated with the 
internal secondary (goat Anti-rabbit Alexa-488 1:500). All incubations were performed in a wet chamber 
(see a scheme of the process in Figure 10) 
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Figure 10: Scheme of the internalization assay of Kv1.5 in the presence of calphostin C. In these 
experiments an HA-tagged Kv1.5 construction (A) was used in order to label the channel present in cell 
surface. After this, the cells were treated with calphostin C. At this time, channels have been 
internalized (B). Thus, the amount of the channels which remains in the membrane of the cell was 
labeled in red (C), and then, the cells were permeabilized and the internalized channel were labeled in 
green (D). Note that in this way, only will be reachable for the second secondary antibody, those 
channels that were present previously in the membrane. 
 
In that experiments performed to analyze effects of Lgi on the actin cytoskeleton, cells were 
transfected with Kv1.5-CFP (provided by Dr. A Felipe), Lgi1-GFP (provided by Dr S Adhikari), phalloidin-
Alexa546 5:200 (Molecular Probes) for labeling the actin cytoskeleton and To-Pro-3 1:500 (Molecular 
Probes) for the labeling of the nucleuses.  
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Finally, and before mounting the coverslips with ProlongGold antifade reagent (Molecular 
Probes); cells were incubated with DAPI 1:10,000 (Molecular Probes) for 20 min at 37°C (less in that 
experiments performed to analyzed the Lgi1 effects) and the coverslips were briefly immersed in distilled 
water, MilliQ quality, and ethanol 100%. Stained cells were visualized using a Confocal Scanning 
Microscope LSM 710 (from Zeiss) and a 63x objective. Values of intensity fluorescence and quantification 
were obtained performed with Image J software (NIH).  
3.6.2. Live cell imaging 
HEK293 cells were cultured in 35 mm μ-dishes for live cell imaging (Ibidi GmbH), transfected with 
Kv1.5-HA-Kvβ1.3 construction and labeled as previously described (Zadeh et al., 2008). Briefly, cells were 
incubated with mouse-anti-HA (1:250, Novus Biologicals) at 4°C for 30 min in culture medium without serum 
or antibiotics. After this period, cells were washed and labeled with a 1:500 dilution of a goat anti-mouse Alexa-
488 (Molecular Probes) for 30 min at 4°C in a similar medium. Then, cells were washed three times with cold 
medium and live-imaged using a Microscope Cell Observer Z1 system (Carl Zeiss MicroImaging GmbH) 
equipped with a controlled environment chamber (37°C constant temperature, 5% CO2 atmosphere) and 
Camera Cascade 1k. Images were collected every 5 min with a 63x Plan Apochromat objective, from 0 to 3 h. 
After image stabilization, all images were deconvolved with Huygens Professional software version 4.0 
(Scientific Volume Imaging) using a theoretical point spread function for each channel and the Quick Maximum 
Likelihood Estimation algorithm (QMLE) and the theorist Point Spread Function (PSF). The signal to noise 
ratios and background intensities were manually determined and taken into account during the deconvolution 
process. Finally time-lapse movies were formatted using ImageJ software and exported in *.avi format.  
3.6.3. Fluorescence resonance energy transference (FRET) 
Fluorescent resonance energy transfer (FRET) involves the radiation-less transfer of energy from a 
“donor” fluorophore to an “acceptor” fluorophore. But to that phenomena take place both fluorophores 
(“donor” and “acceptor”) has to meet: a) both spectra have to overlap, so that the donor emission 
spectrum coincides, at least in part with the absorption spectrum of the acceptor; and b) both fluorophores 
has to approximate, not only to a short distance, but also in the adequate orientation (Figure 11). FRET-
based assays are able to transduce a near-field interaction into a far-field signal, a unique optical tool to 
assess biological phenomena well below the resolution of standard optical microscopy (Roy et al., 2008). 
Due to the light attenuation, FRET can only allow energy transfer to occur when the distance between the 
donor and the acceptor fluorophores are within 1–10 nanometers (nm) of each other. An excited 
fluorophore emits an essentially virtual photon, which is then absorbed by a receiving fluorophore (Zadran 
et al., 2012). And, for all these reasons, FRET is commonly utilized to demonstrate near-field 
communication or interaction between two molecules (Day et al., 2001).  Due to these physical properties, 
different biological applications of this technique can be carried out. Among them, it is possible to do 
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possible estimation of interfluorophore distances between amino acyl residues in disordered or partially 
folded proteins and, the performance of “multiple molecular triangulation” with fluorophores located at 
various positions, provided a useful initial constraint on the coarse structure of the proteins (Miranda et al., 
2008; Miranda et al., 2013).  
 
 
Figure 11: Scheme of FRET technique. A, The energy of donor emission must be an energy that 
the acceptor can absorb. In other words, the emission spectrum from the donor fluorophore must 
overlap with the excitation spectrum of the acceptor fluorophore. B, If the FRET donor and acceptor 
are more than 10 nm apart, then no FRET occurs and the donor emits fluorescence. If the donor and 
acceptor are within ≈10 nm of one another, then energy transfer can occur from the donor (CFP) to 
the acceptor (Venus). C, If the donor and acceptor fluorophore dipoles are perpendicular to one 
another, then the donor molecule will emit fluorescence. However, if the dipoles are parallel to each 
other, FRET will occur [taken from (Broussard et al., 2013)]. 
 
After tagging and transfection of the used proteins, measurements of FRET by acceptor 
photobleaching as previously described (Miranda et al., 2013). Briefly, FRET measurements were 
performed in cells bathed in standard extracellular saline following the increase (dequenching) in donor 
(CFP) fluorescence signal during incremental photobleaching of acceptor (V/YFP). Background 
fluorescence of both fluorophores was determined from a region of the same field located outside the cell 
and the averaged pixel intensity of this area was subtracted from the mean intensities measured in the 
regions of interest corresponding to the individual fluorescent cell areas. A Zeiss Axiovert 100 microscope 
with a 40x/0.75 Plan-NeoFluar objective (Carl Zeiss) was used. The fluorescence imaging system (Till-
Photonics) consisted of a monochromator Polychrome IV, a dual band CFP/YFP filter set and a 12-bit 
CCD camera (IMAGO) combined with a DUAL-View Micro-Imager (Optical Insights) for dual emission 
image acquisition. Control of monochromator and camera as well as image recording and processing were 
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performed with TILLvisION software (Till-Photonics). The standard acceptor bleach protocol consisted of 
30 cycles every 2 s with 50–100 ms of exposure of donor and acceptor near their excitation maximum (at 
440 and 515 nm, respectively) to detect CFP and V/YFP fluorescence without V/YFP-bleaching, followed 
by 180–240 additional cycles separated by periods in which the V/YFP remains permanently illuminated at 
515 nm to photobleach it. Photoconversion of V/YFP into CFP-like species was negligible under our 
photobleaching conditions as evidenced by the total absence of fluorescence in the CFP channel when 
cells expressing exclusively V/YFP-labeled proteins were submitted to the standard acceptor bleaching 
protocol. Individual cells showing dim fluorescence leading to very low signal-to-noise ratios and those in 
which the fluorescence of V/YFP did not average at least 13 or 10 fold that of the lower intensity CFP 
probe, respectively, were discarded to prevent low acceptor-to-donor ratio contributing to uncontrolled and 
reduced FRET signals. This implies that almost exclusively 2:2 and/or 1:3 CFP:V/YFP-tagged subunit 
stoichiometries will contribute to FRET. Quantitative FRET levels were expressed as FRET efficiency 
(EFRET), defined as the proportion of the excited states of the donor that become transferred to the 
acceptor and calculated as follows: 
 E = (Fd-Fa)/ Fd 
in which Fa and Fd are the fluorescence intensities of the donor before and after complete photobleaching 
of the acceptor. 
3.6.3.1. Total internal reflection fluorescence microscopy-FRET (TIRFM-FRET) 
system 
In addition, measurements were performed under total internal reflection microscopy (TIRFM) to 
selectively measure FRET in the proximity of the plasma membrane Figure 12A, because only fluorescent 
proteins illuminated by the evanescent wave, at a distance of ≈100 nm above the glass coverslip, where the 
cells are attached are studied, thus avoiding most of the contamination from cytoplasmic signals (Axelrod, 
2003; Fernandez-Trillo et al., 2011). This fact is possible thanks to the refractive indices of the glass slide 
(1.518) and the aqueous specimen medium (approximately 1.35) which are appropriate to support total 
internal reflection within the glass slide. With adjustment of the laser excitation incidence angle to a value 
greater than the critical angle, the illuminating beam is entirely reflected back into the microscope slide upon 
encountering the interface, and an evanescent field is generated in the specimen medium immediately 
adjacent to the interface. On the other hand, this technique led us to get images, with a higher contrast, less 
background and higher sharpness images of the cell and its membrane (Figure 12B), which has a direct effect 
in the goodness of the data derived from them. This is very important because it could be possible that only a 
reduced fraction of the total fluorescence, corresponding to properly assembled and fully functional complexes, 
is detected in the perimeter (i.e. the plasma membrane) of the channel-labeled expressing cells (Miranda et 
al., 2008).  
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Figure 12: Theoretical and practical representation of TIRFM technique.   A, Right panel: generation of structured 
evanescent illumination by interference of two plane waves; middle and right panels: schematic representation showing 
how the fluorophores in contact with the slide are illuminated [taken from (Axelrod & Davidson, 2012; Ross et al., 2013; 
Gerrer et al., 2013)].  B, Comparison of wide-field epi-fluorescence (left) and TIRF illumination (right) after focusing the 
objective at the level of the glass coverslip-water interface. Note the notorious reduction of the background and out-of-
focus fluorescence under TIRF conditions, associated with a remarkable increase in the sharpness and contrast of the 
layer corresponding to the cell footprint in contact with the glass, mainly representing the plasma membrane environment. 
C, TIRF-induced preferential photobleaching of labeled proteins in and near the plasma membrane abutting the 
coverglass. Note the very similar fluorescence levels observed in the cells imaged with epifluorescence microscopy and 
focused near the cell center, both before and after nearly complete selective photobleaching [B and C, taked from 
(Fernandez-Trillo et al., 2011)]. 
 
Subsequently, a CFP-YFP construction was used as a positive control linked in tandem by a pleckstrin 
homology domain (CFP-PH-YFP), which can bind phosphatidylinositol lipids within biological membranes. By 
using this construction, not only we can make sure that we obtain the maximum value of EFRET (since both 
proteins are closed), but also this construction it can be used as plasma membrane marker in the trafficking of 
proteins or to delimit the cells in fluorescence assays. 
3.6.4. Immunohistochemistry 
Sections (4 μm) of paraffin-embedded tissues mounted on slides coated with 3-
aminopropyltriethoxy-silane (Sigma Chemical Co.) were deparaffinized and submitted twice to microwave 
pretreatment for 2.5 min at 800 W in sodium citrate buffer 0.01 M (pH 6). Subsequently, the tissue was 
blocked with Tris-buffered saline containing 1% BSA. All sections were incubated overnight at 4°C. After 
incubation with the primary antibody and a biotinylated secondary antibody, an ABC method was used (a 
complex performed by Avidin DH and biotinylated horseradish peroxidase H, Vector Laboratories). Then, 
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sections were carefully washed and the supersensitive peroxidase detection system (BioGenex) was 
used. These reactions were revealed by incubation with DAB (3,3-diaminobenzidine/H2O2). Positive 
controls were treated with anti-collagen or anti-vimentin antibodies. Nucleuses were counterstained with 
Harris haematoxylin and the sections were mounted in Dpex mounting medium (Panreac) or aqueous 
mounting medium (ClearMount Solution, Zymed Laboratories).  
 
3.7. TRAFFICKING ASSAYS 
 
3.7.1. Biotinylation of membrane proteins 
In these experiments HEK293 cells were transfected with pBK-Kvβ1.3-IRES-Kv1.5-FLAG 
construction, described above. Cell surface biotinylation was carried out with the Pierce® Cell Surface 
Protein Isolation Kit (Pierce) following the manufacturer instructions. Briefly, 48 h after transfection, the 
cells were washed twice with chilled PBS and then all cell surface proteins, including FLAG-tagged Kv1.5, 
were biotin-labeled using Sulfo-NHS-SS-biotin (sulfosuccinimidyl-2-(biotinamide) ethyl-1,3-
dithiopropionate; Pierce) and incubated at 4°C under soft shaking conditions for 30 min. The unreacted 
biotin was quenched and cells were warmed at 37°C to allow channel endocytosis for different times, as 
indicated. The remaining cell surface biotin was stripped using MesNa solution (100 mM sodium 2-
mercaptoethanesulfonate, 50 mM Tris, 100 mM NaCl, 1 mM EDTA, 0.2% BSA). Then, cells were washed 
in chilled PBS and lysed with in ice-cold lysis solution (Figure 13). The protected (endocytosed) biotin-
tagged channels were subjected to pulldown using 25 μl of NeutrAvidin-agarose that was added to 500 μg 
of total protein. Proteins were resolved by SDS-PAGE (10% gel) and transferred to PVDF membranes by 
immunoblot analysis of Kv1.5 channels internalyzed using polyclonal rabbit antibody anti-Kv1.5 (Alomone). 
3.1.1. Trafficking disruptors 
In these experiments cDNA constructions with single point mutations known to confer a GTP-
bound/constitutively active state of Rab GTPase 4 and 11 were used and kindly provided by Dr. JA 
Esteban (CBMSO, CSIC-UAM). HEK293 cells were transiently co-transfected Kv1.5-Kvβ1.3 and with 
constitutively active mutants of Rab 4 (Q67L) and 11 (Q70L) using the same transfection protocol 
previously stated in this Doctoral Thesis. The constructions of these mutants have been widely described 
previously (Gerges et al., 2004). Briefly, Rab4a and Rab11a coding sequences were cloned by PCR from 
a commercial rat brain cDNA preparation (catalog no. 7150; Clontech). 
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Figure 13:  Scheme of the recycling study of Kv1.5 by biotinylation. In these experiments a 
Flag-tagged Kv1.5 construction (A) was used in order to take the free lysines present in the tag (-
GDYKDDDKG-) since the Sulfo-NHS-SS-Biotin (B) used needs the presence of free amino groups 
in the external side of the cell to bind them. After that, a reducer solution such as MesNa (sodium 2-
mercaptoethanesulfonate) will strip the remained biotin bonded to cell surface proteins (C). In 
this way, biotin only will remain tagged those proteins protected or endocytosed (D). 
 
3.2. STATISTICAL ANALYSIS 
 
Results are expressed as mean±SEM. Direct comparisons between mean values in control 
conditions versus mean values in the presence of drugs for a single variable were performed by a paired 
Student's t test. ANOVA was used to compare more than two groups. Student's t test was also used to 
compare two regression lines. Differences were considered significant when P-value was less than 
0.05.The curve-fitting procedure used a non-linear least-squares (Gauss-Newton) algorithm; results were 
displayed in linear format. Goodness of fit was judged by the 2 criterion and by inspection for systematic 
non-random trends in the difference plot.  
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Table 4. Principal reagents and drugs used in this Doctoral Thesis. 
Name Brief description Reference and Origin 
Penicilin Antibiotic 10270-106, Gibco 
Streptomycin Antibiotic 15140-122, Gibco 
Calphostin C PKC inhibitor 208725, Calbiochem 
Dynabeads Microbeads precoated antibodies 11147D, Invitrogen 
Lgi1 protein Human recombinant protein H00009211-P01-0002, Tebu-Bio 
Protease inhibitor Protease inhibitor cocktail 11836145001, Roche Diagnostics 
Pierce® Direct IP Kit Antibodies covalent binding 26148, Thermo Scientific 
ECL-plus reagent Chemiluminiscent signal for WB RPN2132, GE Healthcare 
ProlongGold Mounting medium P36930, Molecular Probes 
DAPI Nucleus marker D1306, Molecular Probes 
3-aminopropyltriethoxy-silane Coating glass reagent 440140, Sigma Chemical Co 
Sulfo-NHS-SS-biotin Membrane proteins marker 21331, Pierce 
Racemic bupivacaine Local anesthetic B5274, Sigma-Aldrich 
Racemic quinidine Antiarrhythmic drug Q0750, Sigma-Aldrich 
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4.1 PROTEIN KINASE C ACTIVITY REGULATES FUNCTIONAL EFFECTS OF 
Kvβ1.3 SUBUNIT ON Kv1.5 CHANNELS: IDENTIFICATION OF A CARDIAC 
CHANNELOSOME. 
 
4.1.1 Effects of PIP2 and OAG on Kvβ1.3-induced fast inactivation 
It has been proposed that PIP2 associates with the amino terminus of the Kvβ1.3 subunit, and 
when the β subunit dissociates from PIP2, it assumes a hairpin structure that can enter the central cavity 
of an open Kv1.5 channel, triggering Kvβ1.3-induced N-type inactivation. Therefore, it is assumed that 
Kvβ1.3-induced fast inactivation is mediated by equilibrium binding of the amino terminus of Kvβ1.3, 
which switches between binding to phosphoinositides (PIPs) and the inner pore region of Kv1.5 
channels (Decher et al., 2008). Stimulation of α1-receptors activates PLCγ is capable of cleaving PIP2 
into IP3 and DAG, thus activating classical and novel PKCs.  
The effects of PIP2 and OAG (a non-degradable DAG analog) were analyzed by adding these 
compounds to the internal solution (Figure 14). Cells dialyzed with PIP2 exhibited a lower degree of fast 
inactivation just after patch rupture in comparison with control cells (55 ± 4% versus 68 ± 6%, n = 4, 
p<0.05) (Figure 14A). However, after 8 min of dialysis with PIP2, the degree of N-type inactivation 
increased significantly (from 55 ± 4% to 70 ± 4%, n = 4, p<0.05) (Figure 14A). These effects could be 
because of a decrease of the PIP2 concentration due to its cleavage into IP3 and DAG. In fact, the 
degradation of PIP2 would increase the ability of the N terminus of Kvβ1.3 to inactivate Kv1.5 (Decher et 
al., 2008). In contrast, cells dialyzed with OAG exhibited a similar degree of N-type inactivation than 
control cells, both after patch rupture and after 8 min of dialysis with OAG (65 ± 3% to 67 ± 2%, n = 5, 
p>0.05) (Figure 14B). These results are in agreement with the involvement of classical and novel PKC 
isoforms in the effects of calphostin C and PKC siRNA on the fast Kvβ1.3-induced inactivation. To test 
whether the PIP2 effects at different times (t=0 or 8 min) were due to the cleavage of PIP2 into DAG and 
IP3, a series of experiments in which cells previously incubated with a PLC inhibitor (U73122, 10 μM) 
and dialyzed with PIP2 was performed (Figure 14C). Under these experimental conditions, the degree of 
fast inactivation was reduced (from 69 ± 2% to 62 ± 2%, n = 9, p<0.01. Figure 14Ca) and, more 
importantly, the Kvβ1.3-induced fast inactivation was abolished, in such a way that the time constant of 
the fast inactivation was increased (Figure 14Cb) and the contribution of the fast component of 
inactivation decreased (Figure 14Cc).  
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Figure 14: Effects of PIP2, OAG, and PLC on Kvβ1.3-induced fast inactivation. A, Representative current 
traces obtained after depolarization from a holding potential of −80 mV to +60 mV, just after patch rupture (t = 0 
min) and after 8 min (t = 8 min), in control conditions and during PIP2 dialysis. The graph shows the degree of 
inactivation in control cells and in cells dialyzed with PIP2 at t = 0 min and t = 8 min. Note that at t = 0, the degree 
of fast inactivation was significantly lower than that after 8 min of dialysis in PIP2 and control dialyzed cells. B, 
Representative current traces obtained at +60 mV at t = 0 and t = 8 min in control conditions and during OAG 
dialysis. The graph shows the degree of fast inactivation in control cells and in cells dialyzed with OAG at t = 0 min 
and t = 8 min. The degree of fast inactivation was similar in all experimental conditions. C, Representative current 
traces obtained at +60 mV at t = 0 (U73122, 10 μm) and t = 8 min (U73122 + PIP2) after inhibition of PLC with 
U73122 and after PIP2 dialysis. The upper right (Ca), bottom left (Cb), and bottom right (Cc) of the panel show 
graphs of the degree of fast inactivation, the fast inactivation kinetics, and the contribution of the fast component of 
inactivation to the total process (Afast/(Afast + Aslow)) under both experimental conditions, respectively. *, p<0.05; **, 
p<0.01; ***, p<0.001. 
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4.1.2 PKC inhibition results in a shift of the inactivation curve. 
Assembly of the Kvβ1.3 subunit causes fast inactivation of the Kv1.5 outward current (Hoshi et 
al., 1990; England et al., 1995a; England et al., 1995b; Leicher et al., 1996). Therefore, it was surprising 
to observe that even when these subunits remained assembled, Kvβ1.3-induced fast inactivation was 
abolished either by inhibition of PKC with calphostin C or by silencing PKC. Kv1.5-Kvβ1.3 current is 
activated at −30 mV and inactivates at potentials positive to 0 mV, exhibiting a degree of inactivation of 
70 ± 2% (n = 23) when measured at +60 mV (David et al., 2012). After PKC inhibition with calphostin C- 
or siRNA-mediated PKC silencing, Kv1.5-Kvβ1.3 currents showed a degree of slow inactivation that 
ranged between 20 and 30%, whereas pulse steps to potentials positive to +60 mV revealed the 
presence of the typical Kvβ1.3-induced fast inactivation (Figure 15A). Figure 15A also shows the mean 
values of the inactivation degrees obtained at +100 mV recorded in at least four experiments. These 
results further suggest that Kv1.5 and Kvβ1.3 remain assembled after PKC inhibition. This outcome 
suggests that after PKC inhibition, the inactivation curve of Kv1.5-Kvβ1.3 current is shifted toward more 
positive membrane potentials. To test this hypothesis, a series of experiments was performed in which 
a double-pulse protocol was applied (Figure 15B).  
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Figure 15: Voltage dependence of inactivation of Kv1.5 and Kv1.5-Kvβ1.3. A, Current traces obtained after 
depolarization from a holding potential of −80 mV to +60 (red) and +100 mV (black) in HEK293 cells transfected 
with Kv1.5-Kvβ1.3 and with scrambled siRNA (50 nM) (left), with PKC siRNA-transfected cells (middle) and in 
calphostin C-treated cells (right). B, Original current records obtained in control and calphostin C-treated cells. C, 
Voltage dependence of inactivation under control and after calphostin C treatment. Note that calphostin C shifts 
the inactivation curve to more positive potentials. 
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These results show that the inactivation curve in calphostin C-treated cells was shifted toward 
more positive potentials (Vh = −26.5 ± 0.6 versus −8.5 ± 1.9 mV in the presence and in the absence of 
calphostin C, respectively; n = 10; see Figure 15C and Table 5). Moreover, the degree of inactivation in 
calphostin C-treated cells decreased from 47.3 ± 5.7% (n = 5) to 34.6 ± 2.2% (n = 7) (p<0.05) 
. 
TABLE 5. Voltage-dependent inactivation parameters. Vh: half voltage of inactivation. s: slope of the 
Boltzmann equation. Data represent the mean ± S.E.M. (n = 7 experiments). Statistically significant differences 
are indicated by asterisks. 
 
 
 
Vh1 (mV) 
 
Vh2 (mV) 
 
s1 (mV) 
 
s2 (mV) 
      
Kv1.5-Kvβ1.3 
 
-26.5±0.6 
 
19.0±0.6 
 
4.2±0.6 
 
28.7±7.8 
 
Kv1.5-Kvβ1.3 (Calphostin C) 
 
-8.5±1.9* 
 
 
 
9.8±.9* 
 
 
 
4.1.3 The Kv1.5 macromolecular complex in HEK293 cells contains Kv1.5, 
Kvβ1.3, RACK1, PKCβI, PKCβII, and PKCθ. 
Several ion channels have been reported to be modulated by PKC via RACK1 (Ron et al., 1994). 
We hypothesized that Kv1.5, Kvβ1.3, and PKC form a functional complex in which PKC activity is an 
essential requirement for the induction of fast and incomplete channel inactivation by Kvβ1.3. To assess 
this hypothesis, immunocytochemistry experiments were performed (Figure 16). Figure 16A shows 
confocal images of cells transfected with Kv1.5-HA and Kvβ1.3, in which we stained for Kv1.5 and 
RACK1. Figure 16B shows confocal images of cells transfected with Kv1.5 and Kvβ1.3-Myc, in which we 
stained for Kvβ1.3 and RACK1. As shown, under both experimental conditions, colocalization was 
consistent between Kv1.5 and RACK1, as well as between Kvβ1.3 and RACK1. Given the widespread 
immunolocalization patterns, we confirmed subunit association using immunoprecipitation experiments. 
We immunoprecipitated Kv1.5 channel and blotted for PKCβII to confirm the presence of this enzyme in 
the protein complex. Western blots against RACK1 confirmed the interaction of Kv1.5 with this adaptor 
protein. Collectively, these results demonstrate the presence of a functional complex or channelosome 
that includes Kv1.5, Kvβ1.3, RACK1, and PKCβII. This interaction was demonstrated in controls and was 
found to be absent in PKC-silenced cells (David et al., 2012).  
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Fidure 16: Immunocytochemical staining of Kv1.5-HA or Kvβ1.3-Myc and RACK1 proteins. A, Cells stained 
with anti- Kv1.5-HA, anti-Kvβ1.3-Myc, or anti-RACK1. Colocalization appears as yellow fluorescence due to the 
merge of the green (Kv1.5-HA) and red (RACK1) channels after detection with secondary fluorescent antibodies. 
Cells were cotransfected with Kv1.5-HA+Kvβ1.3-Myc. RACK1 is an endogenous protein. B, Cells stained with anti-
Myc (green) and anti-RACK1 (red). Cells were transfected with Kvβ1.3-Myc alone. In all pictures, the bar 
represents 5 μm. 
 
Along to that experiments, we performed other immunocytochemistry experiments, similar to that 
show in Figure 16, in which we only transfected Kv1.5 and stained for Kv1.5 and RACK1 (data not 
shown) detecting a lower colocalization degree in these cells than in cells transfected with Kv1.5-
Kvβ1.3+RACK1. All these data, led us to hypothesize a ‘linker’ role of Kvβ1.3 in the Kv1.5-RACK1 
interaction. In order to test this hypothesis, after checking the availability of the system with our positive 
control (CFP-PH-YFP tandem construction with an EFRET = 38.22 ± 0.84, n=14; Figure S1) we performed 
TIRF-FRET experiments between Kv1.5-CFP and RACK1-YFP constructions in the absence (Figure 
17A), and in the presence of Kvβ1.3 subunits (Figure 17B). In Figure 17 it can be observed that while 
we obtained a negative FRET (EFRET = -2.08 ± 0.51 %, n=50) in the absence of Kvβ1.3 subunit, a 
positive FRET (EFRET = 6.67 ± 1.18, n=3) was obtained in 3 from 16 cells analyzed in the presence of 
Kvβ1.3 (≈ 20 % of cells studied).  
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Figure 17: Determination of donor fluorescence recovery during disruption of energy transfer by selective 
acceptor photobleaching. Transiently transfected HEK293 cells were imaged for co-expressed Kv1.5 amino 
terminally fused to CFP and RACK1 carboxy terminally fused to YFP in the absence (A) an in the presence of 
Kvβ1.3 subunit (B). Shown are the relative increases in CFP intensities (in percentages) over initial levels and the 
remaining fluorescence intensity of YFP. The symbols represent the calculated mean ± SEM, whereas the thin 
dotted lines correspond to single cell traces.  
 
4.1.4 Characterization of the Kv1.5 channelosome 
To determine which PKC isoforms are present in this macromolecular complex, a series of 
coimmunoprecipitation experiments were performed in which we immunoprecipitated Kv1.5 channels 
and blotted for all PKC isoforms present in HEK293 cells (Figure 18). We observed that only PKCβI, 
PKCβII, and PKCθ were present in the Kv1.5 channelosome. 
4.1.5 The Kv1.5 channelosome is present in rat ventricular but not in atrial myocytes 
In order to determine the physiological relevance of our results, we performed experiments in rat 
cardiac tissue (Figure 19). We performed coimmunoprecipitation experiments in which we 
immunoprecipitated Kv1.5 channels and blotted for PKCβI, PKCβII, PKCθ, RACK1, and Kvβ1.x. 
Samples from ventricular homogenates presented a Kv1.5 channelosome composed of Kv1.5, Kvβ1, 
RACK1, PKCβI, and PKCβII (Figure 19A). Importantly, atrial tissue did not display this Kv1.5 protein 
complex (Figure 19B) since none of the proteins studied, which are forming the Kv1.5 channelosome in 
ventricle, coimmunoprecipitated with Kv1.5 in atrial tissue. 
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Figure 18: Immunoprecipitation of Kv1.5-Kvβ1.3 channel with PKCs. Negative (Ab−) and positive (Ab+) 
immunoprecipitations (IP) blotted against the different PKCs isoforms present in HEK293 cells. Note that only 
PKCβI, PKCβII, and PKCθ coimmunoprecipitated with Kv1.5-Kvβ1.3 channels (n = 3). WB, Western blot; S, 
supernatants. 
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Figure 19: Immunoprecipitation of Kv1.5 channel in cardiac tissue. Negative (Ab−) and positive (Ab+) 
immunoprecipitations (IP) blotted against the different PKC isoforms present in HEK293 channelosome (Figure 
18). Note that a very similar channelosome has been found in ventricular (A), but not in atrial (B), tissue (n = 3). 
WB, Western blot; S, supernatants. 
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4.2 PHARMACOLOGICAL CONSEQUENCES OF PROTEIN KINASE C 
INHIBITION ON Kv1.5-Kvβ1.3 CHANNELS.  
 
4.2.1 Kvβ1.3-induced fast inactivation is abolished by PKC inhibition. 
Figure 20 shows the effects of the Kvβ1.3 subunit on the Kv1.5 channel, which induces a fast and 
partial inactivation, a greater degree of slow inactivation, a slower deactivation process and a shift of the 
activation curve towards more negative potentials (Figure 20A and B, and Table 6). PKC inhibition with 
calphostin C prevents Kvβ1.3-induced fast inactivation of Kv1.5 channels (Murray et al., 1994; Kwak et 
al., 1999a; Kwak et al., 1999b) as a consequence of a shift in the inactivation midpoint towards more 
positive potentials (David et al., 2012). Kv1.5-Kvβ1.3 channels expressed in cells treated with calphostin 
C (Kv1.5-Kvβ1.3-calphostin C channels) exhibited an activation curve intermediate between that 
observed for the Kv1.5 and Kv1.5-Kvβ1.3 channels (Table 6), and similar deactivation kinetics to Kv1.5-
Kvβ1.3 channels (Figures 20B and C). To analyze the electrophysiological characteristics of the 
inactivation process of Kv1.5-Kvβ1.3-calphostin C channels, we applied the double-pulse protocol shown 
at the top of Figure 21. Figure 21A shows the inactivation curves of Kv1.5, Kv1.5-Kvβ1.3 and Kv1.5-
Kvβ1.3-calphostin C channels. PKC inhibition shifted the inactivation curve towards more positive 
potentials, which was similar to the Vh observed in Kv1.5 channels (Table 7). Although the degree of 
inactivation of Kv1.5-Kvβ1.3-calphostin C was decreased in comparison to Kv1.5-Kvβ1.3 channels, it was 
not fully reverted back to that observed in Kv1.5 channels (Figures 20 and 21, and Table 7).  
 
TABLE 6. Voltage-dependent activation parameters of Kv1.5, Kv1.5-Kvβ1.3 and Kv1.5-Kvβ1.3-calphostin C 
channels. Vh: Half-inactivation voltage. s: Slope of the Boltzmann equation. Data represent the mean ± SEM of 
n>7 experiments. 
 
 
 
Vh (mV) 
 
s (mV) 
 
Kv1.5 
 
0.2 ± 3.1 
 
9.0 ± 0.8 
 
Kv1.5+ Kvβ1.3 
Control 
 
-23.6 ± 2.4 
 
3.9 ± 0.2 
 
Kv1.5+ Kvβ1.3 
calphostin C 
 
-15.3 ± 1.2 
 
6.0 ± 0.6 
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Figure 20: Original recordings obtained upon depolarization from a holding potential of −80 mV to +60 mV 
in 10 mV steps and upon repolarization to −40 mV. A, Current recordings obtained from the activation of Kv1.5 
channels. B, Current recordings of Kv1.5 channels in the presence of the Kvβ1.3 subunit. C, Current recordings of 
Kv1.5 channels in the presence of a Kvβ1.3 subunit in cells that had been previously treated with calphostin C (3 
μM) for 2 h. In all cases, the current (top), the deactivation process recorded at -40 mV after a prepulse to +60 mV 
(middle), as well as the IV relations and activation curves (dashed line) obtained (bottom) are shown. Note that the 
deactivation process is faster when the Kv1.5 channel is expressed alone. When PKC is inhibited, the linearity of 
the IV is recovered, and the activation process is shifted toward more negative potential when the Kvβ1.3 subunit 
is present. 
The degree of inactivation of Kv1.5-Kvβ1.3 channels continued to increase as membrane 
potential was more positive, indicating that Kvβ1.3-mediated fast inactivation is voltage-dependent, as 
previously reported (Uebele et al., 1998). However, the inactivation of Kv1.5-Kvβ1.3-calphostin C 
channels did not increase, similar to that observed in Kv1.5 channels (Figure 21A). 
To isolate the fast component of the inactivation induced by the Kvβ1.3 subunit, a double-pulse 
protocol using a 10 ms prepulse from -80 mV to +150 mV in 10 mV steps was applied (Uebele et al., 
1998). Figure 21B shows the inactivation curve obtained after applying this double-pulse protocol. After 
applying this short prepulse, Kv1.5 channels do not inactivate, because they exhibit a slow inactivation 
with a time constant of ≈200 ms. Kv1.5-Kvβ1.3 channels, which exhibit a fast inactivation with a time 
constant of ≈3 ms, display an inactivation curve with a Vh = -5.2  2.5 mV and s = 5.3  0.9 mV (n=4). 
This inactivation curve only represents the voltage-dependence of Kvβ1.3-fast inactivation induced, 
since when cells were treated with calphostin C this process is abolished. Figure 21B also shows that 
when this pulse protocol is applied, the fractional inactivation of Kv1.5-Kvβ1.3 channels did not increase 
with membrane potential, exhibiting similar behavior to that observed when a 250 ms in duration 
prepulse was applied in calphostin C-treated cells (Figure 21B and Table 7). However, when PKC was 
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inhibited, the inactivation process was completely abolished, exhibiting the same phenotype as Kv1.5 
channels alone.  
 
Figure 21: Voltage dependence of Kv1.5-Kvβ1.3 channel inactivation treated or non-treated with calphostin 
C. A, Voltage dependence of inactivation following a 250 ms in duration prepulse. B, Voltage dependence of the 
inactivation following a 10 ms in duration prepulse. 
TABLE 7. Voltage-dependent inactivation parameters of Kv1.5, Kv1.5-Kvβ1.3 and Kv1.5-Kvβ1.3-calphostin C 
channels obtained after applying a 250 ms prepulse. Vh: Half-inactivation voltage. s: Slope of the Boltzmann 
equation. Data represent the mean ± SEM of n>7 experiments *: Statistically significant difference between 
calphostin C and control conditions. #: Statistically significant difference between calphostin C and Kv1.5 channel 
alone. 
 
 
 
Vh (mV) 
 
s (mV) 
 
Degree of 
inactivation (%) 
 
Kv1.5 
 
-1.3 ± 3.4 
 
9.79 ± 1.6 
 
18.0 ± 3.4 
 
Kv1.5-Kv1.3 
Control 
 
-26.5 
 
4.2 
 
48.0 ± 3.0 
 
Kv1.5-Kv1.3 
calphostin C 
 
-6.5 ± 1.8* 
 
10.1 ± 1.1* 
 
33.8 ± 2.2*# 
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4.2.2 The pharmacological properties of Kv1.5-Kvβ1.3 channels after calphostin 
C treatment mimic those of Kv1.5 channels in the absence of the Kvβ1.3 
subunit. 
In previous studies, we have demonstrated that mutations of the Kv1.5 channel or its assembly 
with the Kvβ1.3 subunit modify the pharmacological properties of the channel (Franqueza et al., 1997; 
Gonzalez et al., 2002; Arias et al., 2007). Therefore, we studied the bupivacaine- and quinidine-induced 
blockade of Kv1.5-Kvβ1.3 channels after PKC inhibition. Figure 22 shows current recordings through 
Kv1.5-Kvβ1.3-calphostin C channels obtained in the absence and presence of bupivacaine (50 μM) or 
quinidine (30 μM). The current-voltage (I-V) relationships obtained after plotting the current amplitude 
measured at the end of 250-ms depolarizing pulses at different membrane potentials between −80 and 
+60 mV, in the absence and presence of either drug, are shown in the right panels of Figure 22. Both 
compounds decreased the magnitude of the current at all membrane potentials tested. This blockade 
was not voltage-dependent, exhibiting a similar degree of blockade when measured at +60 to that at 0 
mV (72.3 ± 3.1 vs. 67.9 ± 2.3%, n = 6, p>0.05 for bupivacaine, and 50.7 ± 3.7 vs. 50.4 ± 5.3%, n = 5, 
p>0.05 for quinidine) (Figure 22). 
 
 
Figure 22: Effects of bupivacaine (50 μM) and quinidine (30 μM) on Kv1.5-Kvβ1.3 channels in cells that 
have been treated with calphostin C (3 μM) for 2 h. A, Current recordings, voltage dependence of the blockade 
( ) and IV relationships obtained in the absence (○) and presence of bupivacaine (●). B, Current recordings, 
voltage dependence of the blockade ( ) and IV relationships obtained in the absence (○) and presence of 
quinidine (●). The blockade induced by both drugs was measured at the end of the pulse at +60 mV. Each point 
represents the mean ± S.E.M. of six and five experiments, respectively. 
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4.2.3 Bupivacaine and quinidine exhibit lower potency for blocking Kv1.5-Kvβ1.3 
channels after PKC inhibition. 
 
The concentration-response curves obtained for bupivacaine- and quinidine-produced blockade 
of Kv1.5, Kv1.5-Kvβ1.3 and Kv1.5-Kvβ1.3-calphostin C channels are shown in Figure 23. The 
suppression of the current at the end of 250 ms depolarizing pulses at +60 mV was used as an index of 
blockade. In contrast to the blockade previously reported for Kv1.5-Kvβ1.3 channels (Gonzalez et al., 
2002), bupivacaine-induced blockade of Kv1.5-Kvβ1.3-calphostin C channels showed a biphasic curve, 
with an IC50(1) of 0.2 ± 0.1 nM and an IC50(2) of 21.4 ± 4.1 μM (n = 41). Note that the IC50(2) was similar to 
that of Kv1.5 channels (Gonzalez et al., 2002). PKC inhibition did not modify the nH value (0.74 ± 0.06 
vs. 0.71 ± 0.08 for bupivacaine-produced blockade of Kv1.5-Kvβ1.3 and Kv1.5-Kvβ1.3-calphostin C 
channels, respectively) (Gonzalez et al., 2002) (Figure R23A). Similarly, quinidine-induced blockade of 
Kv1.5-Kvβ1.3 channels was modified by calphostin C treatment (Figure 23B). Indeed, the concentration-
response curve was also a biphasic concentration-response curve, with IC50(1) and IC50(2) values of 3.4 ± 
5.4 μM and 70.4 ± 15.4 μM (n=50), respectively. Interestingly, the IC50(1) value was similar to that 
reported for quinidine-produced blockade of Kv1.5 channels (Yeola et al., 1996), whereas the IC50(2) 
value was similar to the value reported for blockade of Kv1.5-Kvβ1.3 channels (Gonzalez et al., 2002). 
The nH(1) and nH(2) values for this concentration-response curve were 0.34 ± 0.07 and 1.36 ± 0.46, 
respectively. The nH(2) value was similar to that observed in the concentration-response curve of 
quinidine-induced blockade of Kv1.5-Kvβ1.3 channels (Gonzalez et al., 2002). 
 
Figure 23: Concentration dependence of bupivacaine-induced A. and quinine-induced B. blockade of 
calphostin C-treated Kv1.5-Kvβ1.3 channels. The dotted and dashed lines represent the dose-response curves 
obtained for the bupivacaine- and quinidine-produced blockade of Kv1.5 channels alone and Kv1.5-Kvβ1.3 
channels, respectively (taken from Gonzalez et al., 2002). Reduction in the current (relative to the control) at the 
end of depolarizing steps from −80 to +60 mV was used as an index of blockade. Each point represents the mean 
± S.E.M. of three to eight experiments. The continuous line represents the fit of the experimental data to a 
biphasic Hill equation. 
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4.2.4 Time-dependency of block of Kv1.5-Kvβ1.3 channels produced by 
bupivacaine and quinidine after PKC inhibition 
Bupivacaine- and quinidine-produced blockade of Kv1.5-Kvβ1.3-calphostin C channels was time-
dependent, as indicated by the normalized current in the insets of the left panels of Figure 24. To 
analyze the kinetics of blockade induced by both drugs, we plotted the ratio of the drug-sensitive current 
and the current under control conditions [(IControl−IDrug)/IControl] during the first 40 ms in the presence of 20, 
50 and 100 μM bupivacaine and 10, 30, and 100 μM quinidine (right panel of Figures 24A and B, inset). 
Blockade exponentially increased during depolarization, and the time constant of this process was 
faster at higher drug concentrations. Thus, this time constant was considered to be a good index of the 
development of blockade (τBlock). Based on the τBlock values obtained at different bupivacaine 
concentrations, the association (k) and dissociation (l) rate constants were derived, averaging 5.9 ± 0.5 
μM−1s−1 and 252.3 ± 33.0 s−1 versus 3.8 ± 0.3 μM−1s−1 and 108.3 ± 14.3 s−1 (n=14) in Kv1.5-Kvβ1.3 and 
Kv1.5-Kvβ1.3-calphostin C channels, respectively (Figure 24A) (Gonzalez et al., 2002). The IC50 value 
calculated from these values (28.5 μM = l/k) was very similar to that obtained from the concentration-
response curve (21.4 μM). In the case of quinidine, the k and l values for Kv1.5-Kvβ1.3 channels were 
5.1 ± 0.51 μM−1s−1 and 454.7 ± 38.05 s-1, while the k and l values for Kv1.5-Kvβ1.3-calphostin C 
channels were 5.0 ± 0.02 μM−1s−1 and 196.4 ± 1.1 s−1 (n=11) (Figure 24B). However, in this case, the 
IC50 value calculated from these values (39.6 μM = l/k) was not similar to that obtained from the 
concentration-response curve (70.4 μM). Although the blockade induced by both drugs exhibited time 
dependence, as observed during depolarization pulses from -80 to +60 mV, this time dependence was 
not evident in the tail currents recorded at -40 mV (Figure 25). 
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Figure 24: Time dependence of bupivacaine- A. and quinidine-induced B.  blockade of calphostin C-
treated Kv1.5-Kvβ1.3 channels. Left: Superimposed traces for the steps from -80 to +60 mV and those 
normalized to the control values (inset). Right: Relationship between 1/τB values at different concentrations of 
bupivacaine (20, 50 and 100 μM) and quinidine (10, 30 and 100 μM). Each point represents the mean ± SEM of 
three to six experiments. For a first-order blocking scheme, a relationship is expected: 1/τB = k × [Drug] + l. The 
lines represent the fit from which the apparent binding (k) and unbinding (l) rate constants were obtained in the 
control (dashed) and PKC-inhibited (solid) conditions. The relationship between the sensitive current and 
depolarizing time [(IControl −IDrug)/IControl] at three different drug concentrations is plotted in the inset of each panel. 
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Figure 25: Bupivacaine- A. and quinidine-induced B.  effects on the deactivation kinetics of calphostin C-
treated Kv1.5-Kvβ1.3 channels. The currents were obtained after applying the protocol outlined at the top of the 
figure. The tails were superimposed (top) and normalized (bottom) to show the similar deactivation kinetics in the 
absence and presence of both drugs. 
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4.3 PKC REGULATES THE Kv1.5 CHANNEL TRAFFICKING  
 
4.3.1 PKC inhibition reduces the amount of Kv1.5 channel in the cell surface 
Figure 20 shows that PKC inhibition not only modifies the characteristics of the current; 
abolishing the Kvβ1.3-induced fast inactivation and voltage dependence of Kv1.5-Kvβ1.3 channels, as 
previously described (David et al., 2012); but also produces a lower magnitude of the current (from 
719.2 ± 145.2 pA under control conditions, n=14, to 240.4 ± 26.5 pA after PKC inhibition with calphostin 
C, n=41, p<0.05). It was also observed that the magnitude of the currents became smaller with the time 
(data not shown). A possible explanation for this result could be that PKC inhibition results in a 
decrease level of Kv1.5 at the plasma membrane. To assess this hypothesis, we performed an 
extracellular enzymatic digestion of Kv1.5-Kvβ1.3 channels with proteinase K, followed by a western blot 
analysis (Figure 26). This kind of test represents a very sensitive assay for analyzing cell surface 
protein expression, since cytoplasmic proteins are unaffected when this enzyme is applied in living cells 
(Figure 6A) (Manganas et al., 2001; Choi et al., 2005). Densitometric analysis shown in Figure 26B 
demonstrates that cell treatment for two hours with calphostin C results in a significant decrease of the 
channel amount (32.6 ± 7.1%, n=5, p<0.05), without changes in the total channel amount (3.8 ± 4.1 vs., 
n=5, p>0.05). 
 
Figure 26: PKC inhibition significantly decreases Kv1.5 surface expression. HEK293 cells expressing Kv1.5-
Kvβ1.3 channels and treated or untreated with calphostin C 3 μM for 2h and treated with Proteinase K externally 
applied (lanes 3 and 4) or buffer alone (lanes 1 and 2). A, Representative experiment in which the arrows indicate 
the molecular weight at which surface Kv1.5 (digested form) and intracellular Kv1.5 (undigested form) appear. The 
immunoblot of β-actin at the bottom indicates that equal amounts of protein were loaded in each line. B, 
Densitometric analysis of 5 experiments like that shown in panel A. Each data represents the mean ± SEM of five 
experiments, *, p<0.05. 
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4.3.2 Inhibition of PKC with Calphostin C reduces the channel present in the 
cell membrane, increasing its amount into the cytoplasm 
The reduction of the Kv1.5 protein amount at the cell surface after PKC inhibition suggests that 
the trafficking of the Kv1.5 channelosome can be modified either by: 1) an increase of the internalization 
of Kv1.5 channels, or 2) a decrease in the recycling of this protein from endosomes to plasma 
membrane. In order to discriminate between these possibilities, a series of biotinylation experiments 
were performed in which a FLAG-tagged Kv1.5-Kvβ1.3 construction was used in order to increase the 
likelihood of biotinylation (see a representative experiment in Figure 27A). To determine whether the 
functional characteristics of the channels encoded by this construction were affected by the presence of 
the FLAG epitope at the S1-S2 extracellular loop, electrophysiological experiments were performed 
(Figure S2). As it is observed, in Figure S2, the electrophysiological characteristics of the Kv1.5-Kvβ1.3 
channels were not changed in comparison with Kv1.5-Kvβ1.3 observed in those channels without the 
extracellular FLAG epitope. The results obtained in the biotinylation assays are shown in Figure 27B 
and suggest that the protected Kv1.5-Kvβ1.3 channel behavior after PKC inhibition is similar to that 
observed under control conditions at shorter times than 60 min from the beginning of the treatment with 
calphostin C. However calphostin C-treated cells show a significant increase in the amount of 
intracellular channel after two hours of treatment (13.6±1.6 % in control condition vs. 20.7±1.9 % in 
calphostin C treated cells, n=3, p<0.05), suggesting that PKC is involved in the recycle of the channel. 
 
Figure 27: PKC inhibition significantly modify the Kv1.5 recycling. Recycling rates were measured using a 
biotinylation assay (see “Experimental Procedures”). A, Representative Western blot of biotinylated channels 
(internalized) at different times (30, 60 and 120 min). B, Densitometric analysis of experiments like that showed in 
panel A. Each data represents the mean ± SEM of three experiments. *, p<0.05. 
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In order to analyze this process by using another experimental approach, we performed 
immunocytochemical experiments that permitted us to discriminate the internalization of the channel 
after calphostin C treatment. To this end, a Kv1.5-HA+Kvβ1.3 construction was used (with similar 
electrophysiological characteristics than the Kv1.5-FLAG+Kvβ1.3 construction, Figure S3). As it is shown 
in Figure S3, the electrophysiological characteristics of the Kv1.5-Kvβ1.3 channels were unchanged in 
comparison with those observed in those channels without the extracellular HA epitope. These 
experiments were performed in two steps (for more details see the 3.7.2 section of Materials and 
Methods): 1) first we labeled the channel present in the cell membrane with anti-HA before the 
beginning of the treatment with calphostin C. Then, 2) cells were fixed and stained with the secondary 
antibodies. Figure 28 shows representative confocal images of cells transfected with Kv1.5-HA+Kvβ1.3 
under control conditions and after PKC inhibition with calphostin C. Under control conditions, most cells 
exhibited Kv1.5-HA+Kvβ1.3 channels mainly in the cell membrane (red color) (top); whereas after PKC 
inhibition, all stained cells exhibited most Kv1.5-HA+Kvβ1.3 channels in the cytoplasm (green color) and 
less amount of the channels at the cell membrane (bottom).  
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Figure 28: PKC inhibition increases the amount of internalized channel. Representative images of cells in 
control conditions (upper panels) and after PKC inhibition after calphostin C treatment (bottom panels). Note that 
while in control conditions, cells show mainly, although not only, a high red signal (channel present in plasma 
membrane); calphostin C-treated cells exhibit a weaker red signal and significant higher green signal (channel 
internalized and non-recycled towards the cell membrane). In the top part of the figure it has been represent a 
scheme of the process carried out in these assays. 
Moreover, in calphostin C treated cells the amount of channels inside the cells is much greater 
than in control cells. Also it can be seen these results in the Figure S4 where the orthogonal projection 
of these cells have shown where it can be observe a ‘whole’ representation of the staining of each cell. 
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4.3.3 Channel dynamics is also disrupted 
In order to analyze whether the effects of PKC inhibition was modified, not only the channel 
location at the end of the treatment, but also to be able to discriminate the cellular traffic of the channels 
in live cells; we performed live cell imaging assays in a Cell Observer equipment using fluorescence. As 
it shown in Figure 29 and in Videos 1A-C in control conditions, and 2A-C after PKC inhibition (Videos 
1D-F and 2D-F show the same experiments but in the maximal projection instead of one representative 
section as showed in 1A-C and in 2A-C), we observed a dramatic decrease or abolishment of the 
channel dynamic. 
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Figure 29: Influence of PKC inhibition on Kvβ1.3-IRES-Kv1.5-HA mobility in HEK293. Kv1.5-HA labelled by 
fluorescence staining of live cell under control conditions (upper panels) and after PKC inhibition by calphostin C 
treatment (bottom panels) and visualized at different times. Frames extracted from Videos 1B for control and 
Video 2B for calphostin C. 
 
4.3.4 PKC is involved in the slow recycling of the channel 
Rab-GTPases regulate the trafficking of vesicles between plasma membrane and intracellular 
compartments by regulating sorting, tethering and docking of trafficking vesicles. Rab4, associated with 
the early endosome (EE), mediates the fast recycling process while Rab11, linked to the recycling 
endosome (RE), is involved in slow recycling of proteins back to the cell surface (Balse et al., 2009). 
Because we have observed that PKC inhibition strongly decreases the Kv1.5 trafficking, we 
hypothesized that PKC activity is necessary to some of these processes. In order to know which one 
(fast or slow recycling) is involved, immunocytochemistry experiments were carried out. Figure 30 
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shows representative confocal images of cells transfected with Kv1.5-HA+Kvβ1.3 and, either, Rab4 or 
Rab11 constitutively actives (CA). The results shown in this Figure suggest that only in the presence of 
Rab11CA, the amount of channel internalized (green color) (bottom) after calphostin C treatment is 
decreased in comparison with that observed in cells cotransfected with Kv1.5-HA+Kvβ1.3+Rab4CA (top) 
or those cotransfected with Kv1.5-HA+Kvβ1.3 channels (at bottom of Figure 28) and treated with 
calphostin C. Also, it can be seen these results in the Figure S5 where the orthogonal projection of 
these cells have shown where it can be observe a ‘whole’ representation of the staining of each cell. 
R
ab
4C
A
R
ab
11
C
A
 
Figure 30: The cotransfection of Kv1.5-Kvβ1.3 with Rab11CA abolishes the increase of the internalization 
PKC inhibition-mediated. Representative images of cells after cotransfection of Kv1.5-Kvβ1.3 channels with 
Rab4CA (upper panels) and with Rab11CA (bottom panels), after calphostin C treatment. Note that only in the 
presence of Rab11CA, the amount of channel internalized (green color) (bottom) after calphostin C treatment is 
decreased in comparison with that cell cotransfected with Kv1.5-HA+Kvβ1.3+Rab4CA (top) or those cotransfected 
with Kv1.5-HA+Kvβ1.3 channels (at bottom of Figure 28). The amount of channel present in plasma membrane is 
shown in red color. 
 
In order to confirm this hypothesis, electrophysiological experiments were performed in which 
Rab4CA or Rab11CA were cotransfected with Kv1.5-Kvβ1.3. Figure 31 shows representative records 
obtained of outward potassium current after cell cotransfection with Kv1.5-Kvβ1.3 and Rab4CA, and 
treated with calphostin C after 48h post-transfection. As it can be observed, currents obtained exhibited 
similar properties and magnitude than those recorded from cells transfected with Kv1.5-Kvβ1.3 and 
treated with calphostin C (240.4±26.5 pA in Kv1.5-Kvβ1.3 calphostin-treated channels vs. 273.4±58.1 
pA in Kv1.5-Kvβ1.3+Rab4CA, n=5-8, p>0.05, Figure R31A). However, currents recorded from cells 
cotransfected with Kv1.5-Kvβ1.3 and Rab11CA exhibited a greater magnitude at potentials positive to -
10 mV (240.4±26.5 pA in Kv1.5-Kvβ1.3 calphostin-treated channels vs. 511.6±94.2 pA in Kv1.5-
Kvβ1.3+Rab22CA, n=5-8, p<0.05, Figure 31B). 
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Figure 31: PKC activity is involved in Kv1.5-Kvβ1.3 recycling Rab11-meadiated. Representative recordings 
(left panels) and IV relationships (right panels) obtained after calphostin C treatment when Rab4CA (A) or 
Rab11CA (B) is co-transfected with Kv1.5-Kvβ1.3 channels. In both cases, IV relationships are compared with 
Kv1.5+ Kvβ1.3 channels. Note that only when Rab11CA is co-transfected we obtain significant differences and 
these are observed at potentials positive than -10 mV. 
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4.4 Lgi1 effects on Kv1.5-Kvβ1.3 channel complex. Possible role on human 
ventricle  
 
4.4.1 Lgi1 is present in rat ventricle but not in atria 
Lgi1 interferes with Kvβ1-conferred inactivation of Kv1 channels, suggesting that Lgi1 can 
modulate the gating of Kv1 channels. However, the molecular basis of the Lgi1 effect on Kv1 channel 
inactivation is presently unknown (Schulte et al., 2006). It is known that, even when Kvβ1.3 and Kv1.5 
subunits are expressed in human myocardium, a current with the Kv1.5-Kvβ1.3 phenotype has not been 
registered in any territory of the human heart (atrium or ventricle). One possible explanation could be 
that a given protein present in this tissue effect modifies the activity of the Kvβ1.3 subunit. To address 
this hypothesis, we first wanted to confirm the presence of this protein in cardiac tissue. To that end, we 
performed western blots of proteins from rat cardiac tissue (atria and ventricle). Figure 32 shows the 
results of these experiments that demonstrate the presence of Lgi1 protein in rat ventricle but not in 
atria. At least, if there is Lgi1 in rat atria, the level of expression is much lower than in ventricle, as it can 
be observed in Figure 32, comparing them with HEK293 cells transfected with Lgi1.  
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Figure 32: Lgi1 protein is expressed mainly in ventricle. Figure shows an immunoblotting against Lgi1 protein 
in four rat atria and four rat ventricles. HEK293 cells transfected with Lgi1 were used as a positive control (Lgi1 in 
the Figure). Also, this Figure shows a Protein Ladder (P.L.), which is showing two bands with 75 and 100 kDa of 
molecular weight. Note that, to get a weak signal in the case of atria, the film had to be highly exposed. 
 
Next, we analyzed whether Lgi1 is another protein of the Kv1.5 channelosome. In order to 
assess this hypothesis, we performed immunoprecipitation assays in which we immunoprecipitated 
Kv1.5 and immunobloted for Lgi1, and vice versa. Figure 33 shows the results from these experiments. 
When we immunoprecipiteted Kv1.5 channels and we blotted for Lgi1, a band for Lgi1 was observed in 
the positive IP. Unfortunately, when the coIP was performed immunoprecipitating Lgi1 and blotting for 
Kv1.5, we observed a positive band both in the Ab- and in the Ab+ immunoprecipitations, because we 
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only got a positive immunoprecipitation when the samples were not pre-washed with A/G-protein 
previously to the immunoprecipitation process (Figure 33).   
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Figure 33: Immunoprecipitation of Kv1.5-Lgi1 complex in rat ventricular cardiac tissue. A, 
Immunoprecipitation of Kv1.5 channel and blotted against Lgi1 protein. B, Immunoprecipitation of Lgi1 protein and 
blotted against Kv1.5 channel. In both cases, negative (Ab−) and positive (Ab+) immunoprecipitations (IP) were 
performed. Note that when Lgi1 is immunoprecipitated, a residual and unspecific fraction of protein is apparent 
even in the negative IP (n = 3). WB, Western Blot; Sn, Supernatant. 
 
4.4.2 Electrophysiological effects of Lgi1 are beta subunit-dependent 
Given the overlap in the expression pattern between Kvβ1.3 and Lgi1 proteins in cardiac tissue, 
mainly in ventricular tissue, we wonder if Lgi1 subunits produced a functional relevance on Kv channels 
when cotransfected in heterologous system, like HEK293 cells. In these experiments (Figure 34A), we 
observed that cells cotransfected with Kv1.5-Kvβ1.3 and Lgi1 exhibited an outward current without 
Kvβ1.3-induced fast inactivation, a small magnitude of the current, a shift in the activation curve towards 
more positive potentials, as well as an increase in the slope of the activation curve (from Vh = -23.6± 2.4 
mV and s = 3.9 ± 0.2 mV, n=14 , for Kv1.5-Kvβ1.3 channels and Vh = -13.2 ± 1.3 mV and s = 6.4 ± 0.9 
mV for Kv1.5-Kvβ1.3+Lgi1, n=12 , p<0.05 in both cases). Beside this, Kv1.5-Kvβ1.3+Lgi1 channels 
showed an electrophysiological behavior more similar to that exhibited by Kv1.5 channel when they are 
transfected alone (Figure 34B). However, when Lgi1 protein is cotransfected with Kv1.5, without Kvβ1.3, 
we obtained a current of a smaller magnitude, but similar electrophysiological properties (Vh = 0.2 ± 3.1 
mV and s = 9.0 ± 0.8 mV, n=9, for Kv1.5 channels, and Vh = 0.6 ± 4.3 mV and s = 9.4 ± 2.1 mV for 
Kv1.5+Lgi1, n=3, p>0.05; Figure 34B).  
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Figure 34: Effects of Lgi1 protein on the Kv1.5 current with and without the presence of Kvβ1.3 subunit. A, 
Effects of Lgi1 on Kv1.5-Kvβ1.3 channels: Left panels, Recordings obtained in the absence and in the presence of 
Lgi1, respectively; Middle panel, IV relationships before and after normalization by +60 mV value (inset); Right 
panel, Activation curves of both conditions. B, Left panels, Effect of Lgi1 protein on Kv1.5 channels expressed 
alone and in the presence of Lgi1; Middle panel, IV relationships before and after normalization by +60 mV value 
(inset); Right panel, Activation curves of both conditions. 
 
4.4.3 Lgi1 reduces the amount of channel in the cell surface. The effects on the 
actin cytoskeleton are channel-dependent 
Similarly to that observed with the calphostin C treatment on Kv1.5-Kvβ1.3 channels, the Kvβ1.3-
induced fast inactivation abolishment appeared in parallel with a reduction of the magnitude of the 
current. In order to analyze if the amount of the channel protein in the cell surface decreased, 
experiments with proteinase K were performed. As Figure 35 shows, the co-transfection of Kv1.5-Kvβ1.3 
with Lgi1 protein results in a significant decrease in the amount of the channel (32.1 ± 1.9%, n=5, 
p<0.05). It has been widely described, and also showed in the present Doctoral Thesis, that after 
treatment with proteinase K the amount of actin decreased even when the same amount of protein was 
analyzed (Manganas et al., 2001; Choi et al., 2005) (Figure 26). However, the dramatic effect observed 
in this case on the actin cytoskeleton, was only observed when the protein was co-transfected with the 
Kv1.5 channel (Figure 36), being therefore a channel-dependent effect. Moreover, this effect was also 
observed when tubulin was used as a loading control Figure 36B, but not when using GAPDH (Figures 
35A and 36). 
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Figure 35: Lgi1 promotes a significant decrease in Kv1.5 surface expression. HEK293 cells expressing 
Kv1.5-Kvβ1.3 channels in the presence and in the absence of Lgi1 and with the external application of Proteinase 
K (lanes 3 and 4) or buffer alone (lanes 1 and 2). A, Representative experiment in which the arrows points out the 
surface Kv1.5 (digested form) and the intracellular Kv1.5 (undigested form) channel. The immunoblot of GAPDH at 
the bottom indicates that equal amounts of protein were loaded in each line. B, Densitometric analysis of similar 
experiments to that showed in panel A. Each data represents the mean ± S.E.M. of five experiments; *, p<0.05. 
 
 
Figure 36: The effects of the Lgi1 on the actin cytoskeleton are channel-dependent. A, The effects of Lgi1 
on actin cytoskeleton only appear when this protein is co-transfected with Kv1.5-Kvβ1.3 channels. B, The effects of 
Lgi1 on the actin cytoskeleton also appears when this protein is co-transfected with Kv1.5 alone. Note that this 
effect is not observed when any of the proteins (Kv1.5 or Lgi1) are transfected separately. 
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4.4.4 Lgi1 effects are, at least in part, due to extracellular signaling 
In order to study the mechanism of action by which Lgi1 abolishes the Kvβ1.3-induced fast 
inactivation in “real time” we used two different experimental approaches. In the first one, we tried to 
inhibit the inhibitory effects of Lgi1 on the beta subunit using an anti-Lgi1 antibody in the internal 
solution of the patch pipette. But, in these experiments the phenotype of the current elicited was similar 
to that obtained after activate Kv1.5 channels alone, suggesting that after the binding of the anti-Lgi1 
antibody to its epitope, the activity of Kvβ1.3 subunit is compromised (Figure 37).  
 
 
Figure 37: Effects of anti-Lgi1 present into the solution of the patch pipette. A, Current records of Kv1.5. B, 
Current records obtained from the activation of Kv1.5-Kvβ1.3 channels. C, Current records obtained in cells 
cotransfected with Kv1.5-Kvβ1.3 and Lgi1. D, Current records obtained from cells transfected with Kv1.5-
Kvβ1.3+Lgi1 and with anti-Lgi1 in the internal solution of the patch pipette. Note that the current elicited by Kv1.5-
Kvβ1.3 channels in the presence of Lgi1 into the pipette results in a similar abolishment of that showed by them 
after the cotransfection and closer to Kv1.5 current. 
 
Secondly, we carried out experiments in cells transfected with the Kv1.5-Kvβ1.3 construction and, 
filling the internal solution of the pipette with the Lgi1 purified protein (0.5 μg/ml). In these experiments, 
if we broke the seal just after we got it, Lgi1 was not able to abolish the Kvβ1.3-induced fast inactivation 
(Figure 38A). In fact, only when we waited at least 2 min after seal formation, the Kvβ1.3-induced fast 
inactivation was abolished (Figure 38B).  
 
Results  
 
77 
 
100 ms
10
0 
pA
100 ms
10
0 
pA
-40 mV
-80 mV
+60 mV
-40 mV
-80 mV
+60 mV
B
-80 -60 -40 -20 0 20 40 60
0.0
0.2
0.4
0.6
0.8
1.0
N
or
m
al
iz
ed
 ta
il 
cu
rre
nt
s 
(p
A
)
Vm (mV)
 Kv1.5+Kv1.3 Control
Vh = -23.6 ± 2.4
s = 3.9 ± 0.2
 Kv1.5+Kv1.3+Lgi1 int. sol.
Vh = -14.8 ± 3.2
s = 5.8 ± 0.3
-80 -60 -40 -20 0 20 40 60
0.0
0.2
0.4
0.6
0.8
1.0
 Kv1.5+Kv1.3+Lgi1 int. sol.
 Kv1.5+Kv1.3 Control
N
or
m
al
iz
ed
 ta
il 
cu
rr
en
ts
 (p
A
)
Vm (mV)
s = 3.9 ± 0.2
Vh = -23.6 ± 2.4
s = 3.5 ± 0.5
Vh = -19.5 ± 3.1
-80 -60 -40 -20 0 20 40 60
0
200
400
600
800
I (
pA
)
Vm (mV)
 Kv1.5+Kv1.3 Control
 Kv1.5+Kv1.3+Lgi1 int. sol.
-80 -60 -40 -20 0 20 40 60
0.0
0.2
0.4
0.6
0.8
1.0
N
or
m
al
iz
ed
 c
ur
re
nt
 (p
A)
Vm (mV)
-80 -60 -40 -20 0 20 40 60
0
200
400
600
800  Kv1.5+Kv1.3 Control
 Kv1.5+Kv1.3+Lgi1 int. sol.
I (
pA
)
Vm (mV)
-80 -60 -40 -20 0 20 40 60
0.0
0.2
0.4
0.6
0.8
1.0
N
or
m
al
iz
ed
 c
ur
re
nt
 (p
A
)
Vm (mV)
A
 
Figure 38: Lgi1 present into the patch pipette produces its effects on Kv1.5-Kvβ1.3 channels through the 
external side of the cell. A, Representative recordings, IV relationships non- and normalized by +60 mV value 
(inset) and activation curves comparing them with Kv1.5-Kvβ1.3 (from left to right side, respectively) obtained just 
after the rupture of the seal. B, Representative recordings, IV relationship non- and normalized by +60 mV value 
(inset) and action curves comparing them with Kv1.5-Kvβ1.3 (from left to right side, respectively) obtained after 2 
min. after seal formation. 
 
4.4.5. Cellular and tissular location of Lgi1 
Although part of our results seems that the intracellular actions of Lgi1 protein are carried out 
after the binding of this protein from outside beginning a signaling cascade (Figure 38); the fact that the 
same protein has also effects on the actin cytoskeleton makes us wonder which is the cellular location 
of Lgi1 to be able to perform both roles in the cell at the same time. To solve this question we performed 
immunocytochemistry experiments in HEK293 cells cotransfecting Lgi1-GFP and Phalloidin-AF546 in 
the absence and in the presence of Kv1.5-CFP. As it is shown in Figure 39, the presence of Lgi1 is not 
enough to produce those cytoskeleton disorders observed in the western blot assays (Figure 36). 
However, after cotransfection with Kv1.5, the labeling of the actin cytoskeleton is highly decreased not 
only in those cells that express the protein, but also in those that are around (Figure 39). 
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Figure 39: Lgi1 needs the presence of the channel to disrupt the cytoskeleton structure in 
both auto- and paracrine way. The Figure shows representative images of the effect exerted by 
Lgi1 on the actin cytoskeleton. Note that cells, and their neighbors, that only express Lgi1 protein 
(in green) present a cytoskeleton labeling (in red) well defined. However, those cells that express 
Lgi1 and Kv1.5 channel (in blue), as well as their neighbors, does not. Nucleuses are shown in 
magenta. 
 
The presence of Lgi1 in human heart it has been previously described (Gu et al., 2002). 
However, we wanted to know the specific location into the cardiac human tissue and compare it with 
that shown by Kv1.5 channel in the same tissue. To this end, we carried out immunohystochemistry 
assays using ventricular human slices to elucidate not only the location of Lgi1 but also whether if its 
expression pattern overlaps with that showed by Kv1.5 (Figure 40). Figure 40A shows the expression 
pattern shown by Kv1.5 in human ventricle. This channels has a membrane expression pattern 
(arrowheads) and is specifically present at the intercalated disks (arrows), as it was previously 
described (Mays et al., 1995). Figure 40B shows the expression pattern obtained for Lgi1 and, very 
surprisingly, this protein also expresses in the membrane with an expression pattern very similar to that 
showed by Kv1.5 channel. 
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Figure 40: Kv1.5 channel and Lgi1 protein show a similar expression pattern in human ventricle. Figure 
show representative images of: A, Immunodetection of the Kv1.5 channel protein in human myocardium. 5 μm 
sections were prepared from adult ventricle and stained as described in Methods. B, Staining of Lgi1 protein in 
human ventricle following the same procedure than in A. Arrowheads, point out Kv1.5 in the cell membrane. 
Arrows, mark the presence of the channel in the intercalated disks. 
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5.1 PROTEIN KINASE C ACTIVITY REGULATES FUNCTIONAL EFFECTS OF Kvβ1.3 
SUBUNIT ON Kv1.5 CHANNELS: IDENTIFICATION OF A CARDIAC 
CHANNELOSOME. 
 
In the present Doctoral Thesis, we have analyzed the mechanisms by which PKC inhibition calphostin C-
mediated abolishes Kvβ1.3-induced fast inactivation of the Kv1.5 channel. We have demonstrated that the 
inhibition of, at least, classical and novel PKC isoforms is required to abolish Kvβ1.3-induced fast inactivation 
(Kwak et al., 1999a; Kwak et al., 1999b). Furthermore, this effect was not due to Kv1.5-Kvβ1.3 dissociation but to 
a positive shift of the inactivation curve driven by PKC inhibition, because both subunits remained assembled as 
shown by immunocytochemistry, immunoprecipitation and electrophysiological experiments. We have also 
showed that, at least, Kvβ1.3, RACK1, PKCβI, PKCβII and PKCθ are associated with Kv1.5 in HEK293 cells, 
forming a channelosome. Finally, for the first time, we provide evidence pointing to the existence of a native 
ventricular cardiac Kv1.5 channelosome, whose composition is similar to that found in HEK293 cells (with the 
exception of PKCθ, absent in this tissue according to our western blot analyses, data not shown).  
The stimulation of α1-receptors leads to activation of PLCγ. This enzyme cleaves PIP2, generating IP3 and 
DAG, which activates most PKC isoforms either alone or with Ca2+, with the exception of atypical PKCs. The N-
terminus of the Kvβ1.3 subunit associates with membrane-bound PIP2 and when it dissociates from PIP2, it 
assumes a hairpin structure that enters the central cavity of an open Kv1.5 channel, inducing fast inactivation. 
Thus, Kvβ1.3-induced fast inactivation is mediated by a competitive binding between phosphoinositides (PIPs) 
and the inner pore region of Kv1.5 channels for the N-terminus of Kvβ1.3 (Decher et al., 2008). The present 
results obtained for PIP2 and OAG are in agreement with previous reports and indicate a fine-tuned regulation of 
Kvβ1.3-induced fast inactivation by PKC and PIP2. Moreover, the effects of PIP2 in cells in which the PLC was 
inhibited produced a marked decrease of the Kvβ1.3-induced fast inactivation. In the absence of PIP2 into the 
internal solution, the effects observed were qualitatively similar (data not shown), suggesting a role of PLC on the 
fast inactivation induced by this β subunit. 
Most PKC isoforms redistribute into different subcellular compartments upon activation, depending on the 
PKC isoform and the cell type (Dorn & Mochly-Rosen, 2002). A surprising finding of the present study was that all 
of the PKC inhibitors tested (Gö6976, Gö6983, hispidin, and PKCζ-PI), with the exception of calphostin C, failed 
to abolish Kvβ1.3-induced fast inactivation. This result is likely due to the different mechanisms of action of the 
PKC inhibitors used. Indeed, calphostin C inhibits PKC by binding to its C1 domain (DAG and phorbol ester 
binding site) and then irreversibly inactivates the enzyme. Gö6983 and Gö6976 are competitive inhibitors of ATP 
binding to the catalytic domain of PKC, whereas hispidin affects both PKCβI and PKCβII translocation (Kobayashi 
et al., 1989; Qatsha et al., 1993; Sossin, 1997; Wadsworth & Goldfine, 2002; Young et al., 2005). Our results 
suggest that inhibition of classical and novel, but not atypical, PKC isoforms counteracts Kvβ1.3-induced fast 
Discussion 
84 
 
inactivation and shifts the Vh  of the activation curve to values closer to those of Kv1.5 observed in the absence of 
Kvβ1.3, as has been previously described (Kwak et al., 1999b). The potential dissociation of α-β caused by PKC 
inhibition was also analyzed in the present study. Colocalization, immunoprecipitation and electrophysiological 
experiments revealed that these subunits remained assembled in the plasma membrane despite PKC inhibition 
by calphostin C. These results are in agreement with the notion that Kv1.5 and Kvβ1.3 subunits assemble in the 
endoplasmic reticulum during the early stages of their biosynthesis (Nagaya & Papazian, 1997), and 2 h 
incubation with calphostin C is sufficient to eliminate the typical fast inactivation induced by Kvβ1.3 (Kwak et al., 
1999b). Moreover, previous results reported by Kwak and coworkers showed that a tandem construction of Kv1.5 
and Kvβ1.3, which generates a unique protein, showed similar responses to calphostin C (a shift in Vh to more 
positive potentials and a loss of fast inactivation) (Kwak et al., 1999b). These results indicate that mechanisms 
other than subunit dissociation must be involved in the abolishment of Kvβ1.3-induced fast inactivation produced 
by calphostin C. 
Although we were able to rule out a role for atypical PKCs, the involvement of a specific PKC isoform in 
this process has not yet been demonstrated. In addition, experiments in which the membrane potential was 
depolarized to +100 mV indicated that despite PKC inhibition (calphostin C or PKC siRNA), Kvβ1.3 was still 
capable of conferring fast inactivation and thus remained associated with Kv1.5. Furthermore, the co-
immunoprecipitation experiments showed that Kvβ1.3 remained associated with Kv1.5 despite PKC inhibition by 
calphostin C or by PKC silencing by siRNA. These data suggest that Kv1.5 and Kvβ1.3 subunits form a stable 
complex following their biosynthesis in the endoplasmic reticulum and that PKC inhibition and/or activation 
modulates the inactivating effect of Kvβ1.3. It has been demonstrated that residues R5 and T6 of the Kvβ1.3 
subunit are involved in PIP2 binding and mutations (alanine or cysteine) at these residues dramatically increase 
the degree of Kvβ1.3-induced fast inactivation (Decher et al., 2008). It has been described that calphostin C does 
not modify the gating of the Kv1.5 in the absence of β subunits (Kwak et al., 1999b). Therefore, it is likely that the 
effects shown in the present study involve the phosphorylation of some residues present in the Kvβ1.3 subunit. 
One candidate could be threonine at position 6 (T6) of Kvβ1.3. Thus, we may hypothesize that PKC 
phosphorylation of this threonine or another threonine/serine at the N-terminus of the Kvβ1.3 subunit can lead to a 
diminished capability to bind PIP2, thus avoiding the abrogation of fast inactivation caused by PIP2. These 
findings provide an explanation for the effects of PKC inhibition on the Kvβ1.3-induced inactivation, assuming that 
phosphorylated Kvβ1.3 cannot bind PIP2.  Non-phosphorylated Kvβ1.3 would be able to bind PIP2 and this binding 
would abolish N-type inactivation (Decher et al., 2008). However, further experiments are necessary to elucidate 
the residue/s involved in this effect. 
In the past decade, myriads of protein-protein interactions involved in intracellular signaling have been 
described (Hubbard & Cohen, 1993; Mochly-Rosen, 1995; Burack & Shaw, 2000; Wang et al., 2002). 
Determination of the subcellular localization of signal transduction proteins, enzymes, substrates and mediators 
has revealed the rapid and efficient transmission of signals from either the extracellular medium or from 
intracellular sites as an essential feature of optimal signaling (Pawson & Nash, 2003). Despite the high degree of 
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homology between PKC isoforms at both sequence and structural levels, especially within the catalytic domain, 
each PKC isoform mediates unique subcellular functions (Dempsey et al., 2000; Jaken & Parker, 2000) that are 
dependent on the target substrate (Carpenter et al., 1987; Parker et al., 1989). These location mechanisms are 
especially common in plasma membrane proteins because incoming stimuli must be integrated and transmitted 
with a high degree of efficiency. In the present study, we have demonstrated that Kv1.5 and Kvβ1.3 form a highly 
stable protein complex, which is tightly regulated by classical and novel, but not atypical, PKC isoforms. 
Furthermore, our results show that PKCβI, PKCβII and RACK1 coassemble with Kv1.5 and Kvβ1.3. Therefore, the 
Kv1.5 functional channelosome contains, at least, Kv1.5, Kvβ1.3, RACK1, PKCβI, PKCβII, and PKCθ. Besides, a 
similar channelosome has been found in ventricular, but not in atrial tissue, showing a parallel distribution to that 
of Kvβ1.3 (England et al., 1995a), which suggests an important role of this beta subunit in the constitution of the 
macromolecular complex. 
The presence of RACK1 in other ion channel complexes has been previously reported. Indeed, RACK1 
binds to the C-terminus of KCa1.1 channels (Isacson et al., 2007). Moreover, the overexpression of RACK1 with 
KCa1.1 channels in Xenopus oocytes shifts the activation curve towards more positive potentials in the absence, 
but not in the presence, of ectopically expressed β channel subunits (Isacson et al., 2007). Furthermore, PKCβII, 
which is recruited by RACK1, down-regulates Cav1.2 activity following activation (Dorn & Mochly-Rosen, 2002). 
Besides, the functional Kir3.1 complex contains PKA, PP1, PP2A/C and RACK1. Within this complex, RACK1 
binds directly to Gβγ (Dell et al., 2002) and PKC (Ron et al., 1994). Recently, it has been described that TRPC3 
regulates IP3 receptor (IP3R) function by mediating interaction between IP3R and the scaffolding protein RACK1, 
as well as the importance of the Orai1-STIM1-TRPC3-RACK1-IP3R complexes in the fine modulation of 
intracellular Ca2+ stimulated by agonists of these receptors (Woodard et al., 2010). Thus, RACK1 is emerging as 
an important adaptor protein that may play very important roles in the modulation of different ion channels and in 
the interaction between ion pores and ancillary subunits. The variety of signaling proteins linked to RACK1 
(Schechtman & Mochly-Rosen, 2001), which include PKCβII (Ron et al., 1994; Csukai et al., 1997), PLCγ 
(Disatnik et al., 1994), Src (Chang et al., 1998) and dynamin-1 (Rodriguez et al., 1999), among others, could 
explain the diverse effects of PKA and PKC on the Kv1.5-Kvβ1.3 current (Murray et al., 1994; Li et al., 1996; Kwak 
et al., 1999a; Kwak et al., 1999b) and the requirement for simultaneous inhibition of numerous PKC isoforms to 
abolish fast inactivation. 
In conclusion, we have analyzed the mechanisms by which calphostin C abolishes Kvβ1.3-induced fast 
inactivation. Our experiments demonstrate that this effect is not due to the dissociation of Kv1.5 and Kvβ1.3 
subunits and that these subunits remain assembled following PKC inhibition. Our experiments also demonstrate 
that PLC is also involved in the regulation of the Kvβ1.3-induced fast inactivation. In addition, we have 
characterized a Kv1.5 channelosome in which Kv1.5, Kvβ1.3, RACK1, PKCβI, PKCβII and PKCθ physically and 
functionally interact. Importantly, we have identified a very similar macromolecular complex in rat ventricular 
tissue. The description and functional characterization of this channelosome opens up a variety of possible 
mechanisms to explain the differences between IKur recorded in ventricle and atrium in different animal species. 
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Differential composition of this Kv1.5 complex could constitute a primary mechanism of capital importance for the 
modulation of cardiac excitability. 
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5.2 PHARMACOLOGICAL CONSEQUENCES OF PROTEIN KINASE C INHIBITION 
ON Kv1.5-Kvβ1.3 CHANNELS.  
 
In the second part of this Doctoral Thesis, we analyzed the electrophysiological and pharmacological 
consequences of PKC inhibition induced by calphostin C in Kv1.5-Kvβ1.3 channels. We demonstrated that the 
voltage-dependence of Kv1.5-Kvβ1.3 channel inactivation after PKC inhibition resembles that observed in Kv1.5 
channels alone. Inhibition of PKC using calphostin C partially reverted the changes in the pharmacologic 
properties induced by the assembly of the Kvβ1.3 subunit with Kv1.5 channels (Gonzalez et al., 2002; Decher et 
al., 2005) in such a way that the pharmacology of these channels in cells pre-treated with calphostin C resembled 
that exhibited by Kv1.5 channels in the absence of the Kvβ1.3 subunit (Snyders et al., 1992; Valenzuela et al., 
1995a).  
PKC inhibition induced by calphostin C results in the abolishment of Kvβ1.3-induced fast inactivation due 
to a shift in the inactivation midpoint of the Kv1.5-Kvβ1.3 channels (David et al., 2012). Surprisingly, the voltage 
dependence of inactivation of Kv1.5-Kvβ1.3-calphostin C and that of Kv1.5 channels were similar. These results 
suggest not only that the voltage-dependent inactivation induced by this beta subunit is abolished but also that 
the complex behaves as if the Kvβ1.3 subunit does not assemble with Kv1.5 channels. The Kvβ1.3-mediated fast 
inactivation is voltage dependence, in contrast to the N-type inactivation of Shaker channels and the fast 
inactivation produced by Kvβ1.2 on Kv1.5 channels, both of which are insensitive to membrane potential (Zagotta 
et al., 1989; De Biasi et al., 1997; Uebele et al., 1998). The voltage-dependence of Kvβ1.3-mediated inactivation 
may be due to the charge within the blocking particle sensing the transmembrane potential, as well as to some 
voltage-dependent changes in the Kv1.5 channel that are involved in the interaction with the Kvβ1.3 subunit. To 
discriminate between these possibilities, experiments using a pulse protocol with 10 ms depolarizing pre-pulses 
were performed. These experiments led us to isolate the fast inactivation induced by the Kvβ1.3 subunit from the 
slow inactivation characteristic of Kv1.5 channels. Indeed, inactivation curves obtained from Kv1.5-Kvβ1.3 and 
Kv1.5-Kvβ1.3-calphostin C channels were similar after applying 10 ms and 250 ms pre-pulse protocols, 
respectively. Taken together, these data suggest that the voltage dependence of Kvβ1.3-mediated inactivation is 
independent of the electrophysiological properties of the Kv1.5 channel.  
Bupivacaine- and quinidine-induced blockade of Kv1.5 channels result from their binding to an external 
and an internal receptor sites (Yeola et al., 1996; Franqueza et al., 1997; Longobardo et al., 2000; Longobardo et 
al., 2001). Although the molecular determinants of the external binding site remain unknown, both drugs share a 
common internal receptor site, which is located at the S6 segment and that involves a polar interaction with T507 
and two hydrophobic interactions with L510 and V514 (Yeola et al., 1996; Franqueza et al., 1997; Arias et al., 
2007). Moreover, the bupivacaine binding site on Kv1.5 channels overlaps with the binding site of the Kvβ1.3 
subunit in such a way that bupivacaine blocks to a lesser extent Kv1.5-Kvβ1.3 channel than Kv1.5 channels alone 
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(Arias et al., 2007). The pharmacology of the Kv1.5-Kvβ1.3 channels was modified after PKC inhibition for 
bupivacaine and quinidine, decreasing the IC50 for both drugs. In fact, both compounds lost the characteristic 
voltage-dependent blockade that was previously described for the Kv1.5 and Kv1.5-Kvβ1.3 channels (Snyders et 
al., 1992; Valenzuela et al., 1995a; Gonzalez et al., 2002). These results can be explained by the decrease in the 
dissociation rate values obtained in Kv1.5-Kvβ1.3-calphostin C channels with bupivacaine and quinidine, which 
indicates that the drug-channel complex becomes more stable than in Kv1.5-Kvβ1.3 channels, but less stable than 
that observed in Kv1.5 channels. However, the association rate constants remained nearly unchanged in 
comparison to those reported for Kv1.5 and Kv1.5-Kvβ1.3 channels (Gonzalez et al., 2002; Arias et al., 2007). This 
fact also corroborates the finding that the phenotype of Kv1.5-Kvβ1.3-calphostin C channels is closer to that of 
Kv1.5 channels alone (Arias et al., 2007). This gain of potency is a very important result if we keep in mind that 
the expression levels of α- and β-adrenergic receptors, as well as the release of catecholamines, can be modified 
in several cardiac pathologies (Schlaich et al., 2003; Schlaich et al., 2005), and may have important 
consequences in cardiac pharmacology (Longobardo et al., 1998; Gonzalez et al., 2002; Gonzalez et al., 2010; 
Ravens & Wettwer, 2011). 
 In summary, we have characterized the functional contribution of PKC to the modulation of the Kv1.5 
channelosome from an electrophysiological and pharmacological perspective. Importantly, PKC inhibition 
changes the electrophysiological and pharmacological characteristics of Kv1.5-Kvβ1.3 channels, causing them to 
be more similar to those observed in the absence of the Kvβ1.3 subunit. This functional characterization of the 
Kv1.5 channelosome opens up a variety of possible mechanisms that may underlying the development of cardiac 
hypertrophy or other cardiovascular diseases involving modifications in PKC activity.    
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5.3 Kv1.5-Kvβ1.3 CHANNELS TRAFFICKING IS PKC-DEPENDENT 
 
Membrane proteins are removed from the cell surface by endocytosis and are then either recycled back to 
the membrane or subjected to degradation. These sorting mechanisms provide the cell with the ability to adjust 
the density of a given protein at the plasma membrane. In the present Doctoral Thesis, we have analyzed the 
mechanisms underlying the decrease in the Kv1.5-Kvβ1.3 current magnitude observed after inhibition of PKC with 
calphostin C. This study demonstrated that the inhibition of PKC results in a reduction in the number of channels 
present in the cell membrane along to a dramatic accumulation of channels into the cytoplasm. In addition, we 
have demonstrated that this accumulation is not due to an increase in the internalization of the channel, whereas 
it is the consequence of a decrease in the recycle rate. In fact, the results obtained suggest that PKC is involved 
in the proper function of the Kv1.5 slow-recycling Rab11-mediated previously described (Balse et al., 2009).  
We have shown that the current magnitude generated after activation of Kv1.5-Kvβ1.3 channels in cells 
whose PKC has been inhibited is smaller than that recorded under control conditions and this effect seems to be 
due to a decrease of ≈30% in the channel surface density. These data, are in contrast with the role attributed to 
PKC in other ion channels like KCNK3, NMDAR, Cav2 or KATP channels (Lin et al., 2006; Zhang et al., 2008; 
Manna et al., 2010; Gabriel et al., 2012), which are inhibited or even down-regulated after PKC activation. But, 
although PKC activation has not been analyzed in the present Doctoral Thesis, it has been reported that the 
effects of PMA (10 nM for 30 min) does not produce electrophysiological changes on the current generated upon 
their activation (Kwak et al., 1999b; Williams et al., 2002). Our results indicate that PKC is involved in the 
regulation of the channel density in the cell membrane because its inhibition results in a dramatic reduction of the 
number of channels without modifying the total amount of the protein channel. This decrease can be due, at least 
in part, to an increase in the internalization rate or to a decrease in the recycling or going back to the membrane. 
The biotinylation assays suggest that while at the beginning of the calphostin C treatment the behavior is very 
similar to that observed in Kv1.5-Kvβ1.3 channels under control conditions, the amount of internalized channels 
significantly increased at times longer than 1 h. Moreover, live cell imaging experiments showed an abolishment 
of the recycling to the membrane of Kv1.5-Kvβ1.3 channels in cells in which PKC was inhibited. In these cells, we 
observed how the channels were endocytosed but their recycling to the cell membrane was avoided. 
Finally, in this part of the present Doctoral Thesis we demonstrated that PKC is involved in the trafficking 
of Kv1.5-Kvβ1.3 via slow-recycling Rab11-mediated. In fact, cotransfection of Kv1.5-Kvβ1.3 channels with 
Rab11CA in HEK293 cells, elicited potassium currents with similar electrophysiological properties obtained after 
calphostin C treatment but with a greater magnitude. Rab11 is found in pericentriolar recycling endosomes, a 
population of endosomes through which most membrane proteins recycle (Ullrich et al., 1996), and it is also 
found in the trans-Golgi network and post-Golgi vesicles, where it is involved in the trafficking of newly 
synthesized proteins from that organelle to the cell surface (Grosshans et al., 2006). One explanation could be 
that Kv1.5 channels are marked for transport to Rab11-positive vesicles only after multiple Rab4-dependent 
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recycling events, or targeted for degradation (Zadeh et al., 2008). In fact, it has been recently described that both 
processes (recycling and degradation) are PKC-dependent (Manna et al., 2010; Pavarotti et al., 2012) and, more 
interestingly, that PKCα and PKCβII colocalize with Rab11, this last isoform present in the Kv1.5 channelosome.  
 
The evidence that classical PKCs regulate trafficking through the endocytic and exocytic pathways is 
increasing. Indeed, these kinases have been suggested to control the levels of epidermal growth factor receptor 
(EGFR) and transferrin (Idkowiak-Baldys et al., 2009; Pavarotti et al., 2012). Likewise, serotonin receptor 
stimulation that activates classical PKCβII produces the retention of serotonin receptors at the endocytic recycling 
compartment (ERC) (Idkowiak-Baldys et al., 2009). Additional reports show that PMA-induced PKC activation 
diverts internalized EGFR and PAR-1 from a degradative to a recycling pathway controlled by Rab11 (Bao et al., 
2000).  
 
Another explanation for the specific role of PKC in the Kv1.5-Kvβ1.3 traffic regulation would be the 
following. In the same manner that PKC activity can be modulated, not only directly, but also regulating the levels 
or the activity of other proteins that act as scaffold or its receptor, RACK1; the function of Rab proteins is also 
controlled by several families of interacting proteins or FIPs. Indeed, FIP2 directly interacts with the actin-based 
myosin Vb motor protein and this interaction appears to be critical for several aspects of FIP2 function, including 
regulation of plasma membrane recycling (Hales et al., 2002; Horgan & McCaffrey, 2009). It is also important to 
highlight that the activities of Rip11 and FIP2 are regulated by phosphorylation and phospholipids-mediated 
(Horgan & McCaffrey, 2009). 
 
All these results may have an important therapeutic relevance in future studies concerning the basis of 
Kv1.5 trafficking. Moreover, they can stand the molecular basis of the Kv1.5 channels trafficking, together with 
previous reports (McEwen et al., 2007; Zadeh et al., 2008; Balse et al., 2009; Schumacher & Martens, 2010; Burg 
et al., 2010; Svoboda et al., 2012; Mia et al., 2012; Boycott et al., 2013). The effects of quinidine on these 
potassium channels have been partially attributed to its capability to internalize Kv1.5 (Schumacher et al., 2009). 
Therefore, the results obtained in this work show an additional way to reduce the channel amount in plasma 
membrane: through PKC inhibition. Thus, the levels and/or the degree of PKC activity have to be taken into 
account in the antiarrhythmic drug treatment of patients (Gonzalez et al., 2010). 
  
In summary, we have characterized the contribution of the PKC inhibition to the modulation of Kv1.5 
channelosome. Importantly, PKC inhibition modifies the electrophysiological characteristics of Kv1.5-Kvβ1.3 
controlling the slow-recycling Rab11-mediated and, therefore, the amount of the channels in the cell surface. This 
characterization of the Kv1.5 functional complex or channelosome opens up a variety of possible mechanisms 
that can help to understand the variations that can underlay the development of cardiovascular diseases involving 
modifications in PKC activity. 
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5.4 LGI1  EFFECTS ON KV1.5-KVβ1.3 CHANNEL COMPLEX. POSSIBLE ROLE 
ON HUMAN VENTRICLE  
 
In the last part of the present Doctoral Thesis, we have analyzed the electrophysiological and 
cellular effects of Lgi1 on Kv1.5-Kvβ1.3 channels, as well as its presence in cardiac tissue, including 
human myocardium. Lgi1 is a protein that has been related with certain types of epilepsy (Nobile et al., 
2009; Striano et al., 2011; Kusuzawa et al., 2012; Baulac et al., 2012; Manna et al., 2013; Irani et al., 
2013). However, its role in the human heart is currently unknown. It has been reported that Lgi1 protein 
interferes with Kvβ1-conferred fast inactivation of Kv1 channels, suggesting that it can modulate the gating 
of Kv1 channels although the molecular basis by which Lgi1 produces this effect on Kv1 channel 
inactivation is presently unknown (Schulte et al., 2006). On the other hand, it has been demonstrated that 
its differential expression in mice results in a model of cardiac hypertrophy (Mohamed et al., 2012). In this 
Doctoral Thesis we have demonstrated that Lgi1 is expressed in rat heart with a similar pattern of 
expression to that reported for Kvβ1.3, with a higher extent of expression in ventricle than in atria, 
becoming a possible member of the Kv1.5 channelosome. Lgi1 produces a dramatic decrease in the 
channel amount present in the cell membrane as well as in the inactivation of the Kv1.5-Kvβ1.3, which is 
apparent after cotransfection of Kv1.5-Kvβ1.3 and Lgi1, or after adding the Lgi1 soluble protein into the 
patch pipette. Also, a very dramatic effect on the actin cytoskeleton was observed when Lgi1 was present. 
Finally, and very importantly, we demonstrated that Lgi1 is expressed in human ventricle with a pattern of 
expression very similar to that observed for Kv1.5 channels. 
 
Lgi1 decreases the amount of Kv1.5 in the cell membrane and also modifies the conformation of the 
actin cytoskeleton of the cell. It is likely that both actions are related since it has been described that the 
microtubule cytoskeleton is involved in the internal trafficking of Kv1.5 in both heterologous and native cells 
(cardiac) (Choi et al., 2005). On the other hand, ADAM 22/23 (one of the proteins described as Lgi1 
receptor) appear to be involved in cell adhesion (Liu et al., 2009), which is consistent with the suggestion 
that Lgi1 influences cell movement and invasion through reorganization of the actin cytoskeleton (Kunapuli 
et al., 2010b). Lgi1 is a secreted protein (Senechal et al., 2005; Head et al., 2007) and it has been 
described that, in glioma cells, exerts its effects from the external side of the cell membrane, increasing 
the stress fiber formation in the cytoskeleton (Kunapuli et al., 2010b). This report is in agreement with the 
results obtained in this Doctoral Thesis, in which we need, at least, two minutes to observe the 
electrophysiological effects induced by Lgi1 when Lgi1 was added to the internal solution of the patch 
pipette as a soluble protein. Although we do not have enough data to state a complete affirmative 
conclusion, we can hypothesize that Lgi1 needs to bind to some membrane protein that acts like a 
receptor and whose binding leads to the activation or repression of a cascade of second messengers 
responsible of the modulation of Kv1.5-Kvβ1.3 channel activity. In addition, the stress in the fiber formation 
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can produce a deficiency of the anterograde transport of the proteins to the plasma membrane, as well as 
a re-distribution of the cytoskeleton with modifications in the location of Kv1.5 channelosome as it can be 
observed in the cytoskeleton blots (in both heterologous and native cells) in which the integrity of actin is 
clearly compromised. 
 
The effects of Lgi1 on the Kvβ subunit have been described on neural tissue, where the 
electrophysiological effects induced by Lgi1 on Kv1-Kvβ1 were related to the Lgi1 capability to abolish the 
fast inactivation Kvβ1-induced. Mutations in the LGI1 gene have been widely related with epilepsy, as well 
as with some neurodegenerative diseases (Borrie et al., 2012); although the molecular basis of the Lgi1 
effects on Kv1 channels inactivation are presently unknown. However, the effects on cardiac diseases 
have been only reported by Ottman and coworkes. They proposed that Lgi1 mutations have been related 
to certain types of epilepsy, some of them associated to autonomic symptoms (visceral/epigastric and 
cardiac palpitations) that occurred in 45% of patients (Ottman et al., 1995), thus suggesting the existence 
of a link between epilepsy and some cardiac pathologies, that may be represented by Lgi1. As it has been 
shown in the present Doctoral Thesis, Lgi1 is expressed in rat cardiac ventricle with a pattern of 
expression closer to that described for the Kvβ1.3 subunits and induces its actions not only decreasing the 
amount of Kv1.5 channel in the cell membrane, but also abolishing the fast inactivation Kvβ1.3-dependent. 
There are two possible explanations for these results: 1) Lgi1 locates in between the α-β either; or 2) Lgi1 
binds to the Kvβ1.3 subunit and therefore, its activity is directly compromised. The results obtained with 
Kv1.5-Kvβ1.3+Lgi1 vs. Kv1.5+Lgi1, as well as those obtained using the anti-Lgi1 antibody in the patch 
pipette, suggest the second possibility as the most likely to occur. Lgi1 effects were observed when this 
protein was cotransfected with Kv1.5-Kvβ1.3 complex and they were absent when Kv1.5 channels were 
expressed alone. Besides that, in these experiments the electrophysiological phenotype was close to 
Kv1.5. In addition, the results obtained using the anti-Lgi1 in which the electrophysiological phenotype of 
the current was similar to that elicited by the activation of Kv1.5 channels alone instead of Kv1.5-Kvβ1.3, 
led us to hypothesize the possibility that this antibody is forming a complex with Lgi1-Kvβ1.3 that avoids 
the binding within the inner pore of Kv1.5 resulting in a Kv1.5 phenotype. All these data suggest that Lgi1 
acts not only like a ‘new modulatory subunit’ but also as a regulatory subunit of modulatory subunits. 
 
In summary, the coexpression of Lgi1 with Kv1.5-Kvβ1.3 in HEK293 cells results in non-inactivating 
currents with a much smaller magnitude, and it has a dual effect: a), Lgi1 seems to produce an 
intracellular effect mostly Kv1.5-related, which affect the traffic of the channel dramatically reducing the 
channel in the cell surface; and b) an extracellular time-dependent effect in which, its effects seems to be 
more Kvβ subunit dependent. Finally, and very importantly, we demonstrated that Lgi1 is expressed in 
human ventricle with a pattern of expression very similar to that observed for Kv1.5 channels. 
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1. Calphostin C abolishes Kvβ1.3-induced fast inactivation in Kv1.5 channels, due to a shift of the 
inactivation curve towards more positive potentials. Also, PLC activity and PIP2 levels regulate 
Kvβ1.3-induced fast inactivation. We propose that Kvβ1.3 subunit acts as the ‘linker’ between 
Kv1.5 and the PKC receptor, RACK1, and the proteins linked to this channel complex. 
2. We have characterized a Kv1.5 channelosome in which Kv1.5, Kvβ1.3, RACK1, PKCβI, PKCβII, 
and PKCθ physically and functionally interact. This macromolecular complex has been also 
identified in rat ventricular myocardium. The description and functional characterization of this 
channelosome opens up a variety of possible mechanisms that can explain the differences 
between IKur recorded in ventricle and atrium in different animal species. Differential composition 
of this Kv1.5 complex could constitute a primary mechanism of crucial importance for the 
modulation of cardiac excitability.  
3. PKC inhibition modifies the electrophysiological and pharmacological characteristics of Kv1.5-
Kvβ1.3 channels, leading to a similar pharmacological phenotype to that observed in Kv1.5 
channels in the absence of Kvβ subunits. The pharmacological characterization of Kv1.5 
channelosome opens up new pharmacological maneuvers useful in the treatment of cardiac 
pathologies that involve modifications in the PKC activity. 
4. PKC activity is essential in the maintenance of the channels in the membrane and therefore, for 
the regulation of their current magnitude. Indeed, PKC activity is crucial for the slow recycling 
Rab11-mediated and its inhibition by calphostin C results in an increase of the channel in the 
cytoplasm of the cell. 
5. Lgi1 is a protein present in the cardiac tissue that regulates the activity of Kv1.5 channels. This 
modulation can be summarizes as follows, it: 1) decreases the Kv1.5 current magnitude due to a 
reduction in the number of the channels in the cell membrane; 2) abolishes the fast inactivation 
Kvβ1.3-induced likely due to an interaction between both proteins; 3) is capable to produce its 
effects from the external side of the cell, after it is secreted from the cell, likely activating or 
repressing a second messenger pathway, producing its effects on Kv1.5 channels and also on the 
cytoskeleton structure. Finally, the pattern of expression of this protein is very similar to that 
shown by Kv1.5 channels in the human ventricle. All these data led us to propose Lgi1 as a new 
and very important modulatory subunit on the Kv1.5-Kvβ1.3 channels, as well as a novel 
molecular target useful in several cardiac diseases. 
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1. La calfostina C elimina la inactivación rápida inducida por la subunidad Kvβ1.3 en los canales 
Kv1.5, debido a un desplazamiento de la curva de inactivación hacia potenciales más positivos. 
Asimismo, la actividad de la PLC, así como los niveles de PIP2, regulan la inactivación rápida 
inducida por la subunidad Kvβ1.3. Proponemos que la subunidad Kvβ1.3 actúa como molécula 
'conectora' de la unión entre el canal Kv1.5 y el receptor de PKC, RACK1, así como el resto de 
las proteínas asociadas al complejo de señalización del canal Kv1.5. 
2. Hemos caracterizado un canalosoma de Kv1.5 en el que Kv1.5, Kvβ1.3, RACK1, PKCβI, PKCβII y 
PKCθ interactúan física y funcionalmente. Este complejo macromolecular ha podido ser 
identificado también en ventrículo de rata. La descripción y caracterización funcional de este 
canalosoma abre un gran número de mecanismos capaces de explicar las diferencias entre las 
IKur registradas en miocardio ventricular y auricular en diferentes especies animales. La diferente 
composición de este complejo de Kv1.5 podría constituir un mecanismo de vital importancia para 
la modulación de la excitabilidad cardíaca.  
3. La inhibición de PKC modifica las características electrofisiológicas y farmacológicas de los 
canales Kv1.5-Kvβ1.3, produciendo un fenotipo farmacológico similar al que presentan los 
canales Kv1.5 en ausencia de subunidades Kvβ. La caracterización farmacológica del 
canalosoma de Kv1.5 abre una gran variedad de posibles maniobras farmacológicas útiles en el 
tratamiento de patologías cardíacas asociadas a modificaciones en la actividad de PKC. 
4. La actividad PKC es esencial en el mantenimiento de los canales en la membrana y, por lo tanto, 
para la regulación de la magnitud de la corriente. De hecho, la actividad PKC es crucial para el 
reciclaje lento mediado por Rab11, y su inhibición por calfostina C genera un aumento del canal 
internalizado en el citoplasma de la célula. 
5. Lgi1 es una proteína presente en tejido cardíaco capaz de regular la actividad del canalosoma de 
Kv1.5. Esta modulación se caracteriza porque: 1) disminuye la magnitud de la corriente Kv1.5 
debido a una reducción en el número de los canales presentes en la membrana plasmática; 2) 
suprime la inactivación rápida inducida por la subunidad Kvβ1.3; probablemente, debido a una 
interacción entre ambas proteínas; 3) tras su secreción, Lgi1 produce sus efectos 
electrofisiológicos desde la cara externa de la membrana, posiblemente activando o reprimiendo 
una ruta de segundos mensajeros, induciendo así sus efectos sobre los canales Kv1.5 y sobre el 
citoesqueleto. Por último, el patrón de expresión de esta proteína es muy similar al que muestran 
los canales Kv1.5 en el ventrículo humano. Así pues, proponemos que Lgi1 puede representar 
una nueva e importante subunidad moduladora de los canales Kv1.5-Kvβ1.3, así como, una 
nueva diana terapéutica útil en determinadas patologías cardíacas. 
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CFP-PH-YFP 
EFRET = 38.22 ± 0.84 %, n=14
 
Figure S1: Determination of donor fluorescence recovery during disruption of energy transfer by selective 
acceptor photobleaching in the CFP-PH-YFP tandem construction. Transiently transfected HEK293 cells were 
imaged for CFP-PH-YFP tandem construction as indicated in Methods. Shown are the relative increases in CFP 
intensities (in percentages) over initial levels and the remaining fluorescence intensity of YFP. The symbols represent 
the calculated mean ± SEM, whereas the thin dotted lines correspond to single cell traces.  
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Figure S2: FLAG label in S1-S2 extracellular loop of the channel does not modify the electrophysiological 
properties of Kv1.5-Kvβ1.3 construction. A, Representatives traces recorded after transfection of the Kv1.5-
FLAG+Kvβ1.3 construction and applying the pulse protocol showed at the top of the panel. B, IV relationship of the 
construction, in comparison with ‘wild type’ channels, before (left side) and after (right side) normalization by +60 mV 
value. C, Activation curves of ‘wild type’ channels and the construction. D, Inactivation curves of ‘wild type’ channels 
and the construction. 
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Figure S3: HA label in S1-S2 extracellular loop of the channel does not modify the electrophysiological 
properties of Kv1.5-Kvβ1.3 construction. A, Representatives traces recorded after transfection of the Kv1.5-
HA+Kvβ1.3 construction and applying the pulse protocol showed at the top of the panel. B, IV relationship of the 
construction, in comparison with ‘wild type’ channels, before (left side) and after (right side) normalization by +60 mV 
value. C, Activation curves of ‘wild type’ channels and the construction. D, Inactivation curves of ‘wild type’ channels 
and the construction. 
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Figure S4:  PKC inhibition increase the amount of cannel internalized in the inner part of the cell. Maximum 
Projections of the cells showed in Figure 28 in control conditions (upper panels) and after PKC inhibition by 
calphostin C treatment (bottom panels). It is important to highlight that in this particular case the difference in the 
intensity of signal in plasma membrane channels (red signal) is not so clear due to the process of the image 
formation. However, thanks to the ‘reconstruction’ of the cell, the difference between both conditions regarding the 
amount of channel internalized is more patent. 
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Figure S5:  The cotransfection of Kv1.5-Kvβ1.3 with Rab11CA abolishes the increase of the internalization 
PKC inhibition-mediated. Maximum Projections of the cells showed in Figure 30 after cotransfection of Kv1.5-
Kvβ1.3 channels with Rab4CA (upper panels) and with Rab11CA (bottom panels), after calphostin C treatment. Note 
that only in the presence of Rab11CA, the amount of channel internalized (green color) (bottom) after calphostin C 
treatment is decreased in comparison with that cell cotransfected with Kv1.5-HA+Kvβ1.3+Rab4CA (top) or those 
cotransfected with Kv1.5-HA+Kvβ1.3 channels (at bottom of Figure 28). The amount of channel present in plasma 
membrane is shown in red color. 
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9.1 ORIGINAL PAPERS 
Celecoxib blocks cardiac Kv1.5, Kv4.3 and Kv7.1 (KCNQ1) channels: effects on cardiac 
action potentials. 
Macías A*, Moreno C*, Moral-Sanz J, Cogolludo A, David M, Alemanni M, Pérez-Vizcaíno F, Zaza A, 
Valenzuela C, González T. (*Both authors contributed equally to this work). 
Abstract: Celecoxib is a COX-2 inhibitor that has been related to an increased cardiovascular risk and that 
exerts several actions on different targets. The aim of this study was to analyze the effects of this drug on 
human cardiac voltage-gated potassium channels (Kv) involved on cardiac repolarization Kv1.5 (IKur), 
Kv4.3+KChIP2 (Ito1) and Kv7.1+KCNE1 (IKs) and to compare with another COX-2 inhibitor, rofecoxib. 
Currents were recorded in transfected mammalian cells by whole-cell patch-clamp. Celecoxib blocked all 
the Kv channels analyzed and rofecoxib was always less potent, except on Kv4.3+KChIP2 channels. Kv1.5 
block increased in the voltage range of channel activation, decreasing at potentials positive to 0 mV. The 
drug modified the activation curve of the channels that became biphasic. Block was frequency-dependent, 
increasing at fastest frequencies. Celecoxib effects were not altered by TEAout in R487Y mutant Kv1.5 
channels but the kinetics of block was slower and the degree of block was smaller with TEAin, indicating 
that celecoxib acts from the cytosolic side. We confirmed the blocking properties of celecoxib on native Kv 
currents from rat vascular cells, where Kv1.5 are the main contributors (IC50 ≈ 7 μM). Finally, we 
demonstrate that celecoxib prolongs the action potential duration in mouse cardiac myocytes and shortens 
it in guinea pig cardiac myocytes, suggesting that Kv block induced by celecoxib may be of clinical 
relevance. J Mol Cell Cardiol. 2010 Dec; 49(6):984-92. 
 
Irvalec inserts into the plasma membrane causing rapid loss of integrity and necrotic cell 
death in tumor cells. 
Molina-Guijarro JM, Macías Á, García C, Muñoz E, García-Fernández LF, David M, Núñez L, Martínez-
Leal JF, Moneo V, Cuevas C, Lillo MP, Villalobos Jorge C, Valenzuela C, Galmarini CM. 
Abstract: Irvalec is a marine-derived antitumor agent currently undergoing phase II clinical trials. In vitro, 
Irvalec induces a rapid loss of membrane integrity in tumor cells, accompanied of a significant Ca2+ influx, 
perturbations of membrane conductivity, severe swelling and the formation of giant membranous vesicles. 
All these effects are not observed in Irvalec-resistant cells, or are significantly delayed by pretreating the 
cells with Zn2+. Using fluorescent derivatives of Irvalec it was demonstrated that the compound rapidly 
interacts with the plasma membrane of tumor cells promoting lipid bilayer restructuration. Also, FRET 
experiments demonstrated that Irvalec molecules localize in the cell membrane close enough to each 
other as to suggest that the compound could self-organize, forming supramolecular structures that likely 
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trigger cell death by necrosis through the disruption of membrane integrity. PLoS One. 2011 Apr 
27;6(4):e19042. 
 
Ceramide inhibits Kv currents and contributes to TP-receptor-induced vasoconstriction in 
rat and human pulmonary arteries. 
Moral-Sanz J, Gonzalez T, Menendez C, David M, Moreno L, Macías A, Cortijo J, Valenzuela C, Perez-
Vizcaino F, Cogolludo A. 
Abstract: Neutral sphingomyelinase (nSMase)-derived ceramide has been proposed as a mediator of 
hypoxic pulmonary vasoconstriction (HPV), a specific response of the pulmonary circulation. Voltage-
gated K(+) (Kv) channels are modulated by numerous vasoactive factors, including hypoxia, and their 
inhibition has been involved in HPV. Herein, we have analyzed the effects of ceramide on Kv currents and 
contractility in rat pulmonary arteries (PA) and in mesenteric arteries (MA). The ceramide analog C6-
ceramide inhibited Kv currents in PA smooth muscle cells (PASMC). Similar effects were obtained after the 
addition of bacterial sphingomyelinase (SMase), indicating a role for endogenous ceramide in Kv channel 
regulation. Kv current was reduced by stromatoxin and diphenylphosphine oxide-1 (DPO-1), selective 
inhibitors of Kv2.1 and Kv1.5 channels, respectively. The inhibitory effect of ceramide was still present in 
the presence of stromatoxin or DPO-1, suggesting that this sphingolipid inhibited both components of the 
native Kv current. Accordingly, ceramide inhibited Kv1.5 and Kv2.1 channels expressed in Ltk- cells. 
Ceramide-induced effects were reduced in human embryonic kidney 293 cells expressing Kv1.5 channels 
but not the regulatory subunit Kvβ2.1. The nSMase inhibitor GW4869 reduced the thromboxane-
endoperoxide receptor agonist U46619-induced, but not endothelin-1-induced pulmonary vasoconstriction 
that was partly restored after addition of exogenous ceramide. The PKC-ζ pseudosubstrate inhibitor 
(PKCζ-PI) inhibited the Kv inhibitory and contractile effects of ceramide. In MA ceramide had no effect on 
Kv currents and GW4869 did not affect U46619-induced contraction. The effects of SMase were also 
observed in human PA. These results suggest that ceramide represents a crucial signaling mediator in the 
pulmonary vasculature. Am J Physiol Cell Physiol. 2011 Jul; 301(1):C186-94. 
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Protein kinase C (PKC) activity regulates functional effects of Kvβ1.3 subunit on Kv1.5 
channels: identification of a cardiac Kv1.5 channelosome. 
David M*, Macías Á*, Moreno C, Prieto Á, Martínez-Mármol R, Vicente R, González T, Felipe A, Tamkun 
MM, Valenzuela C. (*Both authors contributed equally to this work). 
Abstract: Kv1.5 channels are the primary channels contributing to the ultrarapid outward potassium current 
(IKur). The regulatory Kvβ1.3 subunit converts Kv1.5 channels from delayed rectifiers with a modest degree 
of slow inactivation to channels with both fast and slow inactivation components. Previous studies have 
shown that inhibition of PKC with calphostin C abolishes the fast inactivation induced by Kvβ1.3. In this 
study, we investigated the mechanisms underlying this phenomenon using electrophysiological, 
biochemical, and confocal microscopy approaches. To achieve this, we used HEK293 cells (which lack 
Kvβ subunits) transiently cotransfected with Kv1.5+ Kvβ1.3 and also rat ventricular and atrial tissue to study 
native α-β subunit interactions. Immunocytochemistry assays demonstrated that these channel subunits 
colocalize in control conditions and after calphostin C treatment. Moreover, coimmunoprecipitation studies 
showed that Kv1.5 and Kvβ1.3 remain associated after PKC inhibition. After knocking down all PKC 
isoforms by siRNA or inhibiting PKC with calphostin C, Kvβ1.3-induced fast inactivation at +60 mV was 
abolished. However, depolarization to +100 mV revealed Kvβ1.3-induced inactivation, indicating that PKC 
inhibition causes a dramatic positive shift of the inactivation curve. Our results demonstrate that calphostin 
C-mediated abolishment of fast inactivation is not due to the dissociation of Kv1.5 and Kvβ1.3. Finally, 
immunoprecipitation and immunocytochemistry experiments revealed an association between Kv1.5, 
Kvβ1.3, the receptor for activated C kinase (RACK1), PKCβI, PKCβII, and PKCθ in HEK293 cells. A very 
similar Kv1.5 channelosome was found in rat ventricular tissue but not in atrial tissue. J Biol Chem. 2012 
Jun 15; 287(25):21416-28. 
 
Modulation of Voltage-Dependent and Inward Rectifier Potassium Channels by 15-Epi-
Lipoxin-A4 in Activated Murine Macrophages: Implications in Innate Immunity. 
Cristina Moreno*, Patricia Prieto*, Álvaro Macías*, María Pimentel-Santillana*, Alicia de la Cruz, Paqui G. 
Través, Lisardo Boscá, and Carmen Valenzuela. 
Potassium channels modulate macrophage physiology. Blockade of voltage-dependent potassium 
channels (Kv) by specific antagonists decreases macrophage cytokine production and inhibits proliferation. 
In the presence of aspirin, acetylated cyclooxygenase-2 loses the activity required to synthesize PGs but 
maintains the oxygenase activity to produce 15R-HETE from arachidonate. This intermediate product is 
transformed via 5-LOX into epimeric lipoxins, termed 15-epi-lipoxins (15-epi-lipoxin A4 [e-LXA4]). Kv have 
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been proposed as anti-inflammatory targets. Therefore, we studied the effects of e-LXA4 on signaling and 
on Kv and inward rectifier potassium channels (Kir) in mice bone marrow–derived macrophages (BMDM). 
Electrophysiological recordings were performed in these cells by the whole-cell patch-clamp technique. 
Treatment of BMDM with e-LXA4 inhibited LPS-dependent activation of NF-kB and IkB kinase b activity, 
protected against LPS activation–dependent apoptosis, and enhanced the accumulation of the Nrf-2 
transcription factor. Moreover, treatment of LPS-stimulated BMDM with e-LXA4 resulted in a rapid 
decrease of Kv currents, compatible with attenuation of the inflammatory response. Long-term treatment of 
LPS-stimulated BMDM with e-LXA4 significantly reverted LPS effects on Kv and Kir currents. Under these 
conditions, e-LXA4 decreased the calcium influx versus that observed in LPS-stimulated BMDM. These 
effects were partially mediated via the lipoxin receptor (ALX), because they were significantly reverted by 
a selective ALX receptor antagonist. We provide evidence for a new mechanism by which e-LXA4 
contributes to inflammation resolution, consisting of the reversion of LPS effects on Kv and Kir currents in 
macrophages. The Journal of Immunology, 2013 Dec 15;191(12):6136-46. 
 
9.2  REVIEWS 
 
Kv1.5-Kv beta interactions: molecular determinants and pharmacological consequences. 
González T, David M, Moreno C, Macías A, Valenzuela C. 
Abstract: Kv1.5 channels are homotetramers of alpha-pore subunits mainly present in human atrium and 
pulmonary vasculature. Thus, Kv1.5 is a pharmacological target for cardiovascular diseases. Kv beta 1.3 
assemblies with Kv alpha 1.5 and modifies its gating and pharmacology. A further knowledge of alpha-beta 
interactions and pharmacology will lead a better design of new drugs. Mini Rev Med Chem. 2010 Jun; 
10(7):635-42. 
 
Effects of n-3 polyunsaturated fatty acids on cardiac ion channels. 
Moreno C, Macías A, Prieto A, de la Cruz A, González T, Valenzuela C. 
Abstract: Dietary n-3 polyunsaturated fatty acids (PUFAs) have been reported to exhibit antiarrhythmic 
properties, and these effects have been attributed to their capability to modulate ion channels. In the 
present review, we will focus on the effects of PUFAs on a cardiac sodium channel (Nav1.5) and two 
potassium channels involved in cardiac atrial and ventricular repolarization (Kv) (Kv1.5 and Kv11.1). n-3 
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PUFAs of marine (docosahexaenoic, DHA and eicosapentaenoic acid, EPA) and plant origin (alpha-
linolenic acid, ALA) block Kv1.5 and Kv11.1 channels at physiological concentrations. Moreover, DHA and 
EPA decrease the expression levels of Kv1.5, whereas ALA does not. DHA and EPA also decrease the 
magnitude of the currents elicited by the activation of Nav1.5 and calcium channels. These effects on 
sodium and calcium channels should theoretically shorten the cardiac action potential duration (APD), 
whereas the blocking actions of n-3 PUFAs on Kv channels would be expected to produce a lengthening of 
cardiac action potential. Indeed, the effects of n-3 PUFAs on the cardiac APD and, therefore, on cardiac 
arrhythmias vary depending on the method of application, the animal model, and the underlying cardiac 
pathology. Front Physiol. 2012 Jul 9; 3:245. 
 
Polyunsaturated Fatty acids modify the gating of Kv channels. 
Moreno C, Macías A, Prieto A, De La Cruz A, Valenzuela C. 
Abstract: Polyunsaturated fatty acids (PUFAs) have been reported to exhibit antiarrhythmic properties, 
which are attributed to their capability to modulate ion channels. This PUFAs ability has been reported to 
be due to their effects on the gating properties of ion channels. In the present review, we will focus on the 
role of PUFAs on the gating of two Kv channels, Kv1.5 and Kv11.1. Kv1.5 channels are blocked by n-3 
PUFAs of marine [docosahexaenoic acid (DHA) and eicosapentaenoic acid] and plant origin (alpha-
linolenic acid, ALA) at physiological concentrations. The blockade of Kv1.5 channels by PUFAs steeply 
increased in the range of membrane potentials coinciding with those of Kv1.5 channel activation, 
suggesting that PUFAs-channel binding may derive a significant fraction of its voltage sensitivity through 
the coupling to channel gating. A similar shift in the activation voltage was noted for the effects of n-6 
arachidonic acid (AA) and DHA on Kv1.1, Kv1.2, and Kv11.1 channels. PUFAs- Kv1.5 channel interaction is 
time-dependent, producing a fast decay of the current upon depolarization. Thus, Kv1.5 channel opening is 
a prerequisite for the PUFA-channel interaction. Similar to the Kv1.5 channels, the blockade of Kv11.1 
channels by AA and DHA steeply increased in the range of membrane potentials that coincided with the 
range of Kv11.1 channel activation, suggesting that the PUFAs- Kv channel interactions are also coupled to 
channel gating. Furthermore, AA regulates the inactivation process in other Kv channels, introducing a fast 
voltage-dependent inactivation in non-inactivating Kv channels. These results have been explained within 
the framework that AA closes voltage-dependent potassium channels by inducing conformational changes 
in the selectivity filter, suggesting that Kv channel gating is lipid dependent. Front Pharmacol. 2012 Sep 
10; 3:163. 
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Stereoselective interactions between local anesthetics and ion channels. 
Valenzuela C, Moreno C, de la Cruz A, Macías Á, Prieto Á, González T. 
Abstract: Local anesthetics are useful probes of ion channel function and structure. Stereoselective 
interactions are especially interesting because they can reveal three-dimensional relationships between 
drugs and channels with otherwise identical biophysical and physicochemical properties. Furthermore, 
stereoselectivity suggests direct and specific receptor-mediated action, and identification of such 
stereospecific interactions may have important clinical consequences. The fact that drug targets are able 
to discriminate between the enantiomers present in a racemic drug is the consequence of the ordered 
asymmetric macromolecular units that form living cells. However, almost 25% of the drugs used in the 
clinical practice are racemic mixtures, and their individual enantiomers frequently differ in both their 
pharmacodynamic and pharmacokinetic profiles. Moreover, their effects can be similar to or different from 
the pharmacological effect of the drug and may contribute to the undesired effects of the drug. In other 
cases, the pharmacological effects induced by the two enantiomers on the molecular target are opposite. 
In the present manuscript, we will review the stereoselective effects of bupivacaine-like local anesthetics 
on cardiac sodium and potassium channels. Chirality. 2012 Nov;24(11):944-50. 
 
9.2  PUBLICATIONS IN PROGRESS 
PKC inhibition results in a Kv1.5-Kvβ1.3 pharmacology closer to Kv1.5 channels. 
A Macías, A de la Cruz, A Prieto, MM Tamkun, T González, C Valenzuela. 
Abstract: Background and purpose: The Kvβ1.3 subunit modifies the gating and pharmacology of Kv1.5 
channels in a protein kinase C (PKC)-dependent manner, decreasing their sensitivity to drug-mediated 
blockade. Cardiac Kv1.5 channels associate with RACK1, the Kvβ1.3 subunit and different PKC isoforms, 
resulting in the formation of a functional channelosome. The aim of the present study was to investigate 
the pharmacological consequences of PKC inhibition in Kv1.5-Kvβ1.3 channels analysing the effects of 
bupivacaine and quinidine. Experimental approach: HEK293 cells were transfected with Kv1.5-Kvβ1.3 
channels, and currents were recorded using the whole-cell configuration of the patch-clamp technique. 
PKC inhibition was achieved by incubating the cells with calphostin C, and the effects of bupivacaine and 
quinidine were analysed. Key results: The effects on the voltage dependent inactivation of Kv1.5-Kvβ1.3 
channels and their pharmacological behaviour after PKC inhibition were similar to that displayed by Kv1.5 
channels alone. Indeed, the IC50 values for bupivacaine were similar in both cases (21.8 and 13.1 μM). 
Similar results were also observed in the presence of quinidine. Conclusions and Implications: These 
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results suggest that competition for a common binding site between the Kvβ1.3 subunit and both drugs is 
phosphorylation dependent, which may have clinical relevance in diseases that are characterised by 
alterations in kinase activity. British Journal of Pharmacology (under review). 
 
Tumor cells resistant to the marine-derived drug Irvalec present a distinctive pattern of 
lipid composition in their plasma membrane 
José M. Molina-Guijarro, Álvaro Macías, Carolina García, Luis F. García-Fernández, Cristina 
Moreno, Juan F. Martínez-Leal, Carmen Cuevas, M. Pilar Lillo, Carmen Valenzuela and Carlos 
M. Galmarini. 
Abstract: Irvalec is a marine derived synthetic depsipeptide showing cytotoxic activity against a 
wide diversity of tumor cells both in vitro and in vivo. The existing data on the mechanism of 
action of Irvalec indicate that the compound inserts and self-organize in the plasma membrane of 
tumor cells, rapidly inducing loss of membrane integrity and cell permeabilization, giving rise to a 
fast and dramatic necrotic death. By continuous exposure of human colon carcinoma HCT-116 
cells to stepwise increasing concentrations of Irvalec, a resistant subclone of the cell line was 
established (HCT-116-Irv). In dose-response cytotoxicity assays, HCT-116-Irv cells showed an 
IC50 value >100 M. The resistant cells did not show any of the morphological and physiological 
responses to Irvalec observed in parental cells. Due to the direct effect of Irvalec on the cell 
membrane, we searched for possible changes in the lipid composition of the resistant cells. After 
fractionation of the lipid extracts using thin layer cromatography (TLC), two differential fractions 
that were almost completely absent in the resistant cells as compared to wt cells, were identified 
and purified. Interestingly, one of these fractions was able to interact with a biotinylated derivative 
of Irvalec in a standard overlay assay. These results indicated that the lipid composition could be 
directly related to the sensitivity of tumor cells to Irvalec, suggesting that this selected lipid 
fraction exherts a crucial putative biological role mediating the cytotoxic response to Irvalec. 
 
 
 
 
Appendix 2: Publications 
142 
 
Protein kinase C inhibition reduces the slow Kv1.5 recycling Rab11-mediated. 
A Macías, A de la Cruz, A Prieto, T González, C Valenzuela. 
Abstract: The activation of voltage gated potassium channels Kv1.5 generates the Ikur current with slow 
inactivation. The regulatory Kvβ1.3 subunit converts Kv1.5 channels from delayed rectifiers with a modest 
degree of slow inactivation to channels with both fast and slow inactivation components in a protein kinase 
C (PKC)-dependent manner. Previous studies have shown that inhibition of PKC not only abolishes the 
fast inactivation induced by Kvβ1.3, but also decreases the magnitude of the current of Kv1.5-Kvβ1.3 
channels. In this study we investigated the mechanisms underlying this last phenomenon using 
electrophysiological, biochemical, live cell imaging and confocal microscopy approaches. The PKC 
inhibition by calphostin C 3μM for 2 h. results in a decrease of 32.6±7.1% of the number of channels in the 
cell surface due to an increase of them in the inner part of the cell at the end of the treatment. Live cells 
imaging approaches suggest that after this treatment the mobility of the Kv1.5-Kvβ1.3 channels is 
completely abolished and this generates an accumulation of the channels into the cells because the 
channels are able to go in but not to go recycling to the plasma membrane. However, the 
electrophysiological experiments using Rab11CA increase the magnitude of the current with a similar 
degree of inactivation similar to that previously described. These results suggest that the slow trafficking 
regulation of Kv1.5-Kvβ1.3 channels is phosphorylation dependent, and along with its described effect in 
their pharmacology could results clinically relevant mainly in the diseases characterised by alterations in 
kinase activity. 
 
 
  
 
 
 
 
